3-(4-(11H-dibenzo[b,e][1,4]azepin-6-yl)piperazin-1-yl)- and 3-(4-(dibenzo[b,f][1,4]oxazepin / thiazepin / diazepin-11-yl)piperazin-1-yl)-propionic acid derivatives as H1 and 5-HT2A receptor modulators for the treatment of sleep disorders

By developing piperazine-substituted azaghetine derivatives, using their dual-acting H1 inverse agonist and 5-HT2A antagonist activities, the problem of insufficient selection of sleep fragmented treatment in the prior art was solved, and significantly improved sleep Quality and recovery efficiency.

CN114929688BActive Publication Date: 2024-11-01ALAIRION INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080089997.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-03-30
Filing Date
2020-10-20
Publication Date
2024-11-01
Estimated Expiration
2040-10-20

AI Technical Summary

Technical Problem

The pharmacological options for treating sleep fragmentation in the prior art are limited, and the lack of effective clinical treatments makes it difficult for patients with sleep disorders to obtain effective recovery and health benefits.

Method used

A class of piperazine-substituted azaghetine derivatives, dual-acting H1 inverse agonist and 5-HT2A antagonist activity, was developed to regulate H1/5-HT2A receptors as a new drug for the treatment of sleep disorders .

Benefits of technology

By regulating the H1/5-HT2A receptor, it significantly improves sleep quality, reduces sleep interruption, improves sleep recovery efficiency, and effectively treats sleep fragmentation and awakening threshold problems, providing better sleep recovery and health benefits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114929688B_ABST
    Figure CN114929688B_ABST
Patent Text Reader

Abstract

The present disclosure relates to 3-(4-(11H-dibenzo[b,e][1,4]azepin-6-yl)piperazin-1-yl)-, 3-(4-(dibenzo[b,f][1,4]oxazepin-11-yl)piperazin-1-yl)-, 3-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)- and 3-(4-(dibenzo[b,f][1,4]diazepin-11-yl)piperazin-1-yl)-propionic acid derivatives of formula (I), (II') and (II), wherein X is CR7R8, O, S or NR7, and pharmaceutically acceptable salts thereof, pharmaceutical compositions, methods for preparing the same and the compounds for use in medical treatment methods. The compounds disclosed herein can be used to modulate H1 and 5-HT2A receptors and are used to treat sleep disorders such as sleep fragmentation, sleep / wakefulness disorders and wakefulness thresholds. This specification discloses the synthesis and characterization of exemplary compounds and their pharmacological data (e.g., pages 143 to 224; Examples 1 to 33; Compounds 1 to 39; Tables A to R). Exemplary compounds are, for example, 3-(4-(7-chloro-3-methyldibenzo[b,f][1,4]oxazepine-11-yl)piperazine-1-yl)-2,2-dimethylpropionic acid (Example 1, Compound 1). #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related applications

[0002] This application claims priority to and the benefit of U.S. Application No. 62 / 923,762, filed on October 21, 2019, and U.S. Application No. 63 / 002,096, filed on March 30, 2020, the entire contents of each of which are incorporated herein by reference.

[0003] Field of the Disclosure

[0004] The present disclosure relates to piperazine-substituted azapine derivatives, prodrugs and pharmaceutically acceptable salts thereof, which can have dual-action H1 inverse agonists and 5-HT 2A Antagonists (H1 / 5-HT 2A ) activity and are thus useful in methods of treating the human or animal body. The present disclosure also relates to methods of preparing these compounds, pharmaceutical compositions comprising them, and their use in treating sleep disorders such as sleep fragmentation, disturbed sleep / arousals, and arousal threshold.

[0005] background

[0006] Breakthroughs in the field of sleep disorder research have led to widespread scientific and widespread appreciation for the health benefits of restful and restorative sleep. Sleep, along with diet and exercise, is now considered one of the three pillars of good health. The overall prevalence of current or previous sleep disorders in adults is estimated to be 52.4% of the population. Almost two-thirds (i.e. 64%) of the population report having difficulty sleeping at least several times a week (National Sleep Foundation, "2012 Sleep in America" ​​Poll, 2012). The international classification of sleep disorders distinguishes more than 80 different disorders, and each disorder may have far-reaching health and economic impacts. Although the daytime impairment caused by poor sleep has long been recognized, poor sleep also has cascading negative effects on alertness, cognition, learning and memory, vigilance, performance, and a wide range of comorbid health conditions (including acute and chronic pain and pain disorders, psychiatric conditions, neurodegenerative diseases, developmental disorders, metabolic diseases and diabetes, obesity, cardiovascular disease, immune disorders, and many other medical conditions).

[0007] Sleep-disordered subjects are now easily categorized into broader sleep disorder categories and conditions that are more amenable to new and tailored therapies that promise to provide better subject outcomes. Objective measurement of sleep can play a crucial role in understanding poor sleep and its improvement. Despite sleeping 7-8 hours or more, subjects whose sleep is frequently interrupted or "fragmented" suffer all the consequences of sleep deprivation. Indeed, sleep consolidation is essential for the restorative physiological benefits of sleep and comorbid conditions to be realized.

[0008] Pharmacological options for treating sleep fragmentation are limited. In response to the lack of pharmacological options, there is an urgent unmet clinical need to develop new approaches to treat sleep fragmentation, including pharmacological treatments.

[0009] Overview

[0010] In one aspect, the present disclosure provides, inter alia, compounds of formula (I), (II), or (II'):

[0011]

[0012] or a prodrug, solvate or pharmaceutically acceptable salt thereof.

[0013] In one aspect, the disclosure provides compounds obtainable by or obtained by a process for preparing a compound as described herein, such as a process comprising one or more of the steps described in Schemes 1-3.

[0014] In one aspect, the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

[0015] In one aspect, the disclosure provides an intermediate as described herein, which is useful for preparing a compound as described herein (eg, the intermediate is selected from the intermediates described in the syntheses of Examples 1-24).

[0016] In one aspect, the present disclosure provides methods for modulating H1 / 5-HT 2A In one aspect, the present disclosure provides a method for treating or preventing a disease or condition disclosed herein in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0017] In one aspect, the present disclosure provides methods of treating a disease or condition disclosed herein in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0018] In one aspect, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in regulating H1 / 5-HT 2A Activity (eg, in vitro or in vivo). In one aspect, the present disclosure provides a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a disease or condition disclosed herein.

[0019] In one aspect, the present disclosure provides a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in treating a disease or condition disclosed herein.

[0020] In one aspect, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in the preparation of a drug for regulating H1 / 5-HT 2A Use in active (e.g., in vitro or in vivo) medicine.

[0021] In one aspect, the present disclosure provides the use of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating or preventing a disease or condition disclosed herein.

[0022] In one aspect, the present disclosure provides the use of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease or condition disclosed herein.

[0023] In one aspect, the disease or condition to be treated is a sleep disorder.

[0024] In some embodiments, the sleep disorder is increased sleep disturbance, increased sleep fragmentation, increased arousals, or a decreased arousal threshold.

[0025] In some embodiments, the sleep disorder is caused by or comorbid with a medical condition, wherein the medical condition causes or exacerbates the sleep disorder.

[0026] In some embodiments, the sleep disorder is caused by a medical condition, wherein the medical condition causes or worsens the sleep disorder.

[0027] In some embodiments, the sleep disorder is comorbid with a medical condition, wherein the medical condition causes or exacerbates the sleep disorder.

[0028] In one aspect, the present disclosure provides methods of preparing the disclosed compounds.

[0029] In one aspect, the present disclosure provides methods of preparing a compound comprising one or more of the steps described herein.

[0030] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which this disclosure belongs. In this specification, the singular also includes the plural, unless the context clearly stipulates otherwise. Although methods and materials similar or equivalent to those described herein can be used for the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated herein by reference. The references cited herein are not considered to be prior art for the claimed invention. In the event of a conflict, this specification (including definitions) shall prevail. In addition, the materials, methods and embodiments are exemplary only, not restrictive. In the event of a conflict between the chemical structure and the name of the compound disclosed herein, the chemical structure shall prevail.

[0031] Other features and advantages of the disclosure will be apparent from the following detailed description and claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 Depicted are the average aligned sleep bouts per hour following Compound 8 administration, with the thin line depicting Compound 8 administered at 10 mg / kg PO (CT-18, n=9) and the thick line depicting control methylcellulose administered at 1 mL / kg PO (CT-18, n=10).

[0034] Figure 2 The number of transitions to wakefulness per hour after administration of Compound 8 is depicted, with the thin line depicting Compound 8 administered at 10 mg / kg PO (CT-5, n=11) and the thick line depicting control methylcellulose administered at 1 mL / kg PO (CT-5, n=11).

[0035] Figure 3 Normalized EEG delta power following administration of Compound 8 is depicted, with the thin line depicting Compound 8 administered PO at 3 mg / kg (CT-18, n=10) and the thick line depicting control methylcellulose administered PO at 1 mL / kg (CT-18, n=10).

[0036] Figure 4Depicted is the hourly accumulation of total sleep time (NREM+REM sleep) after administration of Compound 8, measured from the time of treatment (hour 0 on the abscissa), relative to an unperturbed baseline 24 hours before treatment, wherein the thin line depicts Compound 8 administered at 30 mg / kg PO (CT-18, n=12) and the thick line depicts control methylcellulose administered at 1 mL / kg PO (CT-18, n=15). The dotted line depicts an increase in total sleep time of approximately 70 minutes.

[0037] Figure 5 The average aligned sleep bouts per hour after administration of Compound 7 are depicted, with the thin line depicting oral administration of Compound 7 at 30 mg / kg (CT-18, n=10) and the thick line depicting oral administration of control methylcellulose at 1 mL / kg (CT-18, n=10).

[0038] Figure 6 The number of awake transitions per hour after administration of compound 7 is depicted, wherein the thin line depicts 30 mg / kg oral administration of compound 7 (CT-5, n=8) and the thick line depicts 2 ml / kg oral administration of control 2HPβCD 20% (CT-5, n=10).

[0039] Figure 7 Normalized EEG delta power following administration of Compound 7 is depicted, with the thin line depicting Compound 7 administered PO at 30 mg / kg (CT-18, n=10) and the thick line depicting control methylcellulose administered PO at 1 mL / kg (CT-18, n=10).

[0040] Figure 8 The mean aligned sleep bouts averaged per hour after administration of Compound 15 are depicted, where the thin line depicts Compound 15 administered orally at 30 mg / kg (CT-18, n=11) and the thick line depicts control 20% 2HPβCD administered orally at 2 ml / kg (CT-18, n=11).

[0041] Figure 9 The number of awake transitions per hour after administration of compound 15 is depicted, where the thin line depicts oral administration of compound 15 at 30 mg / kg (CT-5, n=10) and the thick line depicts oral administration of control 20% 2HPβCD at 2 ml / kg (CT-5, n=20).

[0042] Figure 10 Normalized EEG delta power following administration of Compound 15 is depicted, with the thin line depicting Compound 15 administered PO at 30 mg / kg (CT-18, n=11) and the thick line depicting control 20% 2HPβCD administered PO at 2 ml / kg (CT-18, n=11).

[0043] Detailed description

[0044] The compounds described herein are generally designed to modulate H1 / 5-HT 2A function, thus acting as H1 / 5-HT 2A Receptor antagonists are used to treat and prevent sleep disorders in subjects. As used herein, modulation refers to dual-acting H1 inverse agonists and 5-HT 2A Antagonist activity.

[0045] In certain embodiments, the compounds described herein act as dual-acting H1 inverse agonists and 5-HT 2A Antagonists act, for example, by affecting H1 / 5-HT in a positive or negative manner 2A receptor.

[0046] 5-HT2 receptors are a subclass of serotonin receptors, a group of G-protein coupled receptors and ligand-gated ion channels. 5-HT2 receptors are found in the central nervous system. 2A Receptors mediate excitatory neurotransmission. 2A Antagonists block excitatory neurotransmission. Without wishing to be bound by theory, blocking excitatory neurotransmission may be relevant to promoting better sleep (e.g., treating sleep disorders). The H1 receptor is a G-protein coupled receptor known to induce wakefulness when stimulated. Without wishing to be bound by theory, H1 inverse agonists may induce drowsiness (e.g., treating sleep disorders).

[0047] The present disclosure relates to compounds that are particularly suitable for treating sleep disorders characterized in whole or in part by sleep fragmentation.

[0048] Therefore, the compounds and pharmaceutical compositions provided herein can be used as therapeutic agents for preventing or treating sleep disorders in subjects (e.g., mammals, including humans and non-human mammals). The compounds and pharmaceutical compositions provided herein can be used as therapeutic agents for treating sleep disorders in subjects (e.g., mammals, including humans and non-human mammals). The present disclosure includes and extends within its scope to the methods of treatment, as well as compounds for use in such methods, and the use of such compounds for the preparation of medicaments that can be used in such methods.

[0049] The present disclosure relates to methods for regulating H1 / 5-HT 2A In particular, it is expected to have a compound that is different from the existing H1 / 5-HT 2A - Compounds that have improved physicochemical, pharmacological and pharmaceutical properties compared to regulatory compounds.

[0050] In some embodiments, the present disclosure provides a method for regulating H1 / 5-HT 2A function (e.g. dual-acting H1 inverse agonist and 5-HT 2AIn some embodiments, the present disclosure provides a method for alleviating the symptoms of, treating, or preventing a disease or condition disclosed herein by administering a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure to a subject in need thereof.

[0051] definition

[0052] Unless otherwise stated, the following terms used in the specification and claims have the following meanings as set out below.

[0053] As used herein, "alkyl," "C1, C2, C3, C4, C5, or C6 alkyl," or "C1-C6 alkyl" is intended to include C1, C2, C3, C4, C5, or C6 straight-chain (linear) saturated aliphatic hydrocarbon groups and C2, C3, C4, C5, or C6 branched-chain saturated aliphatic hydrocarbon groups. For example, C1-C6 alkyl is intended to include C1, C2, C3, C4, C5, or C6 alkyl groups. Examples of alkyl groups include moieties having from 1 to 6 carbon atoms, such as, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, or n-hexyl. In some embodiments, a straight-chain or branched alkyl group has six or fewer carbon atoms (e.g., C1-C6 for straight chain and C3-C6 for branched chain), and in another embodiment, a straight-chain or branched alkyl group has four or fewer carbon atoms.

[0054] As used herein, the term "optionally substituted alkyl" refers to unsubstituted alkyl groups or alkyl groups having designated substituents replacing one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), amido (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulphonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaryl moiety.

[0055] As used herein, the term "alkenyl" is included in unsaturated aliphatic groups that are similar to the above-mentioned alkyl groups in length and possible substitution but contain at least one double bond. For example, the term "alkenyl" includes straight chain alkenyls (e.g., vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl) and branched alkenyls. In certain embodiments, straight or branched alkenyls have six or less carbon atoms (e.g., C2-C6 straight chain, C3-C6 side chain) in their backbone. The term "C2-C6" includes alkenyls containing 2 to 6 carbon atoms. The term "C3-C6" includes alkenyls containing 3 to 6 carbon atoms.

[0056] As used herein, the term "optionally substituted alkenyl" refers to unsubstituted alkenyl or alkenyl having the specified substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), amido (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.

[0057] As used herein, the term "alkynyl" includes unsaturated aliphatic groups that are similar to the above-mentioned alkyl groups in length and possible substitution but contain at least one triple bond. For example, "alkynyl" includes straight chain alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl) and branched chain alkynyl. In certain embodiments, straight chain or branched chain alkynyl has six or less carbon atoms (e.g., C2-C6 straight chain, C3-C6 branched chain) in its backbone. The term "C2-C6" includes alkynyl groups containing 2 to 6 carbon atoms. The term "C3-C6" includes alkynyl groups containing 3 to 6 carbon atoms. As used herein, "C2-C6 alkenylene linking group" or "C2-C6 alkynylene linking group" is intended to include C2, C3, C4, C5 or C6 chain (straight or branched) divalent unsaturated aliphatic hydrocarbon groups. For example, a C2-C6 alkenylene linking group is intended to include C2, C3, C4, C5, and C6 alkenylene linking groups.

[0058] As used herein, the term "optionally substituted alkynyl" refers to unsubstituted alkynyl groups or alkynyl groups having designated substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), amido (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and urea), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.

[0059] Other optionally substituted moieties (e.g., optionally substituted cycloalkyl, heterocycloalkyl, aryl, or heteroaryl) include unsubstituted moieties and moieties with one or more specified substituents. For example, substituted heterocycloalkyl includes those substituted with one or more alkyl groups, such as 2,2,6,6-tetramethyl-piperidinyl and 2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridinyl.

[0060] As used herein, the term "cycloalkyl" refers to a group having 3 to 30 carbon atoms (e.g., C3-C 12 、C3-C 10 The term "cycloalkyl" refers to a saturated or partially unsaturated hydrocarbon monocyclic or polycyclic (e.g., fused, bridged, or spiro) system containing C-C or C-C (C). Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,2,3,4-tetrahydronaphthyl, and adamantyl. In the case of polycyclic cycloalkyl groups, only one ring in the cycloalkyl group needs to be non-aromatic.

[0061] As used herein, the term "heterocycloalkyl" refers to a saturated or partially unsaturated 3-8 membered monocyclic, 7-12 membered bicyclic (fused, bridged or spiro) or 11-14 membered tricyclic ring system (fused, bridged or spiro) having one or more heteroatoms (e.g., O, N, S, P or Se), e.g., 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or e.g., 1, 2, 3, 4, 5 or 6 heteroatoms independently selected from nitrogen, oxygen and sulfur, unless otherwise specified. Examples of heterocycloalkyl include, but are not limited to, piperidinyl, piperazinyl, pyrrolidinyl, dioxanyl, tetrahydrofuranyl, isoindolinyl, dihydroindolinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, oxirane, azetidinyl, oxetanyl, thietanyl, 1,2,3,6-tetrahydropyridinyl, tetrahydropyranyl, dihydropyranyl, pyranyl, morpholinyl, tetrahydrothiopyranyl, 1,4-diazepanyl, 1,4-oxazepanyl , 2-oxa-5-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-oxa-6-azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 1,4-dioxa-8-azaspiro[4.5]decyl; 1,4-di-oxaspiro[4.5]decyl, 1-oxaspiro[4.5]decyl, 1-azaspiro[4.5]decyl, 3'H-spiro[cyclohexane-1,1'-isobenzofuran ]-yl, 7'H-spiro[cyclohexane-1,5'-furo[3,4-b]pyridinyl]-yl, 3'H-spiro[cyclohexane-1,1'-furo[3,4-c]pyridinyl]-yl, 3-azabicyclo[3.1.0]hexane, 3-azabicyclo[3.1.0]hexan-3-yl, 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazolyl, 3,4,5,6,7,8-hexahydropyrido[4,3-d]pyrimidinyl, 4,5,6,7-tetrahydro-1H- pyrazolo[3,4-c]pyridinyl, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidinyl, 2-azaspiro[3.3]heptyl, 2-methyl-2-azaspiro[3.3]heptyl, 2-azaspiro[3.5]nonyl, 2-methyl-2-azaspiro[3.5]nonyl, 2-azaspiro[4.5]decyl, 2-methyl-2-azaspiro[4.5]decyl, 2-oxa-azaspiro[3.4]octyl, 2-oxa-azaspiro[3.4]octan-6-yl, etc. In the case of polycyclic heterocycloalkyl groups, only one ring of the heterocycloalkyl group needs to be non-aromatic (e.g., 4,5,6,7-tetrahydrobenzo[c]isoxazolyl).

[0062] As used herein, the term "aryl" includes groups having aromatic properties, including "conjugated" or polycyclic ring systems having one or more aromatic rings and not containing any heteroatoms in the ring structure. The term aryl includes monovalent and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, and the like. Preferably, aryl is phenyl.

[0063] As used herein, the term "heteroaryl" is intended to include stable 5-, 6- or 7-membered monocyclic or 7-, 8-, 9-, 10-, 11- or 12-membered bicyclic aromatic heterocycles consisting of carbon atoms and one or more heteroatoms, such as 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or such as 1, 2, 3, 4, 5 or 6 heteroatoms, independently selected from nitrogen, oxygen and sulfur. The nitrogen atom may be substituted or unsubstituted (i.e., N or NR, where R is H or other substituents, as defined). The nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., N→O and S(O)p, where p=1 or 2). It should be noted that the total number of S and O atoms in the aromatic heterocycle does not exceed 1. Examples of heteroaryl groups include pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, pyrimidine, etc. The heteroaryl group can also be fused or bridged with a non-aromatic alicyclic or heterocyclic ring to form a polycyclic ring system (e.g., 4,5,6,7-tetrahydrobenzo[c]isoxazolyl).

[0064] In addition, the terms "aryl" and "heteroaryl" include polycyclic aromatic and heteroaryl groups, such as tricyclic and bicyclic rings, for example, naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzimidazole, benzothiophene, quinoline, isoquinoline, naphthyridine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine.

[0065] The cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring may be substituted at one or more ring positions (e.g., a ring-forming carbon or heteroatom such as N) with substituents as described above, for example, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, , alkylthiocarbonyl, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), amido (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclic, alkylaryl or aromatic or heteroaromatic moiety. Aryl and heteroaryl groups can also be fused or bridged with non-aromatic alicyclic or heterocyclic rings to form polycyclic ring systems (e.g., tetralin, methylenedioxyphenyl such as benzo[d][1,3]dioxol-5-yl).

[0066] As used herein, the term "substituted" refers to any one or more hydrogen atoms on a designated atom being replaced by a group selected from the group shown, provided that the normal valence of the designated atom is not exceeded and the substitution produces a stable compound. When the substituent is an oxo or keto group (i.e., =O), then the two hydrogen atoms on the atom are replaced. Keto substituents are not present on aromatic moieties. As used herein, a ring double bond is a double bond (e.g., C=C, C=N, or N=N) formed between two adjacent ring atoms. "Stable compound" and "stable structure" mean a compound that is robust enough to withstand isolation from a reaction mixture to a useful purity and formulated into an effective therapeutic agent.

[0067] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom in the ring. When a substituent is listed without indicating the atom through which it is bonded to the rest of the compound of a given formula, then such substituent may be bonded through any atom in that formula. Combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.

[0068] When any variable (e.g., R) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R moieties, then that group can be optionally substituted with up to two R moieties, and R at each occurrence is independently selected from the definition of R. Furthermore, combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.

[0069] As used herein, the term "hydroxy" or "hydroxyl" includes groups having -OH or -O-.

[0070] As used herein, the term "halo" or "halogen" refers to fluorine, chlorine, bromine, and iodine.

[0071] As used herein, the term "optionally substituted haloalkyl" refers to unsubstituted haloalkyl groups having the specified substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), amido (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and urea), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.

[0072] As used herein, unless otherwise indicated, the expressions "one or more of A, B or C", "one or more A, B or C", "one or more of A, B and C", "one or more A, B and C", "selected from the group consisting of A, B and C", "selected from A, B and C", etc. are used interchangeably and all refer to a selection selected from the group consisting of A, B and / or C, i.e., one or more A, one or more B, one or more C or any combination thereof.

[0073] It should be understood that the present disclosure provides methods for synthesizing compounds of any general formula described herein.The present disclosure also provides detailed methods for synthesizing various disclosed compounds of the present disclosure according to the following schemes and those shown in the examples.

[0074] It should be understood that throughout this specification, when a composition is described as having, including, or comprising a particular component, it is intended that the composition also consists essentially of or consists of that component. Similarly, when a method or process is described as having, including, or comprising a particular process step, the process also consists essentially of or consists of that process step. Furthermore, it should be understood that the order of the steps or the order in which certain actions are performed is immaterial so long as the present invention remains operable. Furthermore, two or more steps or actions may be performed simultaneously.

[0075] It should be understood that the synthetic methods of the present disclosure can tolerate a wide variety of functional groups and therefore can use a variety of substituted starting materials. These methods generally provide the desired final compound at or near the end of the entire method, although in some cases it may be necessary to further convert the compound into a pharmaceutically acceptable salt thereof.

[0076] It will be understood that the compounds of the present disclosure can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates by employing standard synthetic methods and procedures known to those skilled in the art or apparent to those skilled in the art in light of the teachings herein. Standard synthetic methods and procedures for preparing organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. Although not limited to any one or a few sources, typical textbooks, such as Smith, MB, March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition, John Wiley & Sons: New York, 2001; Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons: New York, 1999; R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), are useful and recognized reference textbooks on organic synthesis known to those skilled in the art and are incorporated herein by reference.

[0077] Those of ordinary skill in the art will note that during reaction sequence as herein described and synthesis scheme, the order of some steps can be changed, for example, introducing and removing blocking groups. Those of ordinary skill in the art will recognize that some groups may need to be protected from the impact of reaction conditions by using blocking groups. Blocking groups can also be used to distinguish similar functional groups in molecules. The list of blocking groups and how to introduce and remove these groups can be found in Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis, the 3rd edition, John Wiley & Sons: New York, 1999.

[0078] It should be understood that, unless otherwise indicated, any description of a method of treatment includes use of the compound to provide such treatment or prevention as described herein, as well as use of the compound to prepare a medicament for treating or preventing such a condition. It should be understood that, unless otherwise indicated, any description of a method of treatment includes use of the compound to provide such treatment or prevention as described herein, as well as use of the compound to prepare a medicament for treating such a condition. Treatment includes treatment of humans or non-human animals, including rodents and other disease models.

[0079] As used herein, the term "subject" is interchangeable with the term "subject in need thereof," both of which refer to a subject suffering from a disease or condition or having an increased risk of developing a disease or condition. In some embodiments, the subject suffers from a sleep disorder or has an increased risk of developing a sleep disorder. "Subject" includes mammals. The mammal can be, for example, a human or an appropriate non-human mammal, such as a primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep, or pig. The subject can also be a bird or poultry. In one embodiment, the mammal is a human. A subject in need can be a subject that has previously been diagnosed or identified as having a disease or condition disclosed herein. A subject in need can also be a subject currently suffering from a disease or condition disclosed herein. Alternatively, a subject in need can be a subject with an increased risk of developing such a disease or condition relative to the entire population (i.e., a subject that is prone to developing such a condition relative to the entire population). A subject in need can suffer from a refractory or resistant disease or condition disclosed herein (i.e., a disease or condition disclosed herein that has not responded or has not yet responded to treatment). The subject can be resistant at the start of treatment, or can become resistant during treatment. In some embodiments, the subject in need thereof has received and failed all known effective therapies for the disease or condition disclosed herein. In some embodiments, the subject in need thereof has received at least one prior therapy.

[0080] As used herein, the term "treating" or "treatment" describes the management and care of a subject for the purpose of combating a disease, condition, or disorder, and includes the administration of a compound of the present disclosure, or a pharmaceutically acceptable salt, polymorph, or solvate thereof, to alleviate the symptoms or complications of, or eliminate, a disease, condition, or disorder. The term "treatment" may also include treatment of in vitro cells or animal models.

[0081] It should be understood that references to "treating" or "treatment" include alleviating the symptoms of an established condition. Thus, "treating" or "treatment" of a condition, disorder, or condition includes: (1) delaying the onset of clinical symptoms of the condition, disorder, or condition that develops in a person who may be suffering from or susceptible to the condition, disorder, or condition but does not yet experience or display clinical or subclinical symptoms of the condition, disorder, or condition, (2) inhibiting the condition, disorder, or condition, i.e., arresting, reducing, or delaying the disease or its recurrence (in the case of maintenance therapy) or the development of at least one clinical or subclinical symptom thereof, or (3) remitting or palliating the disease, i.e., causing regression of the condition, disorder, or condition, or at least one clinical or subclinical symptom thereof.

[0082] It will be appreciated that the compounds of the present disclosure, or pharmaceutically acceptable salts, polymorphs or solvates thereof, can or may also be used to prevent related diseases, conditions or disorders, or to identify suitable candidates for such purposes.

[0083] As used herein, the terms "preventing," "prevent," or "protecting against" describe the reduction or elimination of the onset of symptoms or complications of such disease, condition, or disorder.

[0084] It should be understood that those skilled in the art can refer to general reference texts for detailed descriptions of known techniques or equivalent techniques discussed herein. These textbooks include Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (2005); Sambrook et al., Molecular Cloning, A Laboratory Manual (3rd Edition), Cold Spring Harbor Press, Cold Spring Harbor, New York (2000); Coligan et al., Current Protocols in Immunology, John Wiley & Sons, NY; Enna et al., Current Protocols in Pharmacology, John Wiley & Sons, NY; Fingl et al., The Pharmacological Basis of Therapeutics (1975), Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 18th Edition (1990). Of course, these textbooks can also be referred to when making or using an aspect of the present disclosure.

[0085] It will be understood that the present disclosure also provides pharmaceutical compositions comprising any of the compounds described herein in combination with at least one pharmaceutically acceptable excipient or carrier.

[0086] As used herein, the term "pharmaceutical composition" is a preparation containing a compound of the present invention in a form suitable for administration to a subject. In one embodiment, the pharmaceutical composition is in bulk or unit dosage form. A unit dosage form is any of a variety of forms, including, for example, a capsule, IV bag, tablet, a single pump or bottle on an aerosol inhaler. The amount of active ingredient (e.g., a preparation of a disclosed compound or its salt, hydrate, solvate, or isomer) in a unit dose composition is an effective amount and varies according to the specific treatment involved. It will be understood by those skilled in the art that it is sometimes necessary to perform routine changes in dosage according to the age and condition of the subject. The dosage will also depend on the route of administration. A variety of routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalation, oral, sublingual, intrapleural, intrathecal, intranasal, etc. Dosage forms for topical or transdermal administration of a compound of the present invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. In one embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that are required.

[0087] As used herein, the term "pharmaceutically acceptable" refers to those compounds, anions, cations, materials, compositions, carriers and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0088] As used herein, the term "pharmaceutically acceptable excipient" refers to an excipient that is useful in preparing a pharmaceutical composition and that is generally safe, non-toxic, and neither biologically nor otherwise undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. A "pharmaceutically acceptable excipient" as used in the specification and claims includes both one and more than one such excipient.

[0089] It should be understood that the pharmaceutical composition of the present disclosure is formulated to be compatible with its intended route of administration. The example of route of administration includes parenteral, such as intravenous, intradermal, subcutaneous, oral (such as ingestion), suction, transdermal (topical) and transmucosal administration. Solutions or suspensions for parenteral, intradermal or subcutaneous application may include the following components: sterile diluents, such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerol, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and reagents for regulating tension such as sodium chloride or dextrose. pH can be adjusted with acid or alkali, such as hydrochloric acid or sodium hydroxide. Parenteral formulations can be encapsulated in ampoules, disposable syringes or multidose bottles made of glass or plastic.

[0090] It should be understood that the compounds or pharmaceutical compositions of the present disclosure can be administered to subjects in many well-known ways. As non-limiting examples, the compounds of the present disclosure can be administered as injections, orally, or through the skin using a patch. The selected dose should be sufficient to constitute an effective treatment, but not so high as to cause unacceptable side effects. The status of the disease condition (e.g., a disease or condition disclosed herein) and the health of the subject should preferably be closely monitored within a reasonable time period during and after treatment.

[0091] As used herein, the term "effective amount" refers to an amount of an agent that treats, ameliorates, or prevents an identified disease, disorder, or condition, or exhibits a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend on the subject's weight, size, and health; the nature and extent of the disorder; and the therapeutic agent or combination of therapeutic agents selected for administration. The therapeutically effective amount for a given situation can be determined by routine experimentation within the skill and judgment of the clinician.

[0092] As used herein, the term "therapeutically effective amount" refers to an amount of an agent that treats or ameliorates an identified disease, disorder or condition or exhibits a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend on the subject's weight, size, and health; the nature and extent of the disorder; and the therapeutic agent or combination of therapeutic agents selected for administration. The therapeutically effective amount for a given situation can be determined by routine experimentation within the skill and judgment of the clinician. A "therapeutically effective amount" can be administered to a subject for the treatment of a disease or disorder. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc. of the subject to be treated.

[0093] It will be understood that for any compound, the therapeutically effective amount can be estimated initially in cell culture assays (e.g., tumor cells) or in animal models (typically rats, mice, rabbits, dogs, or pigs). Animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic / prophylactic efficacy and toxicity can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, such as ED 50 (the dose that is therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio LD 50 / ED 50 Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The dosage may vary within this range depending on the dosage form employed, sensitivity of the subject, and the route of administration.

[0094] Dosage and administration are adjusted to provide adequate levels of the active agent or to maintain the desired effect. Factors that may be considered include the severity of the disease or condition, the general health of the subject, the subject's age, weight and sex, diet, time and frequency of administration, drug combination, reaction sensitivities and tolerance / response to treatment.

[0095] Pharmaceutical compositions containing the active compounds of the present disclosure can be prepared in a generally known manner, for example, by conventional mixing, dissolving, granulating, making dragees, levigating, emulsifying, encapsulating, embedding or lyophilizing methods. Pharmaceutical compositions can be prepared in a conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and / or adjuvants that contribute to processing the active compound into a pharmaceutically usable formulation. Of course, appropriate formulations depend on the selected route of administration.

[0096] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL TM(BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be a fluid that reaches the degree of easy injection. It must be stable under manufacturing and storage conditions and must prevent the contamination of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium, which contains, for example, water, ethanol, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol, etc.) and a suitable mixture thereof. Suitable fluidity can be maintained, for example, by using a coating such as lecithin, in the case of a dispersion, by maintaining the required particle size and by using a surfactant. The effect of preventing microorganisms can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it is preferred to include isotonic agents in the composition, such as sugar, polyols (such as mannitol and sorbitol) and sodium chloride. The extended absorption of the injectable composition can be achieved by including an agent (such as aluminum monostearate and gelatin) that delays absorption in the composition.

[0097] Sterile injectable solutions can be prepared by incorporating the desired amount of the active compound into a suitable solvent together with one or a combination of the ingredients listed above (as needed), followed by filtration sterilization. Typically, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and other ingredients required from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, preparation methods include vacuum drying and freeze drying, which produce a powder of the active ingredient plus any additional required ingredients from its previous sterile filtered solution.

[0098] Oral compositions typically include an inert diluent or an edible pharmaceutically acceptable carrier. They can be encapsulated in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be mixed with excipients and used in the form of tablets, lozenges, or capsules. Oral compositions can also be prepared using a fluid carrier used as a mouthwash, wherein the compound in the fluid carrier is administered orally and swished and expectorated or swallowed. Pharmaceutically compatible binders and / or adjuvant materials can be included as part of the composition. Tablets, pills, capsules, lozenges, etc. may contain any of the following ingredients or compounds of similar properties: binders such as microcrystalline cellulose, tragacanth gum, or gelatin; excipients such as starch or lactose; disintegrants such as alginic acid, Primogel, or corn starch; lubricants such as magnesium stearate or Sterotes; glidants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavorings such as mint, methyl salicylate, or orange flavoring.

[0099] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0100] Systemic administration can also be carried out through transmucosal or transdermal means. For transmucosal or transdermal administration, a penetrant suitable for the barrier to be penetrated is used in the formulation. Such penetrants are generally known in the art and include, for example, detergents, bile salts, and fusidic acid derivatives for transmucosal administration. Transmucosal administration can be achieved by using nasal sprays or suppositories. For transdermal administration, the active compound is formulated into an ointment, salves, gel, or cream commonly known in the art.

[0101] The active compound can be prepared with a pharmaceutically acceptable carrier that protects the compound from rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such preparations will be apparent to those skilled in the art. The materials can also be commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies directed against viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, such as described in U.S. Patent No. 4,522,811.

[0102] It is particularly advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. As used herein, dosage unit form refers to physically discrete units suitable as unit dosages for the subject to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier. The specifications for the dosage unit forms of the present disclosure are dictated by and directly dependent on the unique characteristics of the active compound and the specific therapeutic effect to be achieved.

[0103] In therapeutic applications, the dosage of the pharmaceutical composition used according to the present disclosure varies according to the medicament, the age, weight and clinical condition of the recipient subject, and the experience and judgment of the clinician or practitioner administering the therapy, as well as other factors that affect the selected dosage. Generally, the dosage should be sufficient to cause the symptoms of the disease or condition disclosed herein to slow down, preferably disappear, and also preferably cause complete disappearance of the disease or condition. The effective amount of the medicament is the amount that provides an objectively identifiable improvement as indicated by a clinician or other qualified observer. Improvements in sleep disturbances, sleep fragmentation, wakefulness or wakefulness thresholds indicate disappearance. As used herein, the term "dosage effective manner" refers to the amount of the active compound that produces the desired biological effect in a subject or cell.

[0104] It will be understood that the pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[0105] It is to be understood that for the compounds of the present disclosure that are capable of further forming salts, all such forms are also contemplated as being within the scope of the claimed disclosure.

[0106] As used herein, the term "pharmaceutically acceptable salt" refers to derivatives of the disclosed compounds wherein the parent compound is modified by preparing acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues (e.g., amines), alkali or organic salts of acidic residues (e.g., carboxylic acids), and the like. Pharmaceutically acceptable salts include, for example, conventional non-toxic salts or quaternary ammonium salts of the parent compound formed from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from the group consisting of 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, ethylenediaminetetraacetic acid, ethanedisulfonic acid, 1,2-ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, glycollyarsanilic acid, hexylresorcinic acid, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxymaleic, hydroxynaphthoic, isethionic, lactic, lactobionic, laurylsulfonic, maleic, malic, mandelic, methanesulfonic, napsylic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, subacetic acid, succinic acid, sulfamic acid, sulphanilic acid, sulfuric acid, tannic acid, tartaric acid, toluenesulfonic acid, and commonly present amino acids such as glycine, alanine, phenylalanine, arginine, etc.

[0107] In some embodiments, the pharmaceutically acceptable salt is a sodium salt, potassium salt, calcium salt, magnesium salt, diethylamine salt, choline salt, meglumine salt, benzathine salt, tromethamine salt, ammonium salt, arginine salt, or lysine salt.

[0108] Other examples of pharmaceutically acceptable salts include hexanoic acid, cyclopentanepropionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, muconic acid, and the like. The present disclosure also encompasses salts formed when an acidic proton present in the parent compound is replaced by a metal ion (e.g., an alkali metal ion, an alkaline earth metal ion, or an aluminum ion); or when coordinated with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. In salt form, it is understood that the ratio of the compound to the cation or anion of the salt can be 1:1, or any ratio other than 1:1, such as 3:1, 2:1, 1:2, or 1:3.

[0109] It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same salt.

[0110] The compound or its pharmaceutically acceptable salt is administered orally, nasally, transdermally, pulmonary, by inhalation, buccal, sublingual, intraperitoneal, subcutaneous, intramuscular, intravenous, rectal, intrapleural, intrathecal and parenteral. In one embodiment, the compound is administered orally. Those skilled in the art will recognize the advantages of certain routes of administration.

[0111] As an example, a salt can be formed between an anion and a positively charged group (e.g., an amino group) on a substituted compound disclosed herein. Suitable anions include chloride, bromide, iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronide, glutarate, malate, maleate, succinate, fumarate, tartrate, toluenesulfonate, salicylate, lactate, naphthylsulfonate, and acetate (e.g., trifluoroacetate).

[0112] As used herein, the term "pharmaceutically acceptable anion" refers to an anion suitable for forming a pharmaceutically acceptable salt. Similarly, salts can also be formed between cations and negatively charged groups (e.g., carboxylates) on the substituted compounds disclosed herein. Suitable cations include sodium ions, potassium ions, magnesium ions, calcium ions, and ammonium cations such as tetramethylammonium ions or diethylamine ions. Substituted compounds disclosed herein also include those salts containing quaternary nitrogen atoms.

[0113] It should be understood that the compounds of the present disclosure, such as salts of the compounds, can exist in hydrated or unhydrated (anhydrous) forms or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates, dihydrates, etc. Non-limiting examples of solvates include ethanol solvates, acetone solvates, etc.

[0114] As used herein, the term "solvate" refers to a solvent addition form containing either stoichiometric or non-stoichiometric amounts of a solvent. Some compounds tend to trap fixed molar ratios of solvent molecules in the crystalline solid state, thereby forming a solvate. If the solvent is water, the solvate formed is a hydrate; and if the solvent is an alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more water molecules with one molecule of a substance, where the water remains in its molecular form as HO.

[0115] As used herein, the term "analog" refers to a compound that is structurally similar to another compound but slightly different in composition (e.g., one atom is replaced by an atom of a different element or in the presence of a particular functional group, or one functional group is replaced by another functional group). Thus, an analog is a compound that is similar or equivalent to a reference compound in function and appearance, but not in structure or origin.

[0116] As used herein, the term "derivative" refers to compounds having a common core structure and substituted with various groups as described herein.

[0117] As used herein, the term "bioisostere" refers to a compound produced by the exchange of one atom or group of atoms with another broadly similar atom or group of atoms. The purpose of bioisosteric substitution is to produce new compounds with similar biological properties to the parent compound. Bioisosteric substitution can be based on physicochemical or topological principles. Examples of carboxylic acid bioisosteres include, but are not limited to, acylsulfonamides, tetrazoles, sulfonates, and phosphonates. See, for example, Patani and LaVoie, Chem. Rev. 96, 3147-3176, 1996.

[0118] As used herein, "2HPβCD" refers to (2-hydroxypropyl)-β-cyclodextrin.

[0119] As used herein, "REM" refers to the rapid eye movement sleep stage.

[0120] As used herein, "SEM" refers to standard error of the mean.

[0121] As used herein, "CT" refers to circadian time.

[0122] As used herein, "sleep continuity" refers to a measure of sleep-bout length.

[0123] As used herein, "depth" of sleep is characterized by EEG slow wave activity, which may contribute to sleep continuity or sleep consolidation, one of several determinants of sleep quality.

[0124] As used herein, "SWA" refers to slow wave activity, which can be illustrated as EEG delta power using Fourier analysis.

[0125] As used herein, the terms "rat" and "laboratory rat" are used interchangeably.

[0126] As used herein, the phrase "compounds of the disclosure" refers to those compounds disclosed both generically and specifically herein.

[0127] "Uninterrupted sleep bouts" (average sleep bout duration) are defined herein as the average duration, in minutes, of all uninterrupted sleep bouts that occur per hour. An "interruption" is defined as two or more consecutive 10-second wake periods. The value of the bout length extending into subsequent hours is assigned to the hour in which it begins. Similar quantification can be performed on wake bouts. Sleep bout length is of particular interest because it can reflect the tendency of humans to wake up periodically at night (such wakeups are not usually recalled), which in turn may be an important factor in determining sleep recovery values ​​in humans. Preclinical measurements of sleep bout duration are also strong predictors of hypnotic efficacy in humans.

[0128] "Transitions to wakefulness" (number of transitions from sleep to wakefulness) is a count of the number of awakenings (including any objectively determined wakefulness stages) following sleep (including any objectively determined sleep stages) per hour. For the purposes of this definition, a single qualified 10-second wakefulness period immediately following sleep constitutes a transition from sleep to wakefulness. One or more consecutive 10-second periods of awakening immediately following one or more 10-second periods of sleep or after sleep are also counted as transitions from sleep to wakefulness. 10-second periods containing at least 50% wakefulness content (determined by EEG and EMG within the period) can be classified as wakefulness for the entire period. The number of transitions to wakefulness is interesting because they provide a direct measure of the number of awakenings per hour (transitions from sleep to wakefulness). The number of awakenings is a useful measure of sleep fragmentation in animals and humans. Drugs that improve sleep fragmentation have been shown to improve the restorative benefits of sleep.

[0129] "LMA intensity" is defined as the number of LMA counts per minute of EEG-defined wakefulness. This variable allows assessment of LMA independent of the amount of time spent awake; therefore, it can be used to quantify the specificity of wakefulness- or sleep-promoting effects.

[0130] As used herein, "temporal proximity" means that the administration of one therapeutic agent occurs within a time period before or after the administration of another therapeutic agent, such that the therapeutic effect of one therapeutic agent overlaps with the therapeutic effect of the other therapeutic agent. In some embodiments, the therapeutic effect of one therapeutic agent completely overlaps with the therapeutic effect of the other therapeutic agent. In some embodiments, "temporal proximity" means that the administration of one therapeutic agent occurs within a time period before or after the administration of another therapeutic agent, such that a synergistic effect exists between the one therapeutic agent and the other therapeutic agent. "Temporal proximity" can vary depending on various factors, including but not limited to the age, sex, weight, genetic background, medical condition, disorder, disease history, and treatment history of the subject to whom the therapeutic agent is to be administered; the disease, disorder, or condition to be treated or improved; the therapeutic outcome to be achieved; the dosage, frequency, and duration of administration of the therapeutic agent; the pharmacokinetics and pharmacodynamics of the therapeutic agent; and the route of administration of the therapeutic agent. In some embodiments, "temporal proximity" means within 15 minutes, within 30 minutes, within 1 hour, within 2 hours, within 4 hours, within 6 hours, within 8 hours, within 12 hours, within 18 hours, within 24 hours, within 36 hours, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within 1 week, within 2 weeks, within 3 weeks, within 4 weeks, within 6 weeks, or within 8 weeks. In some embodiments, multiple administrations of one therapeutic agent can occur in temporal proximity to a single administration of another therapeutic agent. In some embodiments, temporal proximity can change during a treatment cycle or within a dosing regimen.

[0131] Unless otherwise expressly stated, the terms "approximately" and "approximately" are synonymous. In some embodiments, "approximately" and "approximately" refer to a listed amount, value, dosage, or duration ±20%, ±15%, ±10%, ±8%, ±6%, ±5%, ±4%, ±2%, ±1% or ±0.5%. In another embodiment, "approximately" and "approximately" refer to a listed amount or duration ±10%, ±8%, ±6%, ±5%, ±4% or ±2%. In some embodiments, "approximately" and "approximately" refer to a listed amount, value, dosage, or duration ±5%. In some embodiments, "approximately" and "approximately" refer to a listed amount, value, dosage, or duration ±2%. In some embodiments, "approximately" and "approximately" refer to a listed amount, value, dosage, or duration ±1%.

[0132] It will also be understood that certain compounds of any of the general formulae disclosed herein may exist in solvated as well as unsolvated forms, such as hydrated forms. Suitable pharmaceutically acceptable solvates are, for example, hydrates, such as hemihydrates, monohydrates, dihydrates, or trihydrates. It will be understood that the present disclosure encompasses compounds having H1 / 5-HT 2A All such solvated forms modulate the activity.

[0133] It is also understood that certain compounds of any of the general formulae disclosed herein may exhibit polymorphic forms, and that the present disclosure encompasses compounds having H1 / 5-HT 2A All such forms or mixtures thereof of modulating activity. It is generally known that crystalline materials can be analyzed using conventional techniques, such as X-ray powder diffraction analysis, differential scanning calorimetry, thermogravimetric analysis, diffuse reflectance infrared Fourier transform (DRIFT) spectroscopy, near infrared (NIR) spectroscopy, solution and / or solid state nuclear magnetic resonance spectroscopy. The water content of such crystalline materials can be determined by Karl Fischer analysis.

[0134] The compounds of any one of the general formulas disclosed herein can exist in many different tautomeric forms, and reference to compounds of formula (I), (II) and (II') includes all of these forms. For the avoidance of doubt, when a compound can exist in one of several tautomeric forms, and only one is specifically described or shown, all other forms are still included in formula (I), (II) or (II'). Examples of tautomeric forms include keto-, enol- and enolate-forms, such as the following tautomeric pairs: keto / enol (as shown below), imine / enamine, amide / imino alcohol, amidine / amidine, nitroso / oxime, thiol / enethiol and nitro / acid nitro.

[0135]

[0136] Compounds of any of the general formulas disclosed herein containing amine functional groups can also form N-oxides. Compounds of formula (I), (II) and (II ') containing amine functional groups mentioned herein also include N-oxides. When a compound contains several amine functional groups, one or more nitrogen atoms can be oxidized to form N-oxides. Specific examples of N-oxides are N-oxides of nitrogen atoms of tertiary amines or nitrogen-containing heterocycles. N-oxides can be formed by treating the corresponding amine with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid), see, for example, Advanced Organic Chemistry, Jerry March, 4th edition, Wiley Interscience, p. 36. Specifically, N-oxides can be prepared by the method of LW Deady (Syn. Comm. 1977, 7, 509-514), wherein an amine compound reacts with meta-chloroperbenzoic acid (mCPBA), for example, in an inert solvent such as dichloromethane.

[0137] The compounds of any of the general formulas disclosed herein can be administered in the form of prodrugs that decompose in the human or animal body to release the compounds of the present disclosure. Prodrugs can be used to modify the physical properties and / or pharmacokinetic properties of the compounds of the present disclosure. Prodrugs can be formed when the compounds of the present disclosure contain suitable groups or substituents to which property-modifying groups can be attached. Examples of prodrugs include derivatives containing alkyl or acyl substituents that are cleavable in vivo at the ester or amide groups in any of the general formulas disclosed herein.

[0138] As used herein, the term "isomerism" refers to compounds that have the same molecular formula but differ in the sequence of bonding of their atoms or the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers," stereoisomers that are not mirror images of one another are termed "diastereomers," and stereoisomers that are non-superimposable mirror images of one another are termed "enantiomers" or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a "racemic mixture."

[0139] As used herein, the term "chiral center" refers to an atom bonded to four different substituents (eg, carbon atoms).

[0140] As used herein, the term "chiral isomer" refers to a compound with at least one chiral center. Compounds with more than one chiral center exist as individual diastereomers or as a mixture of enantiomers, referred to as a "diastereomeric mixture." When one chiral center is present, the stereoisomer is characterized by the absolute configuration (R or S) at that chiral center. Absolute configuration refers to the spatial arrangement of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ordered according to the sequential rules of Cahn, Ingold and Prelog (Cahn et al., Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J. Chem. Educ. 1964, 41, 116).

[0141] As used herein, the term "geometric isomers" refers to diastereomers whose existence is due to hindered rotation around a double bond or a cycloalkyl linker (e.g., 1,3-cyclobutyl). These configurations are distinguished in their names by the prefixes cis and trans or Z and E, which indicate whether the groups are on the same or opposite sides of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.

[0142] It should be understood that the compounds of the present disclosure may be described as different chiral isomers or geometric isomers. It should also be understood that when a compound has chiral or geometric isomeric forms, all isomeric forms are intended to be included within the scope of the present disclosure, and the naming of the compound does not exclude any isomeric form. It should be understood that not all isomers may have the same level of activity.

[0143] It should be understood that the structures and other compounds discussed in this disclosure include all atropisomers thereof. It should also be understood that not all atropisomers may have the same level of activity.

[0144] As used herein, the term "atropisomer" is a type of stereoisomer in which the atoms of the two isomers are arranged differently in space. The existence of atropisomers is due to restricted rotation caused by hindered rotation of large groups around a central bond. Such atropisomers typically exist as a mixture; however, recent advances in chromatographic techniques have made it possible to separate mixtures of two atropisomers under select circumstances.

[0145] As used herein, the term "tautomer" is one of two or more structural isomers that exist in equilibrium and are easily converted from one isomeric form to another. This conversion results in the migration of hydrogen atoms, accompanied by the conversion of adjacent conjugated double bonds. Tautomers exist as a mixture of tautomeric groups in solution. In a solution that may tautomerize, the chemical equilibrium of the tautomers will be reached. The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH. The concept of tautomers that can be mutually converted by tautomerism is called tautomerism. Among the various possible types of tautomerism, two are usually observed. In keto-enol tautomerism, electrons and hydrogen atoms are simultaneously displaced. Ring-chain tautomerism is due to the reaction of an aldehyde group (-CHO) in a sugar chain molecule with one of the hydroxyl groups (-OH) in the same molecule to produce a cyclic (ring-shaped) form, as shown in glucose.

[0146] It should be understood that the compounds of the present disclosure can be described as different tautomers. It should also be understood that when a compound has a tautomeric form, all tautomeric forms are intended to be included within the scope of the present disclosure, and the naming of the compound does not exclude any tautomeric form. It should be understood that certain tautomers can have a higher level of activity than other tautomers.

[0147] Compounds that have the same molecular formula but differ in the nature or order of bonding of their atoms or the arrangement of their atoms in space are termed "isomers". Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers", and those that are non-superimposable mirror images of one another are termed "enantiomers". When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric center and described by the R- and S-ordering rules of Cahn and Prelog, or by the way the molecule rotates the plane of polarized light and designated as right- or left-handed (i.e., (+) or (-)-isomers, respectively). Chiral compounds can exist as individual enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is termed a "racemic mixture".

[0148] The compounds of the present disclosure may have one or more asymmetric centers; thus, such compounds may be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. Unless otherwise indicated, the description or naming of a particular compound in the specification and claims is intended to include individual enantiomers and mixtures, racemic mixtures or other mixtures thereof. Methods for determining stereochemistry and separating stereoisomers are well known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition, J. March, John Wiley and Sons, New York, 2001), for example by synthesis from optically active starting materials or by resolving racemic forms. Some compounds of the present disclosure may have geometric isomeric centers (E- and Z-isomers). It is understood that the present disclosure covers compounds having H1 / 5-HT 2A - All optical isomers, diastereomers and geometric isomers and mixtures thereof that modulate activity.

[0149] Thus, the present disclosure includes those compounds of any of the general formulae disclosed herein as defined above when obtainable by organic synthesis and when obtainable in the human or animal body by cleavage of its prodrug. Thus, the present disclosure includes those compounds of any of the general formulae disclosed herein produced by organic synthesis methods, as well as such compounds produced in the human or animal body by metabolism of precursor compounds, i.e., the compounds of any of the general formulae disclosed herein may be synthetically produced compounds or metabolically produced compounds.

[0150] Suitable pharmaceutically acceptable prodrugs of the compounds of any of the general formulae disclosed herein are prodrugs that are suitable for administration to a subject without undesirable pharmacological activity and without excessive toxicity, based on sound medical judgment. Various forms of prodrugs have been described, for example, in the following documents: a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder et al. (Academic Press, 1985); b) Design of Pro-drugs, edited by H. Bundgaard (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Pro-drugs", H. Bundgaard p. 113-191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya, et al., Chem. Pharm. Bull., 32, 692 (1984); g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, ACSSymposium Series, Vol. 14; and h) E. Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987.

[0151] Suitable pharmaceutically acceptable prodrugs of compounds of any of the general formulas disclosed herein with a hydroxyl group are, for example, esters or ethers thereof that can be cleaved in vivo. An ester or ether that can be cleaved in vivo of a compound of any of the formulae disclosed herein containing a hydroxyl group is, for example, a pharmaceutically acceptable ester or ether that is cleaved in a subject to produce the parent hydroxyl compound. Suitable pharmaceutically acceptable ester-forming groups of hydroxyl groups include inorganic esters, such as phosphates (including phosphoramide cyclic esters). Other suitable pharmaceutically acceptable ester-forming groups of hydroxyl groups include: C1-C 10 Alkanoyl such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, C1-C 10Alkoxycarbonyl is such as ethoxycarbonyl, N, N-(C1-C6 alkyl) 2-carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl. Examples of ring substituents on phenylacetyl and benzoyl include aminomethyl, N-alkylaminomethyl, N, N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-(C1-C4 alkyl) piperazin-1-ylmethyl. Suitable pharmaceutically acceptable ether-forming groups of hydroxyl include α-acyloxyalkyl, such as acetoxymethyl and pivaloyloxymethyl.

[0152] Suitable pharmaceutically acceptable prodrugs of compounds of any of the general formulae disclosed herein having a carboxyl group are, for example, in vivo cleavable amides thereof, such as amides formed with amines such as ammonia, C 1-4 Alkylamines such as methylamine, (C1-C4alkyl)2amines such as dimethylamine, N-ethyl-N-methylamine or diethylamine, C1-C4alkoxy-C2-C4alkylamines such as 2-methoxyethylamine, phenyl-C1-C4alkylamines such as benzylamine, and amino acids such as glycine or its esters.

[0153] Suitable pharmaceutically acceptable prodrugs of compounds of any of the general formulae disclosed herein having an amino group are, for example, amide derivatives thereof that can be cleaved in vivo. Suitable pharmaceutically acceptable amides from the amino group include, for example, amides formed with: C1-C 10 Alkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups. Examples of ring substituents on phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-(C1-C4 alkyl)piperazin-1-ylmethyl.

[0154] The dosage regimen for the compound is selected based on a variety of factors, including the type, species, age, weight, sex, and medical condition of the subject; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the subject; and the specific compound or salt thereof used. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progression of the condition. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to counter, or arrest the progression of the condition.

[0155] Techniques for preparing and administering the disclosed compounds of the present invention can be found in Remington: the Science and Practice of Pharmacy, 19th ed., Mack Publishing Co., Easton, PA (1995). In one embodiment, the compounds described herein and pharmaceutically acceptable salts thereof are used in combination with a pharmaceutically acceptable carrier or diluent in a pharmaceutical formulation. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The compound will be present in such pharmaceutical compositions in an amount sufficient to provide the desired dosage within the range described herein.

[0156] Unless otherwise indicated, all percentages and ratios used herein are by weight. Other features and advantages of the present disclosure will be apparent from various embodiments. The provided examples illustrate various components and methods that can be used to practice the present disclosure. The examples do not limit the disclosure claimed. Based on the present disclosure, those skilled in the art can identify and adopt other components and methods that can be used to implement the present disclosure.

[0157] In the synthetic schemes described herein, for simplicity, compounds may be drawn in one particular configuration. Such a particular configuration should not be construed as limiting the disclosure to one or another isomer, tautomer, regioisomer, or stereoisomer, nor as excluding mixtures of isomers, tautomers, regioisomers, or stereoisomers; however, it should be understood that a given isomer, tautomer, regioisomer, or stereoisomer may have a higher level of activity than another isomer, tautomer, regioisomer, or stereoisomer.

[0158] All publications and patent documents cited herein are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference. The citation of publications and patent documents is not intended to be an admission that any publication or patent document is relevant prior art, nor does it constitute any admission as to its content or date. Having now described the invention by written specification, those skilled in the art will recognize that the invention can be practiced in various embodiments, and the foregoing description and the following examples are intended to illustrate, rather than to limit, the appended claims.

[0159] Compounds of the present disclosure

[0160] In some aspects, the present disclosure provides, inter alia, compounds of formula (I):

[0161]

[0162] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein:

[0163] R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0164] R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl; or

[0165] R1 and R2 together with the atoms to which they are attached form a C3-C6 saturated or partially unsaturated cycloalkyl group or a 3- to 14-membered saturated or partially unsaturated heterocyclic ring containing 1 to 5 heteroatoms selected from N, O and S;

[0166] R3 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0167] R4 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0168] R5 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0169] R6 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0170] R7 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl;

[0171] R8 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; and

[0172] R9 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl or C3-C6 cycloalkyl,

[0173] Provided that at least one of R3, R4, R5 and R6 is H.

[0174] In some aspects, the present disclosure provides, inter alia, compounds of formula (II):

[0175]

[0176] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein:

[0177] X is CR7R8, O, S or NR7;

[0178] R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0179] R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl; or

[0180] R1 and R2 together with the atoms to which they are attached form a C3-C6 saturated or partially unsaturated cycloalkyl group or a 3- to 14-membered saturated or partially unsaturated heterocyclic ring containing 1 to 5 heteroatoms selected from N, O and S;

[0181] R3 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0182] R4 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0183] R5 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0184] R6 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0185] R7 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl;

[0186] R8 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; and

[0187] R9 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl or C3-C6 cycloalkyl,

[0188] The conditions are:

[0189] (a) When R5 is H, X is CR7R8 or S;

[0190] (b) when R5 is halogen, R4 is H, R3 is not methyl, methoxy or Br, and X is CR7R8 or S; and

[0191] (c) When R5 is methoxy or methyl, R4 is not H.

[0192] In some aspects, the present disclosure provides, inter alia, compounds of formula (II'):

[0193]

[0194] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein:

[0195] X is CR7R8, O, S or NR7;

[0196] R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0197] R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl; or

[0198] R1 and R2 together with the atoms to which they are attached form a C3-C6 saturated or partially unsaturated cycloalkyl group or a 3- to 14-membered saturated or partially unsaturated heterocyclic ring containing 1 to 5 heteroatoms selected from N, O and S;

[0199] R3 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0200] R4 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0201] R5 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0202] R6 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0203] R7 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl;

[0204] R8 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl;

[0205] R9 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl or C3-C6 cycloalkyl;

[0206] and

[0207] R 10 is H or halogen,

[0208] The conditions are:

[0209] (a) (i) when R5 is H, X is CR7R8 or S, or (ii) when R5 is H and X is O, R 10 is a halogen;

[0210] (b) when R5 is halogen, R4 is H, R3 is not methyl, methoxy or Br and X is CR7R8 or S; and

[0211] (c) When R5 is methoxy or methyl, R4 is not H.

[0212] It should be understood that for compounds of formula (I), (II) and (II'), X, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R 10 Where applicable, each may be selected from the groups described herein, and herein for X, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R 10 Any of the groups described in any of the above may be combined with any of the groups described herein for the remaining X, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R 10 any combination of one or more of the groups described above.

[0213] For compounds of formula (I), (II) or (II'), where applicable:

[0214] In some embodiments, X is CR7R8, O, S, or NR7. In some embodiments, X is CR7R8, O, or S. In some embodiments, X is CR7R8 or S. In some embodiments, X is CR7R8 or O. In some embodiments, X is CR7R8. In some embodiments, X is O. In some embodiments, X is S. In some embodiments, X is NR7.

[0215] In some embodiments, X is CH2.

[0216] In some embodiments, R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C3-C6 cycloalkyl.

[0217] In some embodiments, R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C3-C6 cycloalkyl.

[0218] In some embodiments, R1 is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0219] In some embodiments, R1 is C1-C6 alkyl. In some embodiments, R1 is methyl. In some embodiments, R1 is ethyl. In some embodiments, R1 is propyl. In some embodiments, R1 is butyl. In some embodiments, R1 is isopropyl. In some embodiments, R1 is isobutyl. In some embodiments, R1 is sec-butyl. In some embodiments, R1 is tert-butyl. In some embodiments, R1 is pentyl. In some embodiments, R1 is isopentyl. In some embodiments, R1 is hexyl. In some embodiments, R1 is isohexyl.

[0220] In some embodiments, R1 is C2-C6 alkenyl. In some embodiments, R1 is C2 alkenyl. In some embodiments, R1 is C3 alkenyl. In some embodiments, R1 is C4 alkenyl. In some embodiments, R1 is C5 alkenyl. In some embodiments, R1 is C6 alkenyl.

[0221] In some embodiments, R1 is C2-C6 alkynyl. In some embodiments, R1 is C2 alkynyl. In some embodiments, R1 is C3 alkynyl. In some embodiments, R1 is C4 alkynyl. In some embodiments, R1 is C5 alkynyl. In some embodiments, R1 is C6 alkynyl.

[0222] In some embodiments, R1 is C1-C6 haloalkyl, C1-C6 alkoxy, or C3-C6 cycloalkyl.

[0223] In some embodiments, R1 is C3-C6 cycloalkyl. In some embodiments, R1 is cyclopropyl. In some embodiments, R1 is cyclobutyl. In some embodiments, R1 is cyclopentyl. In some embodiments, R1 is cyclohexyl.

[0224] In some embodiments, R1 is C1-C6 haloalkyl. In some embodiments, R1 is halomethyl. In some embodiments, R1 is haloethyl. In some embodiments, R1 is halopropyl. In some embodiments, R1 is halobutyl. In some embodiments, R1 is halopentyl. In some embodiments, R1 is halohexyl.

[0225] In some embodiments, R1 is C1-C6 alkoxy. In some embodiments, R1 is methoxy. In some embodiments, R1 is ethoxy. In some embodiments, R1 is propoxy. In some embodiments, R1 is butoxy. In some embodiments, R1 is pentoxy. In some embodiments, R1 is hexyloxy.

[0226] In some embodiments, R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C3-C6 cycloalkyl.

[0227] In some embodiments, R2 is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0228] In some embodiments, R2 is C1-C6 alkyl. In some embodiments, R2 is methyl. In some embodiments, R2 is ethyl. In some embodiments, R2 is propyl. In some embodiments, R2 is butyl. In some embodiments, R2 is isopropyl. In some embodiments, R2 is isobutyl. In some embodiments, R2 is sec-butyl. In some embodiments, R2 is tert-butyl. In some embodiments, R2 is pentyl. In some embodiments, R2 is isopentyl. In some embodiments, R2 is hexyl. In some embodiments, R2 is isohexyl.

[0229] In some embodiments, R2 is C2-C6 alkenyl. In some embodiments, R2 is C2 alkenyl. In some embodiments, R2 is C3 alkenyl. In some embodiments, R2 is C4 alkenyl. In some embodiments, R2 is C5 alkenyl. In some embodiments, R2 is C6 alkenyl.

[0230] In some embodiments, R2 is C2-C6 alkynyl. In some embodiments, R2 is C2 alkynyl. In some embodiments, R2 is C3 alkynyl. In some embodiments, R2 is C4 alkynyl. In some embodiments, R2 is C5 alkynyl. In some embodiments, R2 is C6 alkynyl.

[0231] In some embodiments, R2 is C1-C6 haloalkyl, C1-C6 alkoxy, or C3-C6 cycloalkyl.

[0232] In some embodiments, R2 is C3-C6 cycloalkyl. In some embodiments, R2 is cyclopropyl. In some embodiments, R2 is cyclobutyl. In some embodiments, R2 is cyclopentyl. In some embodiments, R2 is cyclohexyl.

[0233] In some embodiments, R2 is C1-C6 haloalkyl. In some embodiments, R2 is halomethyl. In some embodiments, R2 is haloethyl. In some embodiments, R2 is halopropyl. In some embodiments, R2 is halobutyl. In some embodiments, R2 is halopentyl. In some embodiments, R2 is halohexyl.

[0234] In some embodiments, R2 is C1-C6 alkoxy. In some embodiments, R2 is methoxy. In some embodiments, R2 is ethoxy. In some embodiments, R2 is propoxy. In some embodiments, R2 is butoxy. In some embodiments, R2 is pentoxy. In some embodiments, R2 is hexyloxy.

[0235] In some embodiments, R1 and R2 together with the atoms to which they are attached form a C3-C6 saturated or partially unsaturated cycloalkyl or a 3- to 14-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0236] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C3-C6 saturated or partially unsaturated cycloalkyl.

[0237] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C3 saturated or partially unsaturated cycloalkyl.

[0238] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C4 saturated or partially unsaturated cycloalkyl.

[0239] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C5 saturated or partially unsaturated cycloalkyl.

[0240] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C6 saturated or partially unsaturated cycloalkyl.

[0241] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C3-C6 saturated cycloalkyl.

[0242] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C3 saturated cycloalkyl.

[0243] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C4 saturated cycloalkyl.

[0244] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C5 saturated cycloalkyl.

[0245] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C6 saturated cycloalkyl.

[0246] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C3-C6 partially unsaturated cycloalkyl.

[0247] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C3 partially unsaturated cycloalkyl.

[0248] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C4 partially unsaturated cycloalkyl.

[0249] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C5 partially unsaturated cycloalkyl.

[0250] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a C6 partially unsaturated cycloalkyl.

[0251] In some embodiments, R1 and R2 together with the atoms to which they are attached form a cyclopropyl group. In some embodiments, R1 and R2 together with the atoms to which they are attached form a cyclobutyl group. In some embodiments, R1 and R2 together with the atoms to which they are attached form a cyclopentyl group. In some embodiments, R1 and R2 together with the atoms to which they are attached form a cyclohexyl group.

[0252] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 3- to 14-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0253] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 3-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0254] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 4-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0255] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 5-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0256] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 6-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0257] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 7-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0258] In some embodiments, R1 and R2, together with the atoms to which they are attached, form an 8-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0259] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 9-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0260] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 10-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0261] In some embodiments, R1 and R2, together with the atoms to which they are attached, form an 11-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0262] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 12-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0263] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 13-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0264] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 14-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0265] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 3- to 14-membered saturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0266] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 3-membered saturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0267] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 4-membered saturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0268] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 5-membered saturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0269] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 6-membered saturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0270] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 7-membered saturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0271] In some embodiments, R1 and R2, together with the atoms to which they are attached, form an 8-membered saturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0272] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 9-membered saturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0273] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 10-membered saturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0274] In some embodiments, R1 and R2, together with the atoms to which they are attached, form an 11-membered saturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0275] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 12-membered saturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0276] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 13-membered saturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0277] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 14-membered saturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0278] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 3- to 14-membered partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0279] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 3-membered partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0280] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 4-membered partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0281] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 5-membered partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0282] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 6-membered partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0283] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 7-membered partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0284] In some embodiments, R1 and R2, together with the atoms to which they are attached, form an 8-membered partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0285] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 9-membered partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0286] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 10-membered partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0287] In some embodiments, R1 and R2, together with the atoms to which they are attached, form an 11-membered partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0288] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 12-membered partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0289] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 13-membered partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0290] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 14-membered partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O, and S.

[0291] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 3- to 14-membered saturated or partially unsaturated heterocyclic ring containing one heteroatom selected from N, O, and S.

[0292] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 3- to 14-membered saturated or partially unsaturated heterocyclic ring containing two heteroatoms selected from N, O, and S.

[0293] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 3- to 14-membered saturated or partially unsaturated heterocyclic ring containing three heteroatoms selected from N, O, and S.

[0294] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 3- to 14-membered saturated or partially unsaturated heterocyclic ring containing four heteroatoms selected from N, O, and S.

[0295] In some embodiments, R1 and R2, together with the atoms to which they are attached, form a 3- to 14-membered saturated or partially unsaturated heterocyclic ring containing 5 heteroatoms selected from N, O, and S.

[0296] In some embodiments, R3 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0297] In some embodiments, R3 is H.

[0298] In some embodiments, R3 is halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0299] In some embodiments, R3 is halogen. In some embodiments, R3 is H, F, Cl, or I. In some embodiments, R3 is F, Cl, or Br. In some embodiments, R3 is F or Cl. In some embodiments, R3 is F. In some embodiments, R3 is Cl. In some embodiments, R3 is Br. In some embodiments, R3 is I.

[0300] In some embodiments, R3 is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0301] In some embodiments, R3 is C1-C6 alkyl. In some embodiments, R3 is methyl. In some embodiments, R3 is ethyl. In some embodiments, R3 is propyl. In some embodiments, R3 is butyl. In some embodiments, R3 is isopropyl. In some embodiments, R3 is isobutyl. In some embodiments, R3 is sec-butyl. In some embodiments, R3 is tert-butyl. In some embodiments, R3 is pentyl. In some embodiments, R3 is isopentyl. In some embodiments, R3 is hexyl. In some embodiments, R3 is isohexyl.

[0302] In some embodiments, R3 is C2-C6 alkenyl. In some embodiments, R3 is C2 alkenyl. In some embodiments, R3 is C3 alkenyl. In some embodiments, R3 is C4 alkenyl. In some embodiments, R3 is C5 alkenyl. In some embodiments, R3 is C6 alkenyl.

[0303] In some embodiments, R3 is C2-C6 alkynyl. In some embodiments, R3 is C2 alkynyl. In some embodiments, R3 is C3 alkynyl. In some embodiments, R3 is C4 alkynyl. In some embodiments, R3 is C5 alkynyl. In some embodiments, R3 is C6 alkynyl.

[0304] In some embodiments, R3 is C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0305] In some embodiments, R3 is a C1-C6 haloalkyl. In some embodiments, R3 is a halomethyl. In some embodiments, R3 is a haloethyl. In some embodiments, R3 is a halopropyl. In some embodiments, R3 is a halobutyl. In some embodiments, R3 is a halopentyl. In some embodiments, R3 is a halohexyl.

[0306] In some embodiments, R3 is C1-C6 alkoxy. In some embodiments, R3 is methoxy. In some embodiments, R3 is ethoxy. In some embodiments, R3 is propoxy. In some embodiments, R3 is butoxy. In some embodiments, R3 is pentoxy. In some embodiments, R3 is hexyloxy.

[0307] In some embodiments, R3 is a C1-C6 haloalkoxy group. In some embodiments, R3 is a halomethoxy group. In some embodiments, R3 is a haloethoxy group. In some embodiments, R3 is a halopropoxy group. In some embodiments, R3 is a halobutoxy group. In some embodiments, R3 is a halopentyloxy group. In some embodiments, R3 is a halohexyloxy group.

[0308] In some embodiments, R3 is C3-C6 cycloalkyl. In some embodiments, R3 is cyclopropyl. In some embodiments, R3 is cyclobutyl. In some embodiments, R3 is cyclopentyl. In some embodiments, R3 is cyclohexyl.

[0309] In some embodiments, R3 is -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, or -NH(C1-C6 alkyl).

[0310] In some embodiments, R3 is -S(C1-C6 alkyl). In some embodiments, R3 is -S(methyl). In some embodiments, R3 is -S(ethyl). In some embodiments, R3 is -S(propyl). In some embodiments, R3 is -S(butyl). In some embodiments, R3 is -S(pentyl). In some embodiments, R3 is -S(hexyl).

[0311] In some embodiments, R3 is -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), or -NH2.

[0312] In some embodiments, R3 is -NH2.

[0313] In some embodiments, R3 is -N(C1-C6 alkyl)2. In some embodiments, R3 is -N(methyl)2. In some embodiments, R3 is -N(ethyl)2. In some embodiments, R3 is -N(propyl)2. In some embodiments, R3 is -N(butyl)2. In some embodiments, R3 is -N(pentyl)2. In some embodiments, R3 is -N(hexyl)2.

[0314] In some embodiments, R3 is -NH(C1-C6 alkyl). In some embodiments, R3 is -NH(methyl). In some embodiments, R3 is -NH(ethyl). In some embodiments, R3 is -NH(propyl). In some embodiments, R3 is -NH(butyl). In some embodiments, R3 is -NH(pentyl). In some embodiments, R3 is -NH(hexyl).

[0315] In some embodiments, R3 is H, F, Cl, methyl, or methoxy.

[0316] In some embodiments, R4 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0317] In some embodiments, R4 is H.

[0318] In some embodiments, R4 is halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0319] In some embodiments, R4 is halogen. In some embodiments, R4 is H, F, Cl, or I. In some embodiments, R4 is F, Cl, or Br. In some embodiments, R4 is F or Cl. In some embodiments, R4 is F. In some embodiments, R4 is Cl. In some embodiments, R4 is Br. In some embodiments, R4 is I.

[0320] In some embodiments, R4 is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0321] In some embodiments, R4 is C1-C6 alkyl. In some embodiments, R4 is methyl. In some embodiments, R4 is ethyl. In some embodiments, R4 is propyl. In some embodiments, R4 is butyl. In some embodiments, R4 is isopropyl. In some embodiments, R4 is isobutyl. In some embodiments, R4 is sec-butyl. In some embodiments, R4 is tert-butyl. In some embodiments, R4 is pentyl. In some embodiments, R4 is isopentyl. In some embodiments, R4 is hexyl. In some embodiments, R4 is isohexyl.

[0322] In some embodiments, R4 is C2-C6 alkenyl. In some embodiments, R4 is C2 alkenyl. In some embodiments, R4 is C3 alkenyl. In some embodiments, R4 is C4 alkenyl. In some embodiments, R4 is C5 alkenyl. In some embodiments, R4 is C6 alkenyl.

[0323] In some embodiments, R4 is C2-C6 alkynyl. In some embodiments, R4 is C2 alkynyl. In some embodiments, R4 is C3 alkynyl. In some embodiments, R4 is C4 alkynyl. In some embodiments, R4 is C5 alkynyl. In some embodiments, R4 is C6 alkynyl.

[0324] In some embodiments, R4 is C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0325] In some embodiments, R4 is a C1-C6 haloalkyl. In some embodiments, R4 is a halomethyl. In some embodiments, R4 is a haloethyl. In some embodiments, R4 is a halopropyl. In some embodiments, R4 is a halobutyl. In some embodiments, R4 is a halopentyl. In some embodiments, R4 is a halohexyl.

[0326] In some embodiments, R4 is C1-C6 alkoxy. In some embodiments, R4 is methoxy. In some embodiments, R4 is ethoxy. In some embodiments, R4 is propoxy. In some embodiments, R4 is butoxy. In some embodiments, R4 is pentoxy. In some embodiments, R4 is hexyloxy.

[0327] In some embodiments, R4 is a C1-C6 haloalkoxy group. In some embodiments, R4 is a halomethoxy group. In some embodiments, R4 is a haloethoxy group. In some embodiments, R4 is a halopropoxy group. In some embodiments, R4 is a halobutoxy group. In some embodiments, R4 is a halopentyloxy group. In some embodiments, R4 is a halohexyloxy group.

[0328] In some embodiments, R4 is C3-C6 cycloalkyl. In some embodiments, R4 is cyclopropyl. In some embodiments, R4 is cyclobutyl. In some embodiments, R4 is cyclopentyl. In some embodiments, R4 is cyclohexyl.

[0329] In some embodiments, R4 is -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, or -NH(C1-C6 alkyl).

[0330] In some embodiments, R4 is -S(C1-C6 alkyl). In some embodiments, R4 is -S(methyl). In some embodiments, R4 is -S(ethyl). In some embodiments, R4 is -S(propyl). In some embodiments, R4 is -S(butyl). In some embodiments, R4 is -S(pentyl). In some embodiments, R4 is -S(hexyl).

[0331] In some embodiments, R4 is -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), or -NH2.

[0332] In some embodiments, R4 is -NH2.

[0333] In some embodiments, R4 is -N(C1-C6 alkyl)2. In some embodiments, R4 is -N(methyl)2. In some embodiments, R4 is -N(ethyl)2. In some embodiments, R4 is -N(propyl)2. In some embodiments, R4 is -N(butyl)2. In some embodiments, R4 is -N(pentyl)2. In some embodiments, R4 is -N(hexyl)2.

[0334] In some embodiments, R4 is -NH(C1-C6 alkyl). In some embodiments, R4 is -NH(methyl). In some embodiments, R4 is -NH(ethyl). In some embodiments, R4 is -NH(propyl). In some embodiments, R4 is -NH(butyl). In some embodiments, R4 is -NH(pentyl). In some embodiments, R4 is -NH(hexyl).

[0335] In some embodiments, R4 is H, F, Cl, methyl, or CHF2.

[0336] In some embodiments, R5 is H, halogen, -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), -NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0337] In some embodiments, R5 is H.

[0338] In some embodiments, R5 is halogen, -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), -NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0339] In some embodiments, R5 is halogen. In some embodiments, R5 is F, Cl, Br, or I. In some embodiments, R5 is F, Cl, or Br. In some embodiments, R5 is F or Cl. In some embodiments, R5 is F. In some embodiments, R5 is Cl. In some embodiments, R5 is Br. In some embodiments, R5 is I.

[0340] In some embodiments, R5 is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0341] In some embodiments, R5 is C1-C6 alkyl. In some embodiments, R5 is methyl. In some embodiments, R5 is ethyl. In some embodiments, R5 is propyl. In some embodiments, R5 is butyl. In some embodiments, R5 is isopropyl. In some embodiments, R5 is isobutyl. In some embodiments, R5 is sec-butyl. In some embodiments, R5 is tert-butyl. In some embodiments, R5 is pentyl. In some embodiments, R5 is isopentyl. In some embodiments, R5 is hexyl. In some embodiments, R5 is isohexyl.

[0342] In some embodiments, R5 is C2-C6 alkenyl. In some embodiments, R5 is C2 alkenyl. In some embodiments, R5 is C3 alkenyl. In some embodiments, R5 is C4 alkenyl. In some embodiments, R5 is C5 alkenyl. In some embodiments, R5 is C6 alkenyl.

[0343] In some embodiments, R5 is C2-C6 alkynyl. In some embodiments, R5 is C2 alkynyl. In some embodiments, R5 is C3 alkynyl. In some embodiments, R5 is C4 alkynyl. In some embodiments, R5 is C5 alkynyl. In some embodiments, R5 is C6 alkynyl.

[0344] In some embodiments, R5 is C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0345] In some embodiments, R5 is C1-C6 haloalkyl. In some embodiments, R5 is halomethyl. In some embodiments, R5 is haloethyl. In some embodiments, R5 is halopropyl. In some embodiments, R5 is halobutyl. In some embodiments, R5 is halopentyl. In some embodiments, R5 is halohexyl.

[0346] In some embodiments, R5 is C1-C6 alkoxy. In some embodiments, R5 is methoxy. In some embodiments, R5 is ethoxy. In some embodiments, R5 is propoxy. In some embodiments, R5 is butoxy. In some embodiments, R5 is pentoxy. In some embodiments, R5 is hexyloxy.

[0347] In some embodiments, R5 is a C1-C6 haloalkoxy group. In some embodiments, R5 is a halomethoxy group. In some embodiments, R5 is a haloethoxy group. In some embodiments, R5 is a halopropoxy group. In some embodiments, R5 is a halobutoxy group. In some embodiments, R5 is a halopentyloxy group. In some embodiments, R5 is a halohexyloxy group.

[0348] In some embodiments, R5 is C3-C6 cycloalkyl. In some embodiments, R5 is cyclopropyl. In some embodiments, R5 is cyclobutyl. In some embodiments, R5 is cyclopentyl. In some embodiments, R5 is cyclohexyl.

[0349] In some embodiments, R5 is -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, or -NH(C1-C6 alkyl).

[0350] In some embodiments, R5 is -S(C1-C6 alkyl). In some embodiments, R5 is -S(methyl). In some embodiments, R5 is -S(ethyl). In some embodiments, R5 is -S(propyl). In some embodiments, R5 is -S(butyl). In some embodiments, R5 is -S(pentyl). In some embodiments, R5 is -S(hexyl).

[0351] In some embodiments, R5 is -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), or -NH2.

[0352] In some embodiments, R5 is -NH2.

[0353] In some embodiments, R5 is -N(C1-C6 alkyl)2. In some embodiments, R5 is -N(methyl)2. In some embodiments, R5 is -N(ethyl)2. In some embodiments, R5 is -N(propyl)2. In some embodiments, R5 is -N(butyl)2. In some embodiments, R5 is -N(pentyl)2. In some embodiments, R5 is -N(hexyl)2.

[0354] In some embodiments, R5 is -NH(C1-C6 alkyl). In some embodiments, R5 is -NH(methyl). In some embodiments, R5 is -NH(ethyl). In some embodiments, R5 is -NH(propyl). In some embodiments, R5 is -NH(butyl). In some embodiments, R5 is -NH(pentyl). In some embodiments, R5 is -NH(hexyl).

[0355] In some embodiments, R5 is H, F, Cl, methyl, ethyl, i-propyl, n-propyl, methoxy, methylthio, or CHF2.

[0356] In some embodiments, R6 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0357] In some embodiments, R6 is H.

[0358] In some embodiments, R6 is halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0359] In some embodiments, R6 is halogen. In some embodiments, R6 is H, F, Cl, or I. In some embodiments, R6 is F, Cl, or Br. In some embodiments, R6 is F or Cl. In some embodiments, R6 is F. In some embodiments, R6 is Cl. In some embodiments, R6 is Br. In some embodiments, R6 is I.

[0360] In some embodiments, R6 is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0361] In some embodiments, R6 is C1-C6 alkyl. In some embodiments, R6 is methyl. In some embodiments, R6 is ethyl. In some embodiments, R6 is propyl. In some embodiments, R6 is butyl. In some embodiments, R6 is isopropyl. In some embodiments, R6 is isobutyl. In some embodiments, R6 is sec-butyl. In some embodiments, R6 is tert-butyl. In some embodiments, R6 is pentyl. In some embodiments, R6 is isopentyl. In some embodiments, R6 is hexyl. In some embodiments, R6 is isohexyl.

[0362] In some embodiments, R6 is C2-C6 alkenyl. In some embodiments, R6 is C2 alkenyl. In some embodiments, R6 is C3 alkenyl. In some embodiments, R6 is C4 alkenyl. In some embodiments, R6 is C5 alkenyl. In some embodiments, R6 is C6 alkenyl.

[0363] In some embodiments, R6 is C2-C6 alkynyl. In some embodiments, R6 is C2 alkynyl. In some embodiments, R6 is C3 alkynyl. In some embodiments, R6 is C4 alkynyl. In some embodiments, R6 is C5 alkynyl. In some embodiments, R6 is C6 alkynyl.

[0364] In some embodiments, R6 is C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0365] In some embodiments, R6 is C1-C6 haloalkyl. In some embodiments, R6 is halomethyl. In some embodiments, R6 is haloethyl. In some embodiments, R6 is halopropyl. In some embodiments, R6 is halobutyl. In some embodiments, R6 is halopentyl. In some embodiments, R6 is halohexyl.

[0366] In some embodiments, R6 is C1-C6 alkoxy. In some embodiments, R6 is methoxy. In some embodiments, R6 is ethoxy. In some embodiments, R6 is propoxy. In some embodiments, R6 is butoxy. In some embodiments, R6 is pentoxy. In some embodiments, R6 is hexyloxy.

[0367] In some embodiments, R6 is a C1-C6 haloalkoxy group. In some embodiments, R6 is a halomethoxy group. In some embodiments, R6 is a haloethoxy group. In some embodiments, R6 is a halopropoxy group. In some embodiments, R6 is a halobutoxy group. In some embodiments, R6 is a halopentyloxy group. In some embodiments, R6 is a halohexyloxy group.

[0368] In some embodiments, R6 is C3-C6 cycloalkyl. In some embodiments, R6 is cyclopropyl. In some embodiments, R6 is cyclobutyl. In some embodiments, R6 is cyclopentyl. In some embodiments, R6 is cyclohexyl.

[0369] In some embodiments, R6 is -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, or -NH(C1-C6 alkyl).

[0370] In some embodiments, R6 is -S(C1-C6 alkyl). In some embodiments, R6 is -S(methyl). In some embodiments, R6 is -S(ethyl). In some embodiments, R6 is -S(propyl). In some embodiments, R6 is -S(butyl). In some embodiments, R6 is -S(pentyl). In some embodiments, R6 is -S(hexyl).

[0371] In some embodiments, R6 is -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), or -NH2.

[0372] In some embodiments, R6 is -NH2.

[0373] In some embodiments, R6 is -N(C1-C6 alkyl)2. In some embodiments, R6 is -N(methyl)2. In some embodiments, R6 is -N(ethyl)2. In some embodiments, R6 is -N(propyl)2. In some embodiments, R6 is -N(butyl)2. In some embodiments, R6 is -N(pentyl)2. In some embodiments, R6 is -N(hexyl)2.

[0374] In some embodiments, R6 is –NH(C1-C6 alkyl). In some embodiments, R6 is –NH(methyl). In some embodiments, R6 is –NH(ethyl). In some embodiments, R6 is –NH(propyl). In some embodiments, R6 is –NH(butyl). In some embodiments, R6 is –NH(pentyl). In some embodiments, R6 is –NH(hexyl).

[0375] In some embodiments, R6 is H, methyl, or methoxy.

[0376] In some embodiments, R7 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0377] In some embodiments, R7 is H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0378] In some embodiments, R7 is H or deuterium.

[0379] In some embodiments, R7 is H. In some embodiments, R7 is deuterium.

[0380] In some embodiments, R7 is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0381] In some embodiments, R7 is C1-C6 alkyl. In some embodiments, R7 is methyl. In some embodiments, R7 is ethyl. In some embodiments, R7 is propyl. In some embodiments, R7 is butyl. In some embodiments, R7 is isopropyl. In some embodiments, R7 is isobutyl. In some embodiments, R7 is sec-butyl. In some embodiments, R7 is tert-butyl. In some embodiments, R7 is pentyl. In some embodiments, R7 is isopentyl. In some embodiments, R7 is hexyl. In some embodiments, R7 is isohexyl.

[0382] In some embodiments, R7 is C2-C6 alkenyl. In some embodiments, R7 is C2 alkenyl. In some embodiments, R7 is C3 alkenyl. In some embodiments, R7 is C4 alkenyl. In some embodiments, R7 is C5 alkenyl. In some embodiments, R7 is C6 alkenyl.

[0383] In some embodiments, R7 is C2-C6 alkynyl. In some embodiments, R7 is C2 alkynyl. In some embodiments, R7 is C3 alkynyl. In some embodiments, R7 is C4 alkynyl. In some embodiments, R7 is C5 alkynyl. In some embodiments, R7 is C6 alkynyl.

[0384] In some embodiments, R8 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0385] In some embodiments, R8 is H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0386] In some embodiments, R8 is H or deuterium.

[0387] In some embodiments, R8 is H. In some embodiments, R8 is deuterium.

[0388] In some embodiments, R8 is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0389] In some embodiments, R8 is C1-C6 alkyl. In some embodiments, R8 is methyl. In some embodiments, R8 is ethyl. In some embodiments, R8 is propyl. In some embodiments, R8 is butyl. In some embodiments, R8 is isopropyl. In some embodiments, R8 is isobutyl. In some embodiments, R8 is sec-butyl. In some embodiments, R8 is tert-butyl. In some embodiments, R8 is pentyl. In some embodiments, R8 is isopentyl. In some embodiments, R8 is hexyl. In some embodiments, R8 is isohexyl.

[0390] In some embodiments, R8 is C2-C6 alkenyl. In some embodiments, R8 is C2 alkenyl. In some embodiments, R8 is C3 alkenyl. In some embodiments, R8 is C4 alkenyl. In some embodiments, R8 is C5 alkenyl. In some embodiments, R8 is C6 alkenyl.

[0391] In some embodiments, R8 is C2-C6 alkynyl. In some embodiments, R8 is C2 alkynyl. In some embodiments, R8 is C3 alkynyl. In some embodiments, R8 is C4 alkynyl. In some embodiments, R8 is C5 alkynyl. In some embodiments, R8 is C6 alkynyl.

[0392] In some embodiments, R9 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl.

[0393] In some embodiments, R9 is H.

[0394] In some embodiments, R9 is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0395] In some embodiments, R9 is C1-C6 alkyl. In some embodiments, R9 is methyl. In some embodiments, R9 is ethyl. In some embodiments, R9 is propyl. In some embodiments, R9 is butyl. In some embodiments, R9 is isopropyl. In some embodiments, R9 is isobutyl. In some embodiments, R9 is sec-butyl. In some embodiments, R9 is tert-butyl. In some embodiments, R9 is pentyl. In some embodiments, R9 is isopentyl. In some embodiments, R9 is hexyl. In some embodiments, R9 is isohexyl.

[0396] In some embodiments, R9 is C2-C6 alkenyl. In some embodiments, R9 is C2 alkenyl. In some embodiments, R9 is C3 alkenyl. In some embodiments, R9 is C4 alkenyl. In some embodiments, R9 is C5 alkenyl. In some embodiments, R8 is C6 alkenyl.

[0397] In some embodiments, R9 is C2-C6 alkynyl. In some embodiments, R9 is C2 alkynyl. In some embodiments, R9 is C3 alkynyl. In some embodiments, R9 is C4 alkynyl. In some embodiments, R9 is C5 alkynyl. In some embodiments, R9 is C6 alkynyl.

[0398] In some embodiments, R9 is C1-C6 haloalkyl or C3-C6 cycloalkyl.

[0399] In some embodiments, R9 is C1-C6 haloalkyl. In some embodiments, R9 is halomethyl. In some embodiments, R9 is haloethyl. In some embodiments, R9 is halopropyl. In some embodiments, R9 is halobutyl. In some embodiments, R9 is halopentyl. In some embodiments, R9 is halohexyl.

[0400] In some embodiments, R9 is C3-C6 cycloalkyl. In some embodiments, R9 is cyclopropyl. In some embodiments, R9 is cyclobutyl. In some embodiments, R9 is cyclopentyl. In some embodiments, R9 is cyclohexyl.

[0401] In some embodiments, at least one of R3, R4, R5, and R6 is H.

[0402] In some embodiments, at least one of R3, R4, R5, and R6 is not H.

[0403] In some embodiments, at least one of R3 and R4 is H.

[0404] In some embodiments, at least one of R5 and R6 is H.

[0405] In some embodiments, X is CR7R8 or S, and R5 is H.

[0406] In some embodiments, X is CR7R8, and R5 is H.

[0407] In some embodiments, X is CH2, and R5 is H.

[0408] In some embodiments, X is S, and R5 is H.

[0409] In some embodiments, when R5 is halogen and R4 is H, R3 is not methyl, methoxy, or Br and X is CR7R8 or S.

[0410] In some embodiments, R5 is halogen, R4 is H, X is CR7R8 or S, and R3 is H, F, Cl, I, -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), -NH2, C2-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0411] In some embodiments, when R5 is halogen and R4 is H, X is S and R3 is not methyl, methoxy, or Br.

[0412] In some embodiments, R5 is halogen, R4 is H, X is S, and R3 is H, F, Cl, I, -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), -NH2, C2-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0413] In some embodiments, when R5 is halogen and R4 is H, X is CR7R8 and R3 is not methyl, methoxy, or Br.

[0414] In some embodiments, R5 is halogen, R4 is H, X is CR7R8 and R3 is H, F, Cl, I, -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), -NH2, C2-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 alkoxy, C1-C6 haloalkoxy or C3-C6 cycloalkyl.

[0415] In some embodiments, when R5 is halogen and R4 is H, X is CH2 and R3 is not methyl, methoxy, or Br.

[0416] In some embodiments, R5 is halogen, R4 is H, X is CH2 and R3 is H, F, Cl, I, -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), -NH2, C2-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 alkoxy, C1-C6 haloalkoxy or C3-C6 cycloalkyl.

[0417] In some embodiments, when R5 is halogen and R4 is H, X is not O and R3 is not methyl, methoxy, or Br.

[0418] In some embodiments, R5 is halogen, R4 is H, X is not O, and R3 is H, F, Cl, I, -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), -NH2, C2-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0419] In some embodiments, R5 is halogen, R4 is H, X is CR7R8 or S, and R3 is H, F, or Cl.

[0420] In some embodiments, R5 is halogen, R4 is H, X is CR7R8, and R3 is H, F, or Cl.

[0421] In some embodiments, R5 is halogen, R4 is H, X is CH2, and R3 is H, F, or Cl.

[0422] In some embodiments, R5 is methoxy or methyl and R4 is not H.

[0423] In some embodiments, R5 is methoxy and R4 is not H.

[0424] In some embodiments, R5 is methyl and R4 is not H.

[0425] In some embodiments, R5 is methoxy or methyl and R4 is halogen, -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), -NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl.

[0426] In some embodiments, R5 is methoxy or methyl and R4 is F, Cl, methyl, or CHF2.

[0427] In some embodiments, R 10is H or halogen. In some embodiments, R 10 is H. In some embodiments, R 10 In some embodiments, R 10 is H, F, Cl or I. In some embodiments, R 10 is F, Cl or Br. In some embodiments, R 10 In some embodiments, R 10 is F. In some embodiments, R 10 In some embodiments, R 10 is Br. In some embodiments, R 10 For I.

[0428] In some embodiments, X is O and R9 is H.

[0429] In some embodiments, X is O, R9 is H, and R1 is C1-C6 alkyl.

[0430] In some embodiments, X is O, R9 is H, and R1 is methyl.

[0431] In some embodiments, X is O, R9 is H, R1 is methyl, and R2 is C1-C6 alkyl.

[0432] In some embodiments, X is O, R9 is H, R1 is methyl, and R2 is methyl.

[0433] In some embodiments, X is O, R9 is H, R1 is methyl, R2 is methyl, and R3 is H.

[0434] In some embodiments, X is O, R9 is H, R1 is methyl, R2 is methyl, and R3 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxy.

[0435] In some embodiments, X is O, R9 is H, R1 is methyl, R2 is methyl, and R3 is F, Cl, methyl, CHF2, or methoxy.

[0436] In some embodiments, X is O, R9 is H, R1 is methyl, R2 is methyl, and R4 is H.

[0437] In some embodiments, X is O, R9 is H, R1 is methyl, R2 is methyl, and R4 is halogen, C1-C6 alkyl, or C1-C6 haloalkyl.

[0438] In some embodiments, X is O, R9 is H, R1 is methyl, R2 is methyl, and R4 is F, Cl, methyl, or CHF2.

[0439] In some embodiments, X is O, R9 is H, R1 is methyl, R2 is methyl, and R5 is H.

[0440] In some embodiments, X is O, R9 is H, R1 is methyl, R2 is methyl, and R5 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or S(C1-C6 alkyl).

[0441] In some embodiments, X is O, R9 is H, R1 is methyl, R2 is methyl and R5 is F, Cl, methyl, ethyl, n-propyl, i-propyl, CHF2, methoxy or methylthio.

[0442] In some embodiments, X is O, R9 is H, R1 is methyl, R2 is methyl, and R6 is H.

[0443] In some embodiments, X is O, R9 is H, R1 is methyl, R2 is methyl, and R6 is C1-C6 alkyl or C1-C6 alkoxy.

[0444] In some embodiments, X is O, R9 is H, R1 is methyl, R2 is methyl, and R6 is methyl or methoxy.

[0445] In some embodiments, X is O, R9 is H, and R1 and R2, together with the atoms to which they are attached, form a C3-C6 saturated or unsaturated cycloalkyl.

[0446] In some embodiments, X is O, R9 is H, and R1 and R2, together with the atoms to which they are attached, form a C3-C6 saturated cycloalkyl.

[0447] In some embodiments, X is O, R9 is H, and R1 and R2, together with the atoms to which they are attached, form a cyclopropyl group.

[0448] In some embodiments, X is O, R9 is H, R1 and R2, together with the atoms to which they are attached, form a cyclopropyl group and R3 is H.

[0449] In some embodiments, X is O, R9 is H, R1 and R2 together with the atoms to which they are attached form a cyclopropyl group, and R4 is H.

[0450] In some embodiments, X is O, R9 is H, R1 and R2 together with the atoms to which they are attached form a cyclopropyl group and R4 is halogen or C1-C6 alkyl.

[0451] In some embodiments, X is O, R9 is HR1, and R2 together with the atoms to which they are attached form cyclopropyl and R4 is F, Cl or methyl.

[0452] In some embodiments, X is O, R9 is H, R1 and R2 together with the atoms to which they are attached form a cyclopropyl group, and R5 is H.

[0453] In some embodiments, X is O, R9 is H, R1 and R2 together with the atoms to which they are attached form a cyclopropyl group and R5 is halogen or C1-C6 alkyl.

[0454] In some embodiments, X is O, R9 is H, R1 and R2 together with the atoms to which they are attached form a cyclopropyl group and R5 is F, methyl or ethyl.

[0455] In some embodiments, X is CH2 and R9 is H.

[0456] In some embodiments, X is CH2, R9 is H, and R1 is methyl.

[0457] In some embodiments, X is CH2, R9 is H, R1 is methyl, and R2 is methyl.

[0458] In some embodiments, X is CH2, R9 is H, R1 is methyl, R2 is methyl, and R3 is H.

[0459] In some embodiments, X is CH2, R9 is H, R1 is methyl, R2 is methyl, and R4 is H.

[0460] In some embodiments, X is CH2, R9 is H, R1 is methyl, R2 is methyl, and R4 is halogen or C1-C6 alkyl.

[0461] In some embodiments, X is CH2, R9 is H, R1 is methyl, R2 is methyl, and R4 is Cl or methyl.

[0462] In some embodiments, X is CH2, R9 is H, R1 is methyl, R2 is methyl, and R5 is H.

[0463] In some embodiments, X is CH2, R9 is H, R1 is methyl, R2 is methyl, and R5 is halogen or C1-C6 alkyl.

[0464] In some embodiments, X is CH2, R9 is H, R1 is methyl, R2 is methyl, and R5 is F, Cl, or methyl.

[0465] In some embodiments, X is CH2, R9 is H, and R1 and R2, together with the atoms to which they are attached, form a C3-C6 saturated or unsaturated cycloalkyl.

[0466] In some embodiments, X is CH2, R9 is H, and R1 and R2, together with the atoms to which they are attached, form a C3-C6 saturated cycloalkyl.

[0467] In some embodiments, X is CH2, R9 is H, and R1 and R2, together with the atoms to which they are attached, form a cyclopropyl group.

[0468] In some embodiments, X is CH2, R9 is H, R1 and R2 together with the atoms to which they are attached form a cyclopropyl group and R3 is H.

[0469] In some embodiments, X is CH2, R9 is H, R1 and R2 together with the atoms to which they are attached form a cyclopropyl group and R4 is H.

[0470] In some embodiments, X is CH2, R9 is H, R1 and R2 together with the atoms to which they are attached form a cyclopropyl group and R4 is halogen or C1-C6 alkyl.

[0471] In some embodiments, X is CH2, R9 is H, R1 and R2 together with the atoms to which they are attached form a cyclopropyl group and R4 is Cl or methyl.

[0472] In some embodiments, X is CH2, R9 is H, R1 and R2, together with the atoms to which they are attached, form a cyclopropyl group, and R5 is H.

[0473] In some embodiments, X is CH2, R9 is H, R1 and R2 together with the atoms to which they are attached form a cyclopropyl group and R5 is a C1-C6 alkyl group.

[0474] In some embodiments, X is CH2, R9 is H, R1 and R2 together with the atoms to which they are attached form a cyclopropyl group and R5 is methyl.

[0475] In some embodiments, when R5 is H and X is O, R 10 It is a halogen.

[0476] In some embodiments, when R 10 When not H, X is O. In some embodiments, when R 10 When it is a halogen, X is O.

[0477] In some embodiments, the compound of formula (I) is a compound of formula (Ia):

[0478]

[0479] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein R3, R4, R5 and R6 are as described herein for formula (I).

[0480] In some embodiments, the compound of formula (I) is a compound of formula (Ib):

[0481]

[0482] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein R3, R4, R5 and R6 are as described herein for formula (I).

[0483] In some embodiments, the compound of formula (II) is a compound of formula (IIa):

[0484]

[0485] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R1, R2, R4, R5 and R9 are as described herein for formula (II).

[0486] In some embodiments, the compound of formula (II) is a compound of formula (IIa-1):

[0487]

[0488] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R4 and R5 are as described herein for formula (II).

[0489] In some embodiments, the compound of formula (II) is a compound of formula (IIa-2):

[0490]

[0491] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R4 and R5 are as described herein for formula (II).

[0492] In some embodiments, the compound of formula (II) is a compound of formula (IIb):

[0493]

[0494] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R5 and R9 are as described herein for formula (II).

[0495] In some embodiments, the compound of formula (II) is a compound of formula (IIb-1):

[0496]

[0497] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R3 and R5 are as described herein for formula (II).

[0498] In some embodiments, the compound of formula (II) is a compound of formula (IIb-2):

[0499]

[0500] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R3 and R5 are as described herein for formula (II).

[0501] In some embodiments, the compound of formula (II) is a compound of formula (IIc):

[0502]

[0503] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R6 and R9 are as described herein for formula (II).

[0504] In some embodiments, the compound of formula (II) is a compound of formula (IIc-1):

[0505]

[0506] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R3 and R6 are as described herein for formula (II).

[0507] In some embodiments, the compound of formula (II) is a compound of formula (IIc-2):

[0508]

[0509] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R3 and R6 are as described herein for formula (II).

[0510] In some embodiments, the compound of formula (II') is a compound of formula (II'a):

[0511]

[0512] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R1, R2, R9 and R 10 As described herein for Formula (II').

[0513] It should be understood that for any compound of the formula described herein, X, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R 10 Where applicable, each may be selected from the groups described herein, and any of X, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R 10 Any of the groups described may, where applicable, be combined with any of the groups described herein for X, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R 10 The remainder is any combination of one or more of the aforementioned groups.

[0514] In some embodiments, the compound is selected from the compounds described in 1 or 2 and their prodrugs and pharmaceutically acceptable salts.

[0515] In some embodiments, the compound is selected from the compounds described in 1 or 2 and pharmaceutically acceptable salts thereof.

[0516] In some embodiments, the compound is selected from a prodrug of the compound described in 1 or 2 and a pharmaceutically acceptable salt thereof.

[0517] In some embodiments, the compound is selected from the compounds described in 1 or 2.

[0518] Table 1

[0519]

[0520]

[0521]

[0522] Table 2

[0523]

[0524]

[0525]

[0526]

[0527]

[0528]

[0529]

[0530]

[0531]

[0532]

[0533] In some aspects, the present disclosure provides compounds that are isotopic derivatives (eg, isotopically labeled compounds) of any one of the compounds of the formulae disclosed herein.

[0534] In some embodiments, the compound from Table 1 or 2 has Formula (I).

[0535] In some embodiments, the compound from Table 1 or 2 has Formula (II).

[0536] In some embodiments, the compound from Table 1 or 2 has Formula (II').

[0537] In some embodiments, the compound is compound 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 33, 36, 37, 38, or 39, or a pharmaceutically acceptable salt thereof.

[0538] In some embodiments, the compound is compound 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 33, 36, 37, or 38, or a pharmaceutically acceptable salt thereof.

[0539] In some embodiments, the compound is compound 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 33, or 36, or a pharmaceutically acceptable salt thereof.

[0540] In some embodiments, the compound is compound 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, or 33, or a pharmaceutically acceptable salt thereof.

[0541] In some embodiments, the compound is Compound 7, 8, 15, or 17, or a pharmaceutically acceptable salt thereof.

[0542] In some embodiments, the compound is Compound 7, 8, or 17, or a pharmaceutically acceptable salt thereof.

[0543] In some embodiments, the compound is Compound 7 or a pharmaceutically acceptable salt thereof.

[0544] In some embodiments, the compound is Compound 8 or a pharmaceutically acceptable salt thereof.

[0545] In some embodiments, the compound is Compound 15 or a pharmaceutically acceptable salt thereof.

[0546] In some embodiments, the compound is Compound 17 or a pharmaceutically acceptable salt thereof.

[0547] In some embodiments, the compound is compound 30, 31, 4, or 35, or a pharmaceutically acceptable salt thereof.

[0548] In some embodiments, the compound is Compound 30 or a pharmaceutically acceptable salt thereof.

[0549] In some embodiments, the compound is Compound 31 or a pharmaceutically acceptable salt thereof.

[0550] In some embodiments, the compound is Compound 34 or a pharmaceutically acceptable salt thereof.

[0551] In some embodiments, the compound is Compound 35 or a pharmaceutically acceptable salt thereof.

[0552] In some embodiments, the compound is Compound 36 or a pharmaceutically acceptable salt thereof.

[0553] In some embodiments, the compound is an isotopic derivative of any one of the compounds shown in Table 1 or 2, and prodrugs and pharmaceutically acceptable salts thereof.

[0554] In some embodiments, the compound is an isotopic derivative of any one of the compounds shown in Table 1 or 2 and a pharmaceutically acceptable salt thereof.

[0555] In some embodiments, the compound is an isotopic derivative of any one of the prodrugs of the compounds shown in Table 1 or 2, and pharmaceutically acceptable salts thereof.

[0556] In some embodiments, the compound is an isotopic derivative of any one of the compounds shown in Table 1 or 2.

[0557] It will be appreciated that isotopic derivatives can be prepared using any of a variety of art-recognized techniques. For example, isotopic derivatives can generally be prepared by carrying out the methods disclosed in the schemes and / or examples described herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

[0558] In some embodiments, the isotopic derivative is a deuterium-labeled compound. In some embodiments, the compound is 18 In some embodiments, the compound is 123 I-labeled compounds, 124 I-labeled compounds, 125 I-labeled compounds, 129 I-labeled compounds, 131 I-labeled compounds, 135 I-labeled compound or any combination thereof. In some embodiments, the compound is33 S-labeled compounds, 34 S-labeled compounds, 35 S-labeled compounds, 36 S-labeled compound or any combination thereof.

[0559] It should be understood that 18 F. 123 I. 124 I. 125 I. 129 I. 131 I. 135 I. 3 S. 34 S. 35 S and / or 36 S-labeled compounds can be prepared using any of a variety of art-recognized techniques. For example, deuterium-labeled compounds can typically be prepared using 18 F. 123 I. 124 I. 125 I. 129 I. 131 I. 135 I. 3 S. 34 S. 35 S and / or 36 S-labeled reagents are prepared by carrying out the procedures disclosed in the Schemes and / or Examples described herein, in place of non-isotopically labeled reagents.

[0560] Containing the above 18 F. 123 I. 124 I. 125 I. 129 I. 131 I. 135 I. 3 S. 34 S. 35 S and 36 The compounds of the present invention or pharmaceutically acceptable salts or solvates thereof containing one or more of the following: S atoms are within the scope of the present invention. 18 F. 123 I. 124 I. 125 I. 129 I. 131 I. 135 I. 3 S. 34 S. 35 S and / or 36 S) substitutions may offer certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements.

[0561] For the avoidance of doubt, it should be understood that in this specification, when a group is defined by "described herein," that group includes the first and broadest definition as well as each and all specific definitions for that group.

[0562] The various functional groups and substituents comprising the compounds of formula (I), (II) and (II') are typically selected so that the molecular weight of the compound does not exceed 1000 Daltons. More typically, the molecular weight of the compound will be less than 900, for example less than 800, or less than 750, or less than 700, or less than 650 Daltons. More conveniently, the molecular weight is less than 600, and for example is 550 Daltons or less.

[0563] It is to be understood that the compounds of any formula disclosed herein and any pharmaceutically acceptable salts thereof include stereoisomers, mixtures of stereoisomers, polymorphs of all isomeric forms of the compounds.

[0564] The present disclosure also encompasses compounds of the present disclosure as defined herein, containing one or more isotopic substitutions.

[0565] It is to be understood that references to compounds of any formula herein include the compounds themselves, as well as their salts and their solvates, if applicable.

[0566] The in vivo effects of the compounds of any of the general formulas disclosed herein can be exerted in part by one or more metabolites formed in the human or animal body after administration of the compounds of any of the general formulas disclosed herein. As described above, the in vivo effects of the compounds of any of the general formulas disclosed herein can also be exerted by the metabolism of precursor compounds (prodrugs).

[0567] Suitably, the present disclosure excludes any individual compound that does not possess biological activity as defined herein.

[0568] Synthesis method

[0569] In some aspects, the present disclosure provides methods of preparing the compounds of the present disclosure.

[0570] In some aspects, the present disclosure provides methods of preparing a compound, comprising one or more steps as described herein.

[0571] In some aspects, the present disclosure provides compounds obtainable by or obtained by, or directly obtained by, a method for preparing a compound as described herein.

[0572] In some aspects, the present disclosure provides intermediates as described herein, which are useful in preparing compounds as described herein.

[0573] The compounds of the present disclosure can be prepared by any suitable technique known in the art. Specific methods for preparing these compounds are further described in the accompanying examples.

[0574] In the descriptions of synthetic methods described herein and in any referenced synthetic methods for the preparation of starting materials, it is understood that all proposed reaction conditions, including the choice of solvents, reaction atmospheres, reaction temperatures, duration of experiments, and work-up methods, can be selected by one skilled in the art.

[0575] Those skilled in the art of organic synthesis understand that the functional groups present on the various portions of the molecule must be compatible with the reagents and reaction conditions employed.

[0576] Should be understood that during the synthesis of this disclosed compound in the method defined herein, or during the synthesis of some starting material, it may be necessary to protect some substituents to prevent its undesirable reaction. A skilled chemist will understand when this protection is needed, and how this blocking group is placed in position and removed subsequently. About the example of blocking group, referring to one of many general textbooks about this theme, for example " Protective Groups in Organic Synthesis ", Theodora Green (publisher: John Wiley & Sons). Blocking group can be removed by any method convenient for describing in the document or for skilled chemist known to be suitable for removing the blocking group in question, selects such method to realize the removal of blocking group in the case of minimum interference of other groups in molecule. Therefore, if reactant comprises the group of for example amino, carboxyl or hydroxyl, it may be necessary to protect this group in some reactions mentioned herein.

[0577] As an example, the suitable protecting group of amino or alkylamino is acyl group for example, for example alkanoyl is such as acetyl, alkoxycarbonyl is such as methoxycarbonyl, ethoxycarbonyl or tert-butoxycarbonyl, arylmethoxycarbonyl is such as benzyloxycarbonyl, or aroyl is such as benzoyl.The deprotection condition of above-mentioned protecting group must change with the selection of protecting group.Therefore, for example, acyl group such as alkanoyl or alkoxycarbonyl or aroyl can be removed by for example using suitable alkali such as alkali metal hydroxide such as lithium hydroxide or sodium hydroxide hydrolysis.Or, acyl group such as tert-butoxycarbonyl can be removed by for example using suitable acid such as hydrochloric acid, sulfuric acid or phosphoric acid or trifluoroacetic acid treatment, and arylmethoxycarbonyl such as benzyloxycarbonyl can be removed by for example using catalyzer such as palladium / carbon hydrogenation or by using Lewis acid such as tri(trifluoroacetic acid) boron treatment.The suitable alternative protecting group of primary amino is for example phthaloyl, and it can be removed by using alkylamine such as dimethylaminopropylamine or with hydrazine treatment.

[0578] Suitable protecting groups for hydroxyl groups are, for example, acyl groups, for example, alkanoyl groups such as acetyl groups, aroyl groups such as benzoyl groups, or arylmethyl groups such as benzyl groups. The deprotection conditions for the above-mentioned protecting groups must vary with the choice of protecting group. Thus, for example, acyl groups such as alkanoyl groups or aroyl groups can be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide such as lithium hydroxide, sodium hydroxide or ammonia. Alternatively, arylmethyl groups such as benzyl groups can be removed, for example, by hydrogenation with a catalyst such as palladium / carbon.

[0579] A suitable protecting group for a carboxyl group is, for example, an esterifying group, such as a methyl or ethyl group, which can be removed, for example, by hydrolysis with a base such as sodium hydroxide, or such as a tert-butyl group, which can be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or such as a benzyl group, which can be removed, for example, by hydrogenation over a catalyst such as palladium on carbon.

[0580] Once a compound of formula (I), (II) or (II') has been synthesized by any of the methods defined herein, the method may further comprise the following additional steps: (i) removing any protecting groups present; (ii) converting the compound of formula (I), (II) or (II') into another compound of formula (I), (II) or (II'); (iii) forming a pharmaceutically acceptable salt, hydrate or solvate thereof; and / or (iv) forming a prodrug thereof.

[0581] The resulting compounds of formula (I), (II) and (II') can be isolated and purified using techniques well known in the art.

[0582] Conveniently, the reaction of the compound is carried out in the presence of a suitable solvent, which is preferably inert under the corresponding reaction conditions. Examples of suitable solvents include, but are not limited to, hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichloroethylene, 1,2-dichloroethane, tetrachloromethane, chloroform or dichloromethane; alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF), 2-methyltetrahydrofuran, cyclopentyl methyl ether (CPME), methyl tert-butyl ether (MTBE) or dioxane; glycol ethers such as ethyl ether, diisopropyl ether, tetrahydrofuran (THF), 2-methyltetrahydrofuran, cyclopentyl methyl ether (CPME), methyl tert-butyl ether (MTBE) or dioxane. Glycol monomethyl or monoethyl ether or ethylene glycol dimethyl ether (diglyme); ketones such as acetone, methyl isobutyl ketone (MIBK) or butanone; amides such as acetamide, dimethylacetamide, dimethylformamide (DMF) or N-methylpyrrolidone (NMP); nitriles such as acetonitrile; sulfoxides such as dimethyl sulfoxide (DMSO); nitro compounds such as nitromethane or nitrobenzene; esters such as ethyl acetate or methyl acetate, or mixtures of the aforementioned solvents or mixtures with water.

[0583] In addition, by utilizing the methods described herein, combined with ordinary skills in the art, additional compounds of the present disclosure can be easily prepared. Those skilled in the art will readily understand that known variations of the conditions and methods of the following preparative procedures can be used to prepare these compounds.

[0584] As will be understood by those skilled in the art of organic synthesis, the compounds of the present disclosure can be easily obtained by various synthetic routes, some of which are exemplified in the accompanying examples. Those skilled in the art will readily recognize which reagents and reaction conditions to use and how to apply and adjust them in any particular case (wherever necessary or useful) to obtain compounds of the present disclosure. In addition, some compounds of the present disclosure can be easily synthesized by reacting other compounds of the present disclosure under suitable conditions, for example, by converting a specific functional group present in a compound of the present disclosure or its suitable precursor molecule into another functional group by applying standard synthetic methods (such as reduction, oxidation, addition or substitution reactions); those methods are well known to those skilled in the art. Similarly, those skilled in the art will apply synthetic protection (or protective) groups when necessary or useful; suitable protecting groups and methods for introducing and removing them are well known to those skilled in the art of chemical synthesis and are described in more detail in, for example, PGM Wuts, TW Greene, "Greene's Protective Groups in Organic Synthesis", 4th edition (2006) (John Wiley & Sons).

[0585] In some embodiments, compounds of the present disclosure are prepared as described in Schemes 1, 2, or 3.

[0586] In some embodiments, compounds of the present disclosure are prepared as described in Scheme 1.

[0587] In some embodiments, compounds of the present disclosure are prepared as described in Scheme 2.

[0588] In some embodiments, compounds of the present disclosure are prepared as described in Scheme 3.

[0589] Solution 1

[0590]

[0591] Scheme 1 describes the preparation of methyl 2,2-dimethyl-3-(piperazin-1-yl)propanoate (4), which can be coupled to intermediate 9 in Schemes 2 and 3 to form compound 10 via displacement of the chloride.

[0592] Option 2

[0593]

[0594] Option 3

[0595]

[0596] Schemes 2 and 3 describe synthetic routes for preparing the dual H1 / 5HT2a antagonists exemplified herein. Intermediates 5 and 6 described in Scheme 2 can be readily prepared by one skilled in the art using literature methods. Intermediates 11 and 12 described in Scheme 3 can be readily prepared by one skilled in the art using literature methods.

[0597] Biological assays

[0598] Once the compounds designed, selected and / or optimized by the above methods are generated, they can be characterized using a variety of assays known to those skilled in the art to determine whether the compounds have biological activity. For example, molecules can be characterized by conventional assays, including but not limited to those described below, to determine whether they have the predicted activity, binding activity and / or binding specificity.

[0599] In addition, high throughput screening can be used to accelerate the analysis using such assays. Therefore, the activity of the molecules described herein can be rapidly screened using techniques known in the art. The general method for performing high throughput screening is described in, for example, Devlin (1998) High Throughput Screening, Marcel Dekker, and U.S. Patent No. 5,763,263. High throughput assays can use one or more different assay techniques, including but not limited to those described below.

[0600] Various in vitro or in vivo biological assays may be suitable for detecting the effects of the compounds of the present disclosure. These in vitro or in vivo biological assays may include, but are not limited to, enzyme activity assays, electrophoretic mobility shift assays, reporter gene assays, in vitro cell viability assays, and assays described herein.

[0601] The biological activity of the compounds of the present disclosure can be determined using binding assays. Binding assays can be performed for H1 and 5-HT 2A ,5-HT 2C or D2.

[0602] The biological activity of the compounds of the present disclosure can be determined using binding assays. Binding assays can be performed for H1 and 5-HT 2A ,5-HT 2C or D2.

[0603] The biological activity of the compounds of the present disclosure can be determined using binding assays. Binding assays can be used to determine the activity of H1 and 5-HT 2AThe biological activity of the compounds of the present disclosure can be determined using binding assays. The binding assays can be directed against H1. The biological activity of the compounds of the present disclosure can be determined using binding assays. The binding assays can be directed against 5-HT 2A Binding assays can be directed against D2.

[0604] The compounds of the present disclosure can be assayed in comparison to a reference standard (e.g., ketanserin or pyrilamine). The compounds of the present disclosure can be transferred to an assay plate for nonspecific binding or total binding. The assay plate can be sealed and shaken. After the assay is complete, the reaction mixture can be filtered and washed with buffer. The filter plate can be dried and sealed. The inhibition constant can be calculated using the following equation:

[0605]

[0606] And analyze the data. IC can be calculated 50 And converted into K i .

[0607] The biological activity of the compounds of the present disclosure can be determined using binding assays. Binding assays can be performed for 5-HT 2C The compounds of the present disclosure can be assayed in comparison with a reference standard such as SB-206553 (i.e., 5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-b]indole hydrochloride hydrate). The compounds of the present disclosure can be transferred to an assay plate for nonspecific binding or total binding. The assay plate can be sealed and shaken. After the assay is complete, the reaction mixture can be filtered and washed with buffer. The filter plate can be dried and sealed. The inhibition constant can be calculated using the following equation:

[0608]

[0609] And analyze the data. IC can be calculated 50 And converted into K i .

[0610] The biological activity of the compounds of the present invention can be determined using a binding assay. The binding assay can be directed to D2. The compounds of the present invention can be measured by comparison with a reference standard such as droperidol (i.e., 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one). The compounds of the present invention can be transferred to an assay plate for nonspecific binding or total binding. The assay plate can be sealed and shaken. After the assay is complete, the reaction mixture can be filtered and washed with buffer. The filter plate can be dried and sealed. The inhibition constant can be calculated using the following equation:

[0611]

[0612] And analyze the data. IC can be calculated 50 And converted into K i .

[0613] In some embodiments, the compounds of the present disclosure selectively target H1 / 5-HT2 A In some embodiments, the compounds of the present disclosure do not selectively target 5-HT2 C In some embodiments, the compounds of the present disclosure interact with 5-HT2 C Targets H1 / 5-HT2 to a greater extent than A (For example, when combined with 5-HT2 C When compared, the compound targets H1 / 5-HT2 at a percentage greater than about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, or about 99%. A ).

[0614] In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i The values ​​are about 1 nM to about 5 nM.

[0615] In some embodiments, 5-HT2 A Ki In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i In some embodiments, 5-HT2 A K i The value is approximately 1 nM.

[0616] In some embodiments, the K of H1 i In some embodiments, the K value of H1 is about 1 nM to about 150 nM.i In some embodiments, the K value of H1 is about 1 nM to about 125 nM. i In some embodiments, the K value of H1 is about 1 nM to about 100 nM. i In some embodiments, the K value of H1 is about 1 nM to about 75 nM. i In some embodiments, the K value of H1 is about 1 nM to about 50 nM. i In some embodiments, the K value of H1 is about 1 nM to about 40 nM. i In some embodiments, the K value of H1 is about 1 nM to about 30 nM. i In some embodiments, the K value of H1 is about 1 nM to about 20 nM. i In some embodiments, the K value of H1 is about 1 nM to about 10 nM. i The values ​​are about 1 nM to about 5 nM.

[0617] In some embodiments, the K of H1 i In some embodiments, the K value of H1 is about 150 nM. i In some embodiments, the K value of H1 is about 125 nM. i In some embodiments, the K value of H1 is about 100 nM. i In some embodiments, the K value of H1 is about 90 nM. i In some embodiments, the K value of H1 is about 80 nM. i In some embodiments, the K value of H1 is about 70 nM. i In some embodiments, the K value of H1 is about 60 nM. i In some embodiments, the K value of H1 is about 50 nM. i In some embodiments, the K value of H1 is about 40 nM. i In some embodiments, the K value of H1 is about 30 nM. i In some embodiments, the K value of H1 is about 20 nM. i In some embodiments, the K value of H1 is about 15 nM. i The value is approximately 10 nM.

[0618] In some embodiments, 5-HT2 C K i In some embodiments, 5-HT2 C K i In some embodiments, 5-HT2 C K iIn some embodiments, 5-HT2 C K i In some embodiments, 5-HT2 C K i In some embodiments, 5-HT2 C K i In some embodiments, 5-HT2 C K i In some embodiments, 5-HT2 C K i In some embodiments, 5-HT2 C K i In some embodiments, 5-HT2 C K i In some embodiments, 5-HT2 C K i In some embodiments, 5-HT2 C K i In some embodiments, 5-HT2 C K i The value is approximately 10 μM.

[0619] In some embodiments, the compounds of the present disclosure have an effect on 5-HT2 C Has low affinity (e.g., Ki value greater than about 100 nM, about 200 nM, about 500 nM, about 750 nM, about 1,000 nM, about 1,500 nM, or about 2,000 nM). In some embodiments, Compound No. 7 has a low affinity for 5-HT2 C It has low affinity (eg, Ki value of approximately 2,200 nM).

[0620] In some embodiments, the compounds of the present disclosure have an effect on 5-HT2 A In some embodiments, compound No. 8 has an affinity for 5-HT2 A Has affinity (eg, Ki value of about 87 nM).

[0621] In some embodiments, the K of D2 is i In some embodiments, the K value of D2 is greater than about 100 nM. i In some embodiments, the K value of D2 is greater than about 500 nM. iIn some embodiments, the K value of D2 is greater than about 1,000 nM. i In some embodiments, the K value of D2 is greater than about 10,000 nM. i In some embodiments, the K value of D2 is greater than about 25,000 nM. i The values ​​were greater than about 50,000 nM.

[0622] In some embodiments, the compounds of the present disclosure have low affinity for D2 (e.g., Ki values ​​greater than about 100 nM, about 200 nM, about 500 nM, about 750 nM, about 1,000 nM, about 1,500 nM, about 2,000 nM, about 10,000 nM, about 25,000 nM, or about 50,000 nM). In some embodiments, compound No. 7 has low affinity for D2 (e.g., a Ki value greater than about 50,000 nM).

[0623] Without wishing to be bound by theory, non-selective 5-HT2 modulators (e.g., targeting 5-HT 2A and 5-HT 2C Both) do not relieve the symptoms of, treat, or prevent sleep disorders.

[0624] Furthermore, without wishing to be bound by theory, regulation of 5-HT 2C The function is not intended to relieve the symptoms of, treat, or prevent sleep disorders.

[0625] The biological activity of the disclosed compounds can be determined using projected human clearance (CL) and half-life in humans. Clearance is estimated using the allometric scaling method of individual species scaled by monkey clearance. d Estimated human volume of distribution (V d ), adjusting for differences in plasma protein binding and assuming interspecies unbound V d Similar. Use T 1 / 2 =0.693×(estimated V d / estimated CL), and the human half-life (T 1 / 2 ).

[0626] In some embodiments, the estimated human half-life (t 1 / 2) is about 10 hours to about 1 hour. In some embodiments, the estimated human half-life is about 10 hours. In some embodiments, the estimated human half-life is about 9 hours. In some embodiments, the estimated human half-life is about 8 hours. In some embodiments, the estimated human half-life is about 7 hours. In some embodiments, the estimated human half-life is about 6 hours. In some embodiments, the estimated human half-life is about 5 hours. In some embodiments, the estimated human half-life is about 4 hours. In some embodiments, the estimated human half-life is about 3 hours. In some embodiments, the estimated human half-life is about 2 hours. In some embodiments, the estimated human half-life is about 1 hour.

[0627] Patch clamp electrophysiology systems, such as the SyncroPatch 384PE (Nanion), can be used to obtain data related to ionic currents in individual isolated cells.

[0628] SCORE, a microcomputer-based sleep-wake and physiological monitoring system TM SCORE has been previously described in rodents and can be applied to determine sleep and wakefulness. TM Validation of a sleep stage identification algorithm and its utility in preclinical drug evaluation (Van Gelder et al. 1991; Edgar et al., Psychopharmacology, 1991, 105:374-380; Edgar et al., J Pharmacology & Experimental Therapeutics, 1997, 283:757-769; Edgar et al., J. Pharmacol. Exp. Ther, 1997, 282:420-429; Seidel et al., J Pharmacology & Experimental Therapeutics, 1995, 275:263-273; Olive et al., J Pharmacology & Experimental Therapeutics, 1998, 285:1073-1083).

[0629] The standard recording duration for SCORE data should be no less than 30 hours before and after treatment. The 30-hour pre-treatment baseline recording itself should be at least 24 hours, with the animal undisturbed in its home / recording cage. Rats can be randomly assigned to treatments in parallel groups. Some rats may receive more than one active treatment, in which case a "washout" of at least 7 days will elapse between each treatment.

[0630] Subjects can be surgically prepared for EEG and EMG recordings, and analgesics and antibiotics can be administered, followed by treatment delivery via intraperitoneal or oral administration. TM to determine sleep and wakefulness.

[0631] Statistically significant differences between drug and vehicle can be screened using post hoc Student's T-test applied to hourly binned data and adjusted for repeated measures.

[0632] Compounds of the present disclosure may exhibit improved sleep fragmentation as assessed by evaluating sleep architecture and sleep quality endpoints of several dual-acting H1 inverse agonist and 5-HT2A antagonist compounds with defined affinity and functional activity at this target.

[0633] In some embodiments, sleep fragmentation is improved by (i) reducing the number of awakenings (as measured by the number of transitions to awakenings per hour), or (ii) increasing sleep consolidation (as measured by the average sleep bout duration per hour). In some embodiments, sleep fragmentation is improved by (i) reducing the number of awakenings (as measured by the number of transitions to awakenings per hour) and (ii) increasing sleep consolidation (as measured by the average sleep bout duration per hour). In some embodiments, sleep fragmentation is improved by reducing the number of awakenings (as measured by the number of transitions to awakenings per hour). In some embodiments, sleep fragmentation is improved by increasing sleep consolidation (as measured by the average sleep bout duration per hour).

[0634] Evaluation of the sleep architecture and sleep quality endpoints of the disclosed compounds as dual-acting H1 inverse agonists and 5-HT 2A The effectiveness of antagonist molecules in improving sleep fragmentation.

[0635] H1 and 5-HT of the compounds disclosed herein 2A Binding activity can be assessed by utilizing the assays disclosed herein. In some embodiments, the H1 and 5-HT binding activity of the compounds disclosed herein are assessed by utilizing the assays disclosed herein. 2A The binding activity is compared with another compound.

[0636] In some embodiments, the comparative compound can be assayed in comparison to a reference standard (e.g., ketanserin or pyrilamine). The comparative compound can be transferred to an assay plate for nonspecific binding or total binding. The assay plate can be sealed and shaken. After the assay is complete, the reaction mixture can be filtered and washed with buffer. The filter plate can be dried and sealed. The inhibition constant can be calculated using the following equation:

[0637]

[0638] And analyze the data. IC can be calculated 50 and converted to K i .

[0639] The 5-HT of the compounds disclosed herein 2C Binding activity can be assessed by utilizing the assays disclosed herein. In some embodiments, the 5-HT binding activity of the compounds disclosed herein is assessed by utilizing the assays disclosed herein. 2C The binding activity is compared with another compound.

[0640] The biological activity of the compounds used for comparison can be determined using binding assays. Binding assays can be used to determine the biological activity of the compounds used for comparison. 2C The compounds for comparison can be measured by comparison with a reference standard such as SB-206553 (i.e., 5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole hydrochloride hydrate). The compounds for comparison can be transferred to an assay plate for nonspecific binding or total binding. The assay plate can be sealed and shaken. After the assay is complete, the reaction mixture can be filtered and washed with buffer. The filter plate can be dried and sealed. The inhibition constant can be calculated using the following equation:

[0641]

[0642] And analyze the data. IC can be calculated 50 and converted to K i .

[0643] The D2 binding activity of the compounds of the present disclosure can be assessed by utilizing the assays of the present disclosure. In some embodiments, the D2 binding activity of the compounds of the present disclosure is compared to another compound.

[0644] The biological activity of the compound for comparison can be determined using a binding assay. The binding assay can be directed to D2. The compound for comparison can be measured by comparing with a reference standard such as droperidol (i.e., 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one). The compound for comparison can be transferred to an assay plate for nonspecific binding or total binding. The assay plate can be sealed and shaken. After the assay is complete, the reaction mixture can be filtered and washed with buffer. The filter plate can be dried and sealed. The inhibition constant can be calculated using the following equation:

[0645]

[0646] And analyze the data. IC can be calculated 50 and converted to K i .

[0647] Pharmaceutical composition

[0648] In some aspects, the present disclosure provides pharmaceutical compositions comprising a compound of the present disclosure as an active ingredient. In some embodiments, the present disclosure provides pharmaceutical compositions comprising at least one compound of each of the general formulas described herein, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable carriers or excipients. In some embodiments, the present disclosure provides pharmaceutical compositions comprising at least one compound selected from Table 1.

[0649] As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

[0650] The compounds of the present disclosure can be formulated into forms for oral administration, such as tablets, capsules (each of which includes sustained-release or timed-release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. The compounds of the present disclosure can also be formulated for intravenous (bolus or infusion), intraperitoneal, topical, subcutaneous, intramuscular, or transdermal (e.g., patch) administration, all using forms well known to those of ordinary skill in the pharmaceutical arts.

[0651] The formulations of the present disclosure may be in the form of an aqueous solution comprising an aqueous carrier. The aqueous carrier component may comprise water and at least one pharmaceutically acceptable excipient. Suitable acceptable excipients include those selected from solubility enhancers, chelating agents, preservatives, tonicity agents, viscosity / suspending agents, buffers, and pH regulators, and mixtures thereof.

[0652] Any suitable solubility enhancer can be used. Examples of solubilizing agents include cyclodextrins, for example, selected from hydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin, random methylated-β-cyclodextrin, ethylated-β-cyclodextrin, triacetyl-β-cyclodextrin, peracetylated-β-cyclodextrin, carboxymethyl-β-cyclodextrin, hydroxyethyl-β-cyclodextrin, 2-hydroxy-3-(trimethylammonium)propyl-β-cyclodextrin, glucosyl-β-cyclodextrin, sulfated β-cyclodextrin (S-β-CD), maltosyl-β-cyclodextrin, β-cyclodextrin sulfobutyl ether, branched-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, random methylated-γ-cyclodextrin and trimethyl-γ-cyclodextrin, and mixtures thereof.

[0653] Any suitable chelating agent may be used. Examples of suitable chelating agents include those selected from ethylenediaminetetraacetic acid and its metal salts, disodium ethylenediaminetetraacetate, trisodium ethylenediaminetetraacetate and tetrasodium ethylenediaminetetraacetate and mixtures thereof.

[0654] Any suitable preservative may be used. Examples of preservatives include those selected from the group consisting of quaternary ammonium salts such as benzalkonium halides (preferably benzalkonium chloride), chlorhexidine gluconate, benzethonium chloride, cetylpyridinium chloride, benzyl bromide, phenylmercuric nitrate, phenylmercuric acetate, phenylmercuric neodecanoate, thimerosal, methylparaben, propylparaben, sorbic acid, potassium sorbate, sodium benzoate, sodium propionate, ethylparaben, propylaminopropyl biguanide, and butylparaben, and sorbic acid, and mixtures thereof.

[0655] The aqueous vehicle may also include a tonicity agent to adjust the tonicity (osmotic pressure). The tonicity agent may be selected from glycols (eg, propylene glycol, diethylene glycol, triethylene glycol), glycerol, dextrose, glycerol, mannitol, potassium chloride, sodium chloride, and mixtures thereof.

[0656] The aqueous vehicle may also contain a viscosity / suspending agent. Suitable viscosity / suspending agents include those selected from cellulose derivatives such as methylcellulose, ethylcellulose, hydroxyethylcellulose, polyethylene glycols (e.g., Macrogol 300, Macrogol 400), carboxymethylcellulose, hydroxypropylmethylcellulose, and cross-linked acrylic acid polymers (carbomers), such as acrylic acid polymers cross-linked with polyalkenyl ethers or divinyl glycol (Carbopols—e.g., Carbopol 934, Carbopol 934P, Carbopol 971, Carbopol 974, and Carbopol 974P), and mixtures thereof.

[0657] In order to adjust the formulation to an acceptable pH (typically, a pH range of about 5.0 to about 9.0, more preferably about 5.5 to about 8.5, in particular about 6.0 to about 8.5, about 7.0 to about 8.5, about 7.2 to about 7.7, about 7.1 to about 7.9, or about 7.5 to about 8.0), the formulation may contain a pH adjuster. The pH adjuster is typically an inorganic acid or a metal hydroxide base selected from potassium hydroxide, sodium hydroxide, and hydrochloric acid, and mixtures thereof, preferably sodium hydroxide and / or hydrochloric acid. These acidic and / or alkaline pH adjusters are added to adjust the formulation to the target acceptable pH range. Therefore, it may not be necessary to use both an acid and a base simultaneously - depending on the formulation, adding one of the acid or base may be sufficient to bring the mixture to the desired pH range.

[0658] The aqueous vehicle may also contain a buffer to stabilize the pH. When used, the buffer is selected from phosphate buffers (e.g., sodium dihydrogen phosphate and disodium hydrogen phosphate), borate buffers (e.g., boric acid or salts thereof, including disodium tetraborate), citrate buffers (e.g., citric acid or salts thereof, including sodium citrate), and ε-aminocaproic acid, and mixtures thereof.

[0659] The formulation may further comprise a wetting agent. Suitable classes of wetting agents include those selected from the group consisting of polyoxypropylene-polyoxyethylene block copolymers (poloxamers), polyethoxylated ethers of castor oil, polyoxyethylated sorbitan esters (polysorbates), polymers of oxyethylated octylphenol (Tyloxapol), polyoxyethylene (polyoxyl) 40 stearate, fatty acid glycol esters, fatty acid glycerides, sucrose fatty acid esters, and polyoxyethylene fatty acid esters, and mixtures thereof.

[0660] According to a further aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound of the present disclosure as defined above, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in association with a pharmaceutically acceptable diluent or carrier.

[0661] The compositions of the present disclosure can be in a form suitable for oral use (e.g., as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), in a form suitable for topical use (e.g., as creams, ointments, gels or aqueous or oily solutions or suspensions), in a form suitable for administration by inhalation (e.g., as finely divided powders or liquid aerosols), in a form suitable for administration by insufflation (e.g., as finely divided powders), or in a form suitable for parenteral administration (e.g., as sterile aqueous or oily solutions for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular administration or as suppositories for rectal administration).

[0662] The compositions of the present disclosure can be obtained by conventional procedures using conventional pharmaceutical excipients well known in the art. Thus, compositions for oral use may contain, for example, one or more coloring agents, sweeteners, flavoring agents and / or preservatives.

[0663] An effective amount of a compound of the present disclosure for use in therapy is an amount sufficient to treat or prevent the sleep disorder-related conditions mentioned herein, slow the progression of the same, and / or alleviate the symptoms associated with the conditions.

[0664] An effective amount of a compound of the present disclosure for use in therapy is an amount sufficient to treat the sleep disorder-related conditions mentioned herein, slow the progression thereof, and / or alleviate the symptoms associated with the conditions.

[0665] According to well-known medical principles, the dosage of the compounds of formula (I), (II) and (II') for therapeutic or preventive purposes will naturally vary depending on the nature and severity of the disease, the age and sex of the animal or subject, and the route of administration.

[0666] How to use

[0667] Sleep fragmentation, a human disorder characterized by poor sleep consolidation, includes frequent brief awakenings or micro-awakenings (defined by the American Academy of Sleep Medicine as episodes of cortical EEG activation that last at least 2 seconds to 16 seconds and interrupt sleep) and frequent transitions to lighter stages of sleep. When sleep fragmentation is accompanied by pain, sleep-disordered breathing, and other disease states, this may lead to significant daytime impairment, secondary morbidity, and death. Daytime impairment may include impaired attention and concentration, excessive sleepiness, impaired judgment, impaired memory and learning, and an increased risk of accidents. Subjects suffering from sleep fragmentation are generally unaware of the hundreds of brief awakenings that may occur at night and primarily complain of severe daytime impairment. Subjects with sleep fragmentation often complain that their sleep is not beneficial or refreshing.

[0668] The diagnosis and treatment of sleep fragmentation are different from insomnia, which is a separate and different medical diagnosis. The feature of insomnia is that the subject is aware that they are dissatisfied with their sleep. Most insomniacs have hyperarousal disorder, which makes it difficult to fall asleep and / or to maintain a sleep state, but enables them to function well during the day. Insomnia is diagnosed by measuring the latency of continuous sleep (LPS≥30 minutes meet the definition of sleep-onset insomnia) and / or measuring the amount of time awake after sleep onset (WASO≥50 minutes meet the definition of sleep maintenance insomnia). For insomniacs, particularly the elderly, waking up in the middle of the night and not being able to recover sleep is common. Different from the subject suffering from sleep fragmentation, insomniacs are almost always highly aware that they cannot fall asleep or maintain sleep at night and complain about their nighttime experiences, and usually do not complain about daytime damage.

[0669] The present invention relates to the identification of pharmacological compounds that are particularly suitable for treating sleep disorders characterized in whole or in part by sleep fragmentation. The compounds of the present disclosure can be described as having dual H1 receptor inverse agonist and 5-HT 2A Receptor antagonist activity improves sleep fragmentation, as demonstrated by reduced number of awakenings (measured as a reduction in the number of transitions to wakefulness per hour), increased sleep continuity / consolidation (measured by average sleep bout duration per hour), and increased sleep depth (measured preclinically by electroencephalogram (EEG) spectral analysis to identify power in the EEG frequency band of 0.5-4.0 Hz (EEG "delta power")).

[0670] Has essential H1 inverse agonist and 5-HT 2A Antagonist receptor pharmacology molecules can use improved and expanded versions of (A complex sleep-wake biometry and analysis system, hereinafter referred to as "SCORETM ”) to study their effects on EEG sleep-wakefulness, locomotor activity, drink- and food-related activity, and body temperature in laboratory rats.

[0671] This technology is well-suited for sleep-wake efficacy and physiological and behavioral side effect assessments. Associated with this technology is an extensive pharmacology database with standardized sleep-wake, physiological, and behavioral data for over 500 different molecules. The standardized nature of experimental design, data quality control, and data analysis methods enables direct comparisons between molecules.

[0672] Sleep in rats and humans

[0673] This disclosure provides preclinical drug evaluation using rats. Without wishing to be bound by theory, rat sleep and human sleep share all the necessary fundamental similarities to allow rats to be used as a preclinical model. Thus, compounds that are hypnotic in humans may have a hypnotic effect in rats, and compounds that are hypnotic in rats may have a hypnotic effect in humans. Both rats and humans exhibit robust circadian regulation of sleep tendency and sleep architecture.

[0674] The "homeostatic" control of sleep is similar across mammalian species (including humans) in that loss of sleep increases the homeostatic drive for sleep, as evidenced by a decrease in sleep onset latency, an increase in sleep depth (which can be reflected by the amount of low-frequency "delta" EEG ("EEG slow waves") during non-REM periods), an increase in sleep consolidation as measured by sleep bout duration, or an increase in total sleep time. Sleep deprivation of a subject may cause the subject to fall asleep faster, sleep more deeply, sleep more efficiently (e.g., greater consolidation of sleep bouts), or sleep more (e.g., increased sleep time) until the homeostatic drive for sleep is sufficiently released by the sleep process.

[0675] Uninterrupted, well-consolidated sleep determines sleep quality in rats and humans. Without wishing to be bound by theory, regardless of how much a subject sleeps or what EEG frequencies dominate during sleep, beneficial working of the sleep process requires that sleep be unfragmented (interrupted) by frequent awakenings.

[0676] Without wishing to be bound by theory, compounds of the present disclosure that affect NREM sleep by reducing the latency of sleep onset, increasing sleep duration, increasing the depth and / or consolidation of sleep, reducing wakefulness, or a combination of the above effects in a subject may have the same effect in different subjects. Compounds of the present disclosure that affect NREM sleep by reducing the latency of the sleep onset effect in a subject may have the same effect on subjects of different species. Compounds of the present disclosure that affect NREM sleep by reducing the sleep onset latency in rats may have the same effect on subjects of different species. Compounds of the present disclosure that affect NREM sleep by reducing the sleep onset latency in rats may have the same effect on subjects of different species. Compounds of the present disclosure that affect NREM sleep by reducing the sleep onset latency in rats may have the same effect on humans.

[0677] Without wishing to be bound by theory, compounds of the present disclosure that affect NREM sleep by increasing a subject's sleep time may have the same effect on different subjects. Compounds of the present disclosure that affect NREM sleep by increasing a subject's sleep time may have the same effect on subjects of different species. Compounds of the present disclosure that affect NREM sleep by increasing the sleep time of rats may have the same effect on subjects of different species. Compounds of the present disclosure that affect NREM sleep by increasing the sleep time of rats may have the same effect on humans.

[0678] Without wishing to be bound by theory, compounds of the present disclosure that affect NREM sleep by increasing the depth and / or consolidation of sleep in a subject may have the same effect in different subjects. Compounds of the present disclosure that affect NREM sleep by increasing the depth and / or consolidation of sleep in a subject may have the same effect in subjects of different species. Compounds of the present disclosure that affect NREM sleep by increasing the depth and / or consolidation of sleep in rats may have the same effect in subjects of different species. Compounds of the present disclosure that affect NREM sleep by increasing the depth and / or consolidation of sleep in rats may have the same effect in humans.

[0679] Without wishing to be bound by theory, compounds of the present disclosure that affect NREM sleep by increasing the depth and consolidation of sleep in a subject may have the same effect in different subjects. Compounds of the present disclosure that affect NREM sleep by increasing the depth and consolidation of sleep in a subject may have the same effect in subjects of different species. Compounds of the present disclosure that affect NREM sleep by increasing the depth and consolidation of sleep in rats may have the same effect in subjects of different species. Compounds of the present disclosure that affect NREM sleep by increasing the depth and consolidation of sleep in rats may have the same effect in humans.

[0680] Without wishing to be bound by theory, compounds of the present disclosure that affect NREM sleep by increasing the depth or consolidation of sleep in a subject may have the same effect in different subjects. Compounds of the present disclosure that affect NREM sleep by increasing the depth or consolidation of sleep in a subject may have the same effect in subjects of different species. Compounds of the present disclosure that affect NREM sleep by increasing the depth or consolidation of sleep in rats may have the same effect in subjects of different species. Compounds of the present disclosure that affect NREM sleep by increasing the depth or consolidation of sleep in rats may have the same effect in humans.

[0681] Without wishing to be bound by theory, compounds of the present disclosure that affect NREM sleep by increasing the depth of sleep in a subject may have the same effect in different subjects. Compounds of the present disclosure that affect NREM sleep by increasing the depth of sleep in a subject may have the same effect in subjects of different species. Compounds of the present disclosure that affect NREM sleep by increasing the depth of sleep in rats may have the same effect in subjects of different species. Compounds of the present disclosure that affect NREM sleep by increasing the depth of sleep in rats may have the same effect in humans.

[0682] Without wishing to be bound by theory, compounds of the present disclosure that affect NREM sleep by increasing sleep consolidation in a subject may have the same effect in different subjects. Compounds of the present disclosure that affect NREM sleep by increasing sleep consolidation in a subject may have the same effect in subjects of different species. Compounds of the present disclosure that affect NREM sleep by increasing sleep consolidation in rats may have the same effect in subjects of different species. Compounds of the present disclosure that affect NREM sleep by increasing sleep consolidation in rats may have the same effect in humans.

[0683] Without wishing to be bound by theory, the disclosed compounds that affect NREM sleep by reducing arousals in a subject have the same effect in different subjects. The disclosed compounds that affect NREM sleep by reducing arousals in a subject have the same effect in subjects of different species. The disclosed compounds that affect NREM sleep by reducing arousals in rats have the same effect in subjects of different species. The disclosed compounds that affect NREM sleep by reducing arousals in rats have the same effect in humans.

[0684] Without wishing to be bound by theory, compounds of the present disclosure that affect REM sleep by reducing the latency of sleep onset, increasing sleep duration, increasing the depth and / or consolidation of sleep, reducing arousals, or a combination of the foregoing in a subject may have the same effect in different subjects. Compounds of the present disclosure that affect REM sleep by reducing the latency of the sleep onset effect in a subject may have the same effect on subjects of different species. Compounds of the present disclosure that affect REM sleep by reducing sleep onset latency in rats may have the same effect on subjects of different species. Compounds of the present disclosure that affect REM sleep by reducing sleep onset latency in rats may have the same effect on humans.

[0685] Without wishing to be bound by theory, compounds of the present disclosure that affect REM sleep by increasing a subject's sleep time may have the same effect on different subjects. Compounds of the present disclosure that affect REM sleep by increasing a subject's sleep time may have the same effect on subjects of different species. Compounds of the present disclosure that affect REM sleep by increasing a rat's sleep time may have the same effect on subjects of different species. Compounds of the present disclosure that affect REM sleep by increasing a rat's sleep time may have the same effect on humans.

[0686] Without wishing to be bound by theory, compounds of the present disclosure that affect REM sleep by increasing the depth and / or consolidation of sleep in a subject may have the same effect in different subjects. Compounds of the present disclosure that affect REM sleep by increasing the depth and / or consolidation of sleep in a subject may have the same effect in subjects of different species. Compounds of the present disclosure that affect REM sleep by increasing the depth and / or consolidation of sleep in rats may have the same effect in subjects of different species. Compounds of the present disclosure that affect REM sleep by increasing the depth and / or consolidation of sleep in rats may have the same effect in humans.

[0687] Without wishing to be bound by theory, compounds of the present disclosure that affect REM sleep by increasing the depth and consolidation of sleep in a subject may have the same effect in different subjects. Compounds of the present disclosure that affect REM sleep by increasing the depth and consolidation of sleep in a subject may have the same effect in subjects of different species. Compounds of the present disclosure that affect REM sleep by increasing the depth and consolidation of sleep in rats may have the same effect in subjects of different species. Compounds of the present disclosure that affect REM sleep by increasing the depth and consolidation of sleep in rats may have the same effect in humans.

[0688] Without wishing to be bound by theory, compounds of the present disclosure that affect REM sleep by increasing the depth or consolidation of sleep in a subject may have the same effect in different subjects. Compounds of the present disclosure that affect REM sleep by increasing the depth or consolidation of sleep in a subject may have the same effect in subjects of different species. Compounds of the present disclosure that affect REM sleep by increasing the depth or consolidation of sleep in rats may have the same effect in subjects of different species. Compounds of the present disclosure that affect REM sleep by increasing the depth or consolidation of sleep in rats may have the same effect in humans.

[0689] Without wishing to be bound by theory, compounds of the present disclosure that affect REM sleep by increasing the depth of a subject's sleep may have the same effect in different subjects. Compounds of the present disclosure that affect REM sleep by increasing the depth of a subject's sleep may have the same effect in subjects of different species. Compounds of the present disclosure that affect REM sleep by increasing the depth of sleep in rats may have the same effect in subjects of different species. Compounds of the present disclosure that affect REM sleep by increasing the depth of sleep in rats may have the same effect in humans.

[0690] Without wishing to be bound by theory, compounds of the present disclosure that affect REM sleep by increasing sleep consolidation in a subject may have the same effect in different subjects. Compounds of the present disclosure that affect REM sleep by increasing sleep consolidation in a subject may have the same effect in subjects of different species. Compounds of the present disclosure that affect REM sleep by increasing sleep consolidation in rats may have the same effect in subjects of different species. Compounds of the present disclosure that affect REM sleep by increasing sleep consolidation in rats may have the same effect in humans.

[0691] Without wishing to be bound by theory, compounds of the present disclosure that affect REM sleep by reducing arousals in a subject have the same effect in different subjects. Compounds of the present disclosure that affect REM sleep by reducing arousals in a subject have the same effect in subjects of different species. Compounds of the present disclosure that affect REM sleep by reducing arousals in rats have the same effect in subjects of different species. Compounds of the present disclosure that affect REM sleep by reducing arousals in rats have the same effect in humans.

[0692] Without wishing to be bound by theory, sleep continuity can be measured as the duration of NREM "bouts" or the duration of REM bouts, or the duration of NREM+REM "bouts" where awakening or wakefulness bouts interrupt the NREM-REM cycle.

[0693] In some embodiments, sleep bouts may consist of NREM, REM, or NREM+REM.

[0694] In some embodiments, sleep bouts may consist of NREM. In some embodiments, sleep bouts may consist of REM. In some embodiments, sleep bouts may consist of NREM+REM.

[0695] In some embodiments, NREM and REM sleep alternate, which can be referred to as a NREM-REM cycle. In some embodiments, NREM precedes REM.

[0696] In some embodiments, the ratio of time spent in NREM to REM is the same for different subjects. In some embodiments, the ratio of time spent in NREM to REM is the same for different subjects of different species. In some embodiments, the ratio of time spent in NREM to REM is the same for rats and subjects of different species. In some embodiments, the ratio of time spent in NREM to REM is the same for rats and humans.

[0697] In some embodiments, the ratio of time spent in NREM to REM is about 5:1. In some embodiments, the ratio of time spent in NREM to REM is about 4:1. In some embodiments, the ratio of time spent in NREM to REM is about 3:1. In some embodiments, the ratio of time spent in NREM to REM is about 2:1.

[0698] In some embodiments, the ratio of time spent in NREM to REM is between about 100:1 and about 1:1. In some embodiments, the ratio of time spent in NREM to REM is between about 90:1 and about 1:1. In some embodiments, the ratio of time spent in NREM to REM is between about 80:1 and about 1:1. In some embodiments, the ratio of time spent in NREM to REM is between about 70:1 and about 1:1. In some embodiments, the ratio of time spent in NREM to REM is between about 60:1 and about 1:1. In some embodiments, the ratio of time spent in NREM to REM is between about 50:1 and about 1:1. In some embodiments, the ratio of time spent in NREM to REM is between about 40:1 and about 1:1. In some embodiments, the ratio of time spent in NREM to REM is between about 30:1 and about 1:1. In some embodiments, the ratio of time spent in NREM to REM is between about 20:1 and about 1:1. In some embodiments, the ratio of time spent in NREM to REM is about 10:1 to about 1:1. In some embodiments, the ratio of time spent in NREM to REM is about 5:1 to about 1:1. In some embodiments, the species is a mouse. In some embodiments, the species is an ungulate. In some embodiments, the ungulate is a horse or a cow. In some embodiments, the species is not a laboratory rat. In some embodiments, the species is not a human.

[0699] In some embodiments, hypnotic drugs reduce REM sleep to some extent, and several classes of sleep disorder drugs can strongly suppress REM sleep. Without wishing to be bound by theory, REM sleep suppression may be related to learning, memory and / or mental health.

[0700] Without wishing to be bound by theory, the relative effectiveness of some classes of drugs that inhibit or stimulate REM sleep and are used for sleep disorders, neuropsychiatric disorders, and cardiovascular diseases translates from one subject to another. The relative effects of some classes of drugs that inhibit or stimulate REM sleep and are used for sleep disorders, neuropsychiatric disorders, and cardiovascular diseases translate from one subject to another. The relative effects of some classes of drugs that inhibit or stimulate REM sleep and are used for sleep disorders, neuropsychiatric disorders, and cardiovascular diseases translate from one subject to another. The relative effects of some classes of drugs that inhibit or stimulate REM sleep and are used for sleep disorders, neuropsychiatric disorders, and cardiovascular diseases translate from rats to subjects of different species. The relative effects of some classes of drugs that inhibit or stimulate REM sleep and are used for sleep disorders can be translated from laboratory rats to humans.

[0701] There may be two differences between rat and human sleep. First, rats are active at night, while humans are active during the day. This difference itself may not be important for testing the effects of drugs on sleep and wakefulness. When comparing rat and human sleep, when evaluating the efficacy of drugs on sleep-related variables (such as the inhibition of REM sleep), it is possible to rely on the time of administration relative to the normal sleep period. The difference between rats and humans is the length of sleep bouts, also known as "sleep continuity". In addition, people can consolidate their sleep into a single period every day, interrupted only by short awakening bouts (such as less than 2 hours, less than 1 hour, less than 45 minutes, less than 30 minutes, less than 25 minutes, less than 20 minutes, less than 15 minutes, less than 10 minutes, less than 5 minutes or less than 1 minute). Abnormal conditions may cause human sleep to become fragmented, reducing the restorative benefits of sleep. Rats can have shorter sleep bouts that occur throughout the 24-hour day (for example, rats complete a sleep-wake cycle every 20 minutes on average). During the dark period (when rats may be most active), sleep typically occupies 1 / 3 of every 20-minute cycle, and REM sleep is rare. During the day (lights on), rats typically sleep for about two-thirds of each 20-minute cycle. The polyphasic nature of sleep and the shorter duration of spontaneous sleep bouts in rats enable highly sensitive assessments of drug effects, such as those that increase sleep consolidation (sleep bout duration), reduce the number of awakenings (wake bout number), and various secondary but desirable measures of sleep quality, such as EEG slow wave activity in non-REM sleep, and measures of wakefulness maintenance as measured by wake bout duration. Sleep bout length can also be a sensitive measure of physiological sleepiness and can be a preclinical predictor of hypnotic efficacy in humans.

[0702] Timing of treatment

[0703] Empirical optimization can be carried out by administering sleep-related compounds to evaluate these compounds at two circadian times of the day, CT-18 and CT-5, where CT-0 is defined as lights-on. CT-18 is the midpoint of the rat circadian rhythm cycle activity phase, 6 hours after lights out, and may be sensitive to the effects of hypnotic drugs on sleep bout length, although this effect can be observed at both CT-18 and CT-5. CT-5 begins at a few hours of peak abundance in REM sleep and is therefore a sensitive time for drug-related inhibition of REM sleep. CT-18 and CT-5 are both suitable times of the day for evaluating the impact of drugs on sleep fragmentation, which is measured by awakening (wake bout number of times or the number of times converted to wakefulness), sleep consolidation (sleep bout duration), and assessment of staying awake (wake bout length) and drug-related side effects.

[0704] The preclinical effects observed with CT-5 (treatment administered at a time of day corresponding to 5 hours after lights on) and / or CT-18 (treatment administered at a time of day corresponding to 18 hours after lights on or 6 hours after lights off, when animals are housed on a 24-hour light-dark cycle consisting of 12 hours light and 12 hours dark) are considered sufficient to identify compounds that can reduce sleep fragmentation.

[0705] How to use

[0706] In some embodiments, the present disclosure provides methods for modulating H1 / 5-HT 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A In some embodiments, the present disclosure provides a method for alleviating the symptoms of, treating, or preventing a disease or condition disclosed herein by administering a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure to a subject in need thereof.

[0707] In some embodiments, H1 / 5-HT modulation 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A Antagonist activity, e.g., in vitro or in vivo) to alleviate symptoms of, treat, or prevent sleep disorders.

[0708] In some embodiments, H1 / 5-HT modulation 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A Antagonist activity, e.g., in vitro or in vivo) to alleviate symptoms of or treat a sleep disorder.

[0709] In some embodiments, H1 / 5-HT modulation 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A Antagonist activity, e.g., in vitro or in vivo) for the treatment of sleep disorders.

[0710] In some aspects, the present disclosure provides methods of alleviating symptoms of, treating, or preventing sleep disorders.

[0711] In some embodiments, the present disclosure provides methods of treating or preventing a disease or condition disclosed herein in a subject by administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0712] In some embodiments, the present disclosure provides methods of treating a disease or condition disclosed herein in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0713] In some embodiments, the present disclosure provides for the use of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in treating or preventing a disease or condition.

[0714] In some embodiments, the present disclosure provides for the use of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in treating a disease or condition.

[0715] In some embodiments, the present disclosure provides the use of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating or preventing a disease or condition.

[0716] In some embodiments, the present disclosure provides the use of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease or condition.

[0717] In some embodiments, the present disclosure provides a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a disease or disorder.

[0718] In some embodiments, the present disclosure provides a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in treating a disease or condition.

[0719] In some embodiments, the disease or condition is a sleep disorder.

[0720] In some embodiments, the sleep disorder is increased sleep disturbance, increased sleep fragmentation, increased arousals, or a decreased arousal threshold.

[0721] In some embodiments, the sleep fragmentation is comorbid with a medical condition.

[0722] In some embodiments, the sleep disorder is caused by or comorbid with a medical condition, wherein the medical condition causes or exacerbates the sleep disorder.

[0723] In some embodiments, the sleep disorder is caused by a medical condition, wherein the medical condition causes or exacerbates the sleep disorder.

[0724] In some embodiments, the sleep disorder is comorbid with a medical condition, wherein the medical condition causes or exacerbates the sleep disorder.

[0725] In some aspects, the present disclosure provides methods for alleviating symptoms of, treating, or preventing sleep disorders in a subject by administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0726] In some aspects, the present disclosure provides methods of treating or preventing sleep disorders in a subject by administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0727] In some aspects, the present disclosure provides methods of treating a sleep disorder in a subject by administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0728] In some aspects, the present disclosure provides uses of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in alleviating symptoms of sleep disorders, treating or preventing sleep disorders.

[0729] In some aspects, the present disclosure provides uses of a compound of the present disclosure or a pharmaceutically acceptable salt thereof for alleviating symptoms of sleep disorders.

[0730] In some aspects, the present disclosure provides for use of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in treating a sleep disorder.

[0731] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the preparation of a medicament for alleviating symptoms of sleep disorders, treating or preventing sleep disorders.

[0732] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the preparation of a medicament for alleviating symptoms of a sleep disorder or treating a sleep disorder.

[0733] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a sleep disorder.

[0734] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in alleviating symptoms of sleep disorders, treating or preventing sleep disorders.

[0735] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in alleviating symptoms of a sleep disorder or treating a sleep disorder.

[0736] In some aspects, the present disclosure provides a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in treating a sleep disorder.

[0737] In some embodiments, H1 / 5-HT modulation 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A Antagonist activity, for example, in vitro or in vivo) to alleviate symptoms of, treat or prevent sleep disorders.

[0738] In some embodiments, H1 / 5-HT modulation 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A Antagonist activity, for example, in vitro or in vivo) to alleviate symptoms of sleep disorders and treat sleep disorders.

[0739] In some embodiments, H1 / 5-HT modulation 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A Antagonist activity, e.g., in vitro or in vivo) for the treatment of sleep disorders.

[0740] In some embodiments, the present disclosure provides methods for modulating H1 / 5-HT 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A The invention provides a method for expressing a compound of the present invention or a pharmaceutically acceptable salt thereof, for example, in vitro or in vivo, in order to detect antagonist activity of the compound of the present invention.

[0741] In some embodiments, the present disclosure provides compounds of the present disclosure or pharmaceutically acceptable salts thereof in regulating H1 / 5-HT 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A antagonist activity, e.g., in vitro or in vivo).

[0742] In some embodiments, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in the preparation of a drug for regulating H1 / 5-HT 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A antagonistic activity, for example in vitro or in vivo).

[0743] In some embodiments, the present disclosure provides compounds of the present disclosure or pharmaceutically acceptable salts thereof for use in regulating H1 / 5-HT 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A antagonist activity, e.g., in vitro or in vivo).

[0744] In some embodiments, H1 / 5-HT 2A In some embodiments, H1 / 5-HT 2AFunction to improve sleep disorders. In some embodiments, regulating H1 / 5-HT 2A Function improves sleep disorders. In some embodiments, regulates H1 / 5-HT 2A Function improves sleep fragmentation. In some embodiments, regulates H1 / 5-HT 2A Function improves sleep wakefulness. In some embodiments, regulates H1 / 5-HT 2A Function improves wakefulness threshold. In some embodiments, H1 / 5-HT 2A In some embodiments, H1 / 5-HT 2A Receptor downregulation.

[0745] In some embodiments, the present disclosure provides methods for modulating H1 / 5-HT 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A The method of expressing an antagonist activity of a compound of Formula (I), (II) or (II') or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure, is performed by administering to a subject a therapeutically effective amount of the compound of Formula (I), (II) or (II') or a pharmaceutically acceptable salt thereof.

[0746] In some embodiments, the present disclosure provides a compound of formula (I), (II) or (II') or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the present disclosure for use in regulating H1 / 5-HT 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A antagonist activity, e.g., in vitro or in vivo).

[0747] In some embodiments, the present disclosure provides a compound of formula (I), (II) or (II') or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the present disclosure for use in the preparation of a pharmaceutical composition for regulating H1 / 5-HT 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A antagonist activity, e.g., in vitro or in vivo).

[0748] In some embodiments, the present disclosure provides a compound of formula (I), (II) or (II') or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the present disclosure for use in regulating H1 / 5-HT 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A antagonist activity, e.g., in vitro or in vivo).

[0749] In some embodiments, provided herein are compounds of formula (I), (II), or (II') for use in the treatment of sleep disorders, or pharmaceutically acceptable salts thereof. In some embodiments, provided herein are compounds of formula (I), or pharmaceutically acceptable salts thereof, for use in the treatment of sleep disorders. In some embodiments, provided herein are compounds of formula (II), or pharmaceutically acceptable salts thereof, for use in the treatment of sleep disorders. In some embodiments, provided herein are compounds of formula (II'), or pharmaceutically acceptable salts thereof, for use in the treatment of sleep disorders.

[0750] In some embodiments, provided herein are compounds of formula (I), (II) or (II') or pharmaceutically acceptable salts thereof for use in treating sleep disorders in subjects with co-morbidities with medical conditions. In some embodiments, provided herein are compounds of formula (I) or pharmaceutically acceptable salts thereof for use in treating sleep disorders in subjects with co-morbidities with medical conditions. In some embodiments, provided herein are compounds of formula (II) or pharmaceutically acceptable salts thereof for use in treating sleep disorders in subjects with co-morbidities with medical conditions. In some embodiments, provided herein are compounds of formula (II') or pharmaceutically acceptable salts thereof for use in treating sleep disorders in subjects with co-morbidities with medical conditions.

[0751] In some embodiments, the present disclosure provides the use of a compound of formula (I), (II) or (II') or a pharmaceutically acceptable salt thereof in the treatment of sleep disorders. In some embodiments, the present disclosure provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the treatment of sleep disorders. In some embodiments, the present disclosure provides the use of a compound of formula (II) or a pharmaceutically acceptable salt thereof in the treatment of sleep disorders. In some embodiments, the present disclosure provides the use of a compound of formula (II') or a pharmaceutically acceptable salt thereof in the treatment of sleep disorders.

[0752] In some embodiments, the present disclosure provides the use of a compound of formula (I), (II) or (II') or a pharmaceutically acceptable salt thereof in the treatment of a sleep disorder in a subject suffering from a comorbidity with a medical condition. In some embodiments, the present disclosure provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the treatment of a sleep disorder in a subject suffering from a comorbidity with a medical condition. In some embodiments, the present disclosure provides the use of a compound of formula (II) or a pharmaceutically acceptable salt thereof in the treatment of a sleep disorder in a subject suffering from a comorbidity with a medical condition. In some embodiments, the present disclosure provides the use of a compound of formula (II') or a pharmaceutically acceptable salt thereof in the treatment of a sleep disorder in a subject suffering from a comorbidity with a medical condition.

[0753] In some embodiments, the present disclosure provides the use of a compound of formula (I), (II) or (II') or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a sleep disorder. In some embodiments, the present disclosure provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a sleep disorder. In some embodiments, the present disclosure provides the use of a compound of formula (II) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a sleep disorder. In some embodiments, the present disclosure provides the use of a compound of formula (II') or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a sleep disorder.

[0754] In some embodiments, the present disclosure provides the use of a compound of formula (I), (II) or (II') or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a sleep disorder in a subject suffering from a comorbidity with a medical condition. In some embodiments, the present disclosure provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a sleep disorder in a subject suffering from a comorbidity with a medical condition. In some embodiments, the present disclosure provides the use of a compound of formula (II) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a sleep disorder in a subject suffering from a comorbidity with a medical condition. In some embodiments, the present disclosure provides the use of a compound of formula (II') or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a sleep disorder in a subject suffering from a comorbidity with a medical condition.

[0755] In some embodiments, the present disclosure provides a compound of formula (I), (II) or (II') or a pharmaceutically acceptable salt thereof for use in treating sleep disorders. In some embodiments, the present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in treating sleep disorders. In some embodiments, the present disclosure provides a compound of formula (II) or a pharmaceutically acceptable salt thereof for use in treating sleep disorders. In some embodiments, the present disclosure provides a compound of formula (II') or a pharmaceutically acceptable salt thereof for use in treating sleep disorders.

[0756] In some embodiments, the present disclosure provides a compound of formula (I), (II) or (II') or a pharmaceutically acceptable salt thereof for treating a sleep disorder in a subject suffering from a comorbidity with a medical condition. In some embodiments, the present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for treating a sleep disorder in a subject suffering from a comorbidity with a medical condition. In some embodiments, the present disclosure provides a compound of formula (II) or a pharmaceutically acceptable salt thereof for treating a sleep disorder in a subject suffering from a comorbidity with a medical condition. In some embodiments, the present disclosure provides a compound of formula (II') or a pharmaceutically acceptable salt thereof for treating a sleep disorder in a subject suffering from a comorbidity with a medical condition.

[0757] In some embodiments, the present disclosure provides methods for modulating H1 / 5-HT 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A The method of detecting antagonist activity of a compound 30, 31, 34 or 35, for example, in vitro or in vivo, is performed by administering to a subject a therapeutically effective amount of compound 30, 31, 34 or 35 or a pharmaceutically acceptable salt thereof.

[0758] In some embodiments, the present disclosure provides compounds 30, 31, 34 or 35 or pharmaceutically acceptable salts thereof in regulating H1 / 5-HT 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A antagonist activity, e.g., in vitro or in vivo).

[0759] In some embodiments, the present disclosure provides compounds 30, 31, 34 or 35 or pharmaceutically acceptable salts thereof for use in the preparation of a pharmaceutical composition for regulating H1 / 5-HT. 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A antagonist activity, e.g., in vitro or in vivo).

[0760] In some embodiments, the present disclosure provides compounds 30, 31, 34 or 35 or pharmaceutically acceptable salts thereof for use in regulating H1 / 5-HT 2A Function (e.g. dual-acting H1 inverse agonist and 5-HT 2A antagonist activity, e.g., in vitro or in vivo).

[0761] In some embodiments, the present disclosure provides methods for alleviating symptoms of sleep disorders, treating or preventing sleep disorders by administering to a subject a therapeutically effective amount of compound 30, 31, 34 or 35 or a pharmaceutically acceptable salt thereof.

[0762] In some embodiments, the present disclosure provides methods of alleviating symptoms of sleep disorders or treating sleep disorders by administering to a subject a therapeutically effective amount of compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof.

[0763] In some embodiments, the present disclosure provides methods of treating sleep disorders by administering to a subject a therapeutically effective amount of compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof.

[0764] In some embodiments, the present disclosure provides use of compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof, in alleviating symptoms of sleep disorders, treating, or preventing sleep disorders.

[0765] In some embodiments, the present disclosure provides use of compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof, in alleviating symptoms of sleep disorders or treating sleep disorders.

[0766] In some embodiments, the present disclosure provides use of compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof, in treating a sleep disorder.

[0767] In some embodiments, the present disclosure provides the use of compound 30, 31, 34 or 35 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for alleviating symptoms of sleep disorders, treating or preventing sleep disorders.

[0768] In some embodiments, the present disclosure provides the use of compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for alleviating symptoms of a sleep disorder or treating a sleep disorder.

[0769] In some embodiments, the present disclosure provides the use of compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a sleep disorder.

[0770] In some embodiments, the present disclosure provides Compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof, for use in alleviating symptoms of, treating, or preventing sleep disorders.

[0771] In some embodiments, the present disclosure provides Compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof, for use in alleviating symptoms of a sleep disorder or treating a sleep disorder.

[0772] In some embodiments, the present disclosure provides Compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof, for use in treating a sleep disorder.

[0773] In some embodiments, the present disclosure relates to alleviating symptoms of, treating or preventing a sleep disorder, wherein the sleep disorder is increased sleep disturbance, increased sleep fragmentation, increased wakefulness or a lowered wakefulness threshold in a subject, wherein the sleep disorder is caused by or is comorbid with sleep apnea, restless legs syndrome, a high respiratory disturbance index (RDI), a neurological disease, a circadian rhythm disorder, pain, periodic leg movement disorder (PLMD), REM behavior disorder, elderly fragmented sleep, age-related sleep fragmentation, postmenopausal sleep disorder, substance abuse, substance abuse withdrawal, narcolepsy, a psychiatric disorder, increased sensitivity to pain, cardiovascular disease, hypertension, non-restorative sleep, stroke, a metabolic disorder or a cognitive disorder.

[0774] In some embodiments, the present disclosure relates to alleviating symptoms of, treating or preventing a sleep disorder, wherein the sleep disorder is increased sleep disturbance, increased sleep fragmentation, increased wakefulness or a lowered wakefulness threshold in a subject, wherein the sleep disorder is caused by sleep apnea, restless legs syndrome, a high respiratory disturbance index (RDI), a neurological disease, a circadian rhythm disorder, pain, periodic leg movement disorder (PLMD), REM behavior disorder, geriatric fragmented sleep, age-related sleep fragmentation, postmenopausal sleep disorder, substance abuse, substance abuse withdrawal, narcolepsy, a psychiatric disorder, increased sensitivity to pain, cardiovascular disease, hypertension, non-restorative sleep, stroke, a metabolic disorder or a cognitive disorder.

[0775] In some embodiments, the present disclosure relates to alleviating symptoms of, treating or preventing a sleep disorder, wherein the sleep disorder is increased sleep disturbance, increased sleep fragmentation, increased wakefulness or a lowered wakefulness threshold in a subject, wherein the sleep disorder is comorbid with sleep apnea, restless legs syndrome, a high respiratory disturbance index (RDI), a neurological disease, a circadian rhythm disorder, pain, periodic leg movement disorder (PLMD), REM behavior disorder, geriatric fragmented sleep, age-related sleep fragmentation, postmenopausal sleep disorder, substance abuse, substance abuse withdrawal, narcolepsy, a psychiatric disorder, increased sensitivity to pain, cardiovascular disease, hypertension, non-restorative sleep, stroke, a metabolic disorder or a cognitive disorder.

[0776] In some embodiments, the present disclosure relates to alleviating the symptoms of, treating or preventing a sleep disorder, wherein the sleep disorder is increased sleep disturbance, increased sleep fragmentation, increased wakefulness or a lowered wakefulness threshold in a subject, wherein the sleep disorder is caused by or is comorbid with sleep apnea, restless legs syndrome, a high respiratory disturbance index (RDI), a neurological disease, a circadian rhythm disorder, pain, periodic leg movement disorder (PLMD), REM behavior disorder, geriatric fragmented sleep, age-related sleep fragmentation, postmenopausal sleep disorder, substance abuse, substance abuse withdrawal, narcolepsy, a psychiatric disorder or non-restorative sleep.

[0777] In some embodiments, the present disclosure relates to alleviating symptoms of, treating or preventing a sleep disorder, wherein the sleep disorder is increased sleep disturbance, increased sleep fragmentation, increased wakefulness or a lowered wakefulness threshold in a subject, wherein the sleep disorder is caused by sleep apnea, restless legs syndrome, a high respiratory disturbance index (RDI), a neurological disease, a circadian rhythm disorder, pain, periodic leg movement disorder (PLMD), REM behavior disorder, geriatric fragmented sleep, age-related sleep fragmentation, postmenopausal sleep disorder, substance abuse, substance abuse withdrawal, narcolepsy, a psychiatric disorder or non-restorative sleep.

[0778] In some embodiments, the present disclosure relates to alleviating symptoms of, treating or preventing a sleep disorder, wherein the sleep disorder is increased sleep disturbance, increased sleep fragmentation, increased wakefulness or a lowered wakefulness threshold in a subject, wherein the sleep disorder is comorbid with sleep apnea, restless legs syndrome, a high respiratory disturbance index (RDI), a neurological disease, a circadian rhythm disorder, pain, periodic leg movement disorder (PLMD), REM behavior disorder, geriatric fragmented sleep, age-related sleep fragmentation, postmenopausal sleep disorder, substance abuse, substance abuse withdrawal, narcolepsy, a psychiatric disorder or non-restorative sleep.

[0779] In some embodiments, the sleep disorder is caused by or is comorbid with one or more types of pain.

[0780] In some embodiments, the sleep disturbance is caused by one or more types of pain.

[0781] In some embodiments, the sleep disorder is comorbid with one or more types of pain.

[0782] In some embodiments, the pain is selected from inflammatory pain, nociceptive pain, neuropathic pain, mixed nociceptive and neuropathic pain, postoperative pain, post-herpetic pain, traumatic pain, phantom limb pain, fibromyalgia, back pain, cancer pain, and osteoarthritic pain.

[0783] In some embodiments, the pain is chronic pain.

[0784] In some embodiments, the pain is arthritic pain.

[0785] In some embodiments, the pain is inflammatory pain.

[0786] In some embodiments, the inflammatory pain is arthritis. In some embodiments, the arthritis is rheumatoid arthritis. In some embodiments, the arthritis is osteoarthritis.

[0787] In some embodiments, the pain is nociceptive pain. In some embodiments, the nociceptive pain is acute. In some embodiments, the nociceptive pain is chronic. In some embodiments, the nociceptive pain is caused by cancer therapy. In some embodiments, the nociceptive pain is caused by surgery.

[0788] In some embodiments, the pain is neuropathic pain. In some embodiments, the neuropathic pain is chronic. In some embodiments, the neuropathic pain is acute. In some embodiments, the neuropathic pain is back pain. In some embodiments, the neuropathic pain is caused by spinal cord injury. In some embodiments, the neuropathic pain is caused by multiple sclerosis. In some embodiments, the neuropathic pain is caused by stroke. In some embodiments, the neuropathic pain is caused by diabetes. In some embodiments, the neuropathic pain is caused by a metabolic disorder.

[0789] In some embodiments, the pain is mixed nociceptive and neuropathic pain.

[0790] In some embodiments, the pain is postoperative pain.

[0791] In some embodiments, the pain is post-herpetic pain.

[0792] In some embodiments, the pain is traumatic pain. In some embodiments, the traumatic pain is caused by causalgia.

[0793] In some embodiments, the pain is phantom limb pain.

[0794] In some embodiments, the pain is fibromyalgia.

[0795] In some embodiments, the pain is back pain. In some embodiments, the pain is low back pain.

[0796] In some embodiments, the pain is cancer pain. In some embodiments, the cancer pain is cancer. In some embodiments, the cancer pain is caused by a tumor. In some embodiments, the cancer pain is caused by cancer treatment. In some embodiments, the cancer pain is caused by chemotherapy. In some embodiments, the cancer pain is radiation therapy. In some embodiments, the cancer pain is caused by surgery.

[0797] In some embodiments, the pain is osteoarthritic pain.

[0798] In some embodiments, the pain may be characterized by changes in mood.

[0799] In some embodiments, the sleep disorder is caused by or comorbid with sleep apnea.

[0800] In some embodiments, the sleep disorder is caused by sleep apnea.

[0801] In some embodiments, the sleep disorder is comorbid with sleep apnea.

[0802] In some embodiments, sleep apnea is obstructive sleep apnea

[0803] In some embodiments, the sleep apnea is obstructive sleep apnea due to a high respiratory disturbance index (RDI) associated with elevated respiratory event-related arousals (RERA), with or without accompanying apneas.

[0804] In some embodiments, the sleep apnea is obstructive sleep apnea due to a high respiratory disturbance index (RDI) associated with elevated respiratory event-related arousals (RERA), with accompanying apneas.

[0805] In some embodiments, the sleep apnea is obstructive sleep apnea due to a high respiratory disturbance index (RDI) associated with elevated respiratory event-related arousals (RERA), with or without accompanying hypopneas.

[0806] In some embodiments, the sleep apnea is obstructive sleep apnea due to a high respiratory disturbance index (RDI) associated with elevated respiratory event-related arousals (RERA), with accompanying hypopneas.

[0807] In some embodiments, the sleep apnea is obstructive sleep apnea due to a high respiratory disturbance index (RDI) associated with elevated respiratory event-related arousals (RERA), with or without accompanying acute hemoglobin desaturation.

[0808] In some embodiments, the sleep apnea is obstructive sleep apnea due to a high respiratory disturbance index (RDI) associated with elevated respiratory event-related arousals (RERA), with concomitant acute hemoglobin desaturation.

[0809] In some embodiments, obstructive sleep apnea may be characterized by excessive daytime sleepiness.

[0810] In some embodiments, obstructive sleep apnea can be characterized by the presence of cardiovascular biomarkers.

[0811] In some embodiments, the sleep apnea is central sleep apnea.

[0812] In some embodiments, the sleep apnea is low arousal threshold sleep apnea.

[0813] In some embodiments, sleep apnea is hypopnea.

[0814] In some embodiments, the sleep disorder is caused by or comorbid with restless legs syndrome.

[0815] In some embodiments, the sleep disorder is caused by restless legs syndrome.

[0816] In some embodiments, the sleep disorder is comorbid with restless legs syndrome.

[0817] In some embodiments, the sleep disorder is caused by or comorbid with a high respiratory disturbance index (RDI).

[0818] In some embodiments, the sleep disturbance is caused by a high respiratory disturbance index (RDI).

[0819] In some embodiments, the sleep disorder is comorbid with a high respiratory disturbance index (RDI).

[0820] In some embodiments, the RDI is associated with elevated respiratory event-related arousals (RERA) with or without associated apneas.

[0821] In some embodiments, the RDI is associated with elevated respiratory event-related arousals (RERA) with associated apneas.

[0822] In some embodiments, the RDI is associated with elevated respiratory event-related arousals (RERA) with or without accompanying hypopnea.

[0823] In some embodiments, the RDI is associated with elevated respiratory event-related arousals (RERA) with associated hypopneas.

[0824] In some embodiments, the RDI is associated with elevated respiratory event-related arousals (RERA) with or without accompanying acute hemoglobin desaturation.

[0825] In some embodiments, the RDI is associated with elevated respiratory event-related arousals (RERA) with acute hemoglobin desaturation.

[0826] In some embodiments, the RDI is associated with elevated respiratory event-related arousals (RERA) with or without accompanying hemoglobin desaturation.

[0827] In some embodiments, the RDI is associated with elevated respiratory event-related arousals (RERA) with accompanying hemoglobin desaturation.

[0828] In some embodiments, the sleep disorder is caused by or is comorbid with a psychiatric disorder.

[0829] In some embodiments, the sleep disorder is caused by a psychiatric disorder.

[0830] In some embodiments, the sleep disorder is comorbid with a psychiatric disorder.

[0831] In some embodiments, the psychiatric disorder is depression, major depressive disorder, post-traumatic stress disorder, anxiety disorder, bipolar disorder, or schizophrenia.

[0832] In some embodiments, the mental disorder is depression. In some embodiments, the mental disorder is major depressive disorder. In some embodiments, the mental disorder is post-traumatic stress disorder. In some embodiments, the mental disorder is anxiety disorder. In some embodiments, the mental disorder is bipolar disorder. In some embodiments, the mental disorder is schizophrenia.

[0833] In some embodiments, PTSD may be characterized by the occurrence of nightmares.

[0834] In some embodiments, PTSD may be characterized by decreased sleep quality.

[0835] In some embodiments, post-traumatic stress disorder may be characterized by disruptive nocturnal behaviors.

[0836] In some embodiments, post-traumatic stress disorder may be comorbid with depression.

[0837] In some embodiments, post-traumatic stress disorder may be comorbid with anxiety.

[0838] In some embodiments, the sleep disorder is caused by or is comorbid with a neurological disease.

[0839] In some embodiments, the sleep disorder is caused by a neurological disease.

[0840] In some embodiments, the sleep disorder is comorbid with a neurological disorder.

[0841] In some embodiments, the neurological disease is a neurodegenerative disease.

[0842] In some embodiments, the neurodegenerative disease is a Lewy body disease (ie, Lewy body dementia). In some embodiments, the Lewy body disease is diffuse.

[0843] In some embodiments, the neurodegenerative disease is amyotrophic lateral sclerosis (ALS). In some embodiments, the neurodegenerative disease is Huntington's disease. In some embodiments, the neurodegenerative disease is Parkinson's disease. In some embodiments, the neurodegenerative disease is Alzheimer's disease. In some embodiments, the neurodegenerative disease is synucleinopathy.

[0844] In some embodiments, the synucleinopathy is Alzheimer's disease, Parkinson's disease, or Lewy body dementia. In some embodiments, the synucleinopathy is Alzheimer's disease. In some embodiments, the synucleinopathy is Parkinson's disease. In some embodiments, the synucleinopathy is Lewy body dementia. In some embodiments, the synucleinopathy is multiple system atrophy.

[0845] In some embodiments, Parkinson's disease can be characterized by Parkinson's disease-related sleep disturbances.

[0846] In some embodiments, Parkinson's disease may be characterized by the occurrence of nightmares.

[0847] In some embodiments, Parkinson's disease can be characterized by the occurrence of hallucinations.

[0848] In some embodiments, Parkinson's disease may be characterized by excessive daytime sleepiness.

[0849] In some embodiments, Alzheimer's disease can be characterized by Alzheimer's disease-related sleep disturbances.

[0850] In some embodiments, Alzheimer's disease may be characterized by nocturnal wandering.

[0851] In some embodiments, the neurological disease is a neurodevelopmental disease. In some embodiments, the neurodevelopmental disease is autism. In some embodiments, the neurological disease is muscular dystonia. In some embodiments, muscular dystonia is neuromuscular dystonia. In some embodiments, the neuromuscular dystonia is spasmodic torticollis.

[0852] In some embodiments, the neurological disease is multiple sclerosis (MS).

[0853] In some embodiments, the sleep disorder is caused by or comorbid with a circadian rhythm disorder.

[0854] In some embodiments, the sleep disorder is caused by a circadian rhythm disorder.

[0855] In some embodiments, the sleep disorder is comorbid with a circadian rhythm disorder.

[0856] In some embodiments, the circadian rhythm disorder is an advanced sleep-wake period disorder. In some embodiments, the circadian rhythm disorder is an irregular sleep-wake rhythm disorder. In some embodiments, the circadian rhythm disorder is jet lag syndrome. In some embodiments, the circadian rhythm disorder is shift work sleep disorder. In some embodiments, the circadian rhythm disorder is delayed sleep phase syndrome. In some embodiments, the circadian rhythm disorder is a non-24-hour rhythm disorder.

[0857] In some embodiments, the sleep disorder is caused by or comorbid with sleep fragmentation in the elderly.

[0858] In some embodiments, the sleep disorder is caused by fragmented sleep in the elderly.

[0859] In some embodiments, the sleep disorder is comorbid with geriatric sleep fragmentation.

[0860] In some embodiments, the sleep disorder is caused by or comorbid with age-related sleep fragmentation.

[0861] In some embodiments, the sleep disorder is caused by age-related sleep fragmentation.

[0862] In some embodiments, the sleep disorder is comorbid with age-related sleep fragmentation.

[0863] In some embodiments, the sleep disorder is caused by or comorbid with postmenopausal sleep disorder.

[0864] In some embodiments, the sleep disorder is caused by postmenopausal sleep disorder.

[0865] In some embodiments, the sleep disorder is comorbid with a postmenopausal sleep disorder.

[0866] In some embodiments, the sleep disorder is caused by or comorbid with substance abuse.

[0867] In some embodiments, the sleep disorder is caused by substance abuse.

[0868] In some embodiments, the sleep disorder is comorbid with substance abuse.

[0869] In some embodiments, the substance abuse is opioid abuse or alcoholism. In some embodiments, the substance abuse is opioid abuse. In some embodiments, the substance abuse is alcoholism.

[0870] In some embodiments, the sleep disorder is caused by or comorbid with substance abuse withdrawal.

[0871] In some embodiments, the sleep disorder results from withdrawal from a substance of abuse.

[0872] In some embodiments, the sleep disorder is comorbid with substance abuse withdrawal.

[0873] In some embodiments, the substance abuse withdrawal is opioid withdrawal or alcohol withdrawal. In some embodiments, the substance abuse withdrawal is opioid withdrawal. In some embodiments, the substance abuse withdrawal is alcohol withdrawal.

[0874] In some embodiments, the sleep disorder is caused by or comorbid with narcolepsy.

[0875] In some embodiments, the sleep disorder is caused by narcolepsy.

[0876] In some embodiments, the sleep disorder is comorbid with narcolepsy.

[0877] In some embodiments, the sleep disorder is caused by or comorbid with periodic leg movement disorder (PLMD).

[0878] In some embodiments, the sleep disorder is caused by periodic leg movement disorder (PLMD).

[0879] In some embodiments, the sleep disorder is comorbid with periodic leg movement disorder (PLMD).

[0880] In some embodiments, the sleep disorder is caused by or comorbid with REM behavior disorder.

[0881] In some embodiments, the sleep disorder is caused by REM behavior disorder.

[0882] In some embodiments, the sleep disorder is comorbid with REM behavior disorder.

[0883] In some embodiments, the sleep disorder is caused by or comorbid with geriatric fragmented sleep.

[0884] In some embodiments, the sleep disorder is caused by fragmented sleep in the elderly.

[0885] In some embodiments, the sleep disorder is comorbid with geriatric sleep fragmentation.

[0886] In some embodiments, the sleep disorder is caused by or comorbid with idiopathic hypersomnia.

[0887] In some embodiments, the sleep disorder is caused by idiopathic hypersomnia.

[0888] In some embodiments, the sleep disorder is comorbid with idiopathic hypersomnia.

[0889] In some embodiments, the sleep disorder is caused by or comorbid with non-restorative sleep.

[0890] In some embodiments, the sleep disorder is caused by non-restorative sleep.

[0891] In some embodiments, the sleep disorder is comorbid with non-restorative sleep.

[0892] In some embodiments, the sleep disorder is caused by or comorbid with snoring.

[0893] In some embodiments, the sleep disorder is caused by snoring.

[0894] In some embodiments, the sleep disorder is comorbid with snoring.

[0895] In some embodiments, the sleep disorder is caused by or comorbid with increased sensitivity to pain.

[0896] In some embodiments, the sleep disorder is caused by increased sensitivity to pain.

[0897] In some embodiments, the sleep disorder is comorbid with increased sensitivity to pain.

[0898] In some embodiments, the sleep disorder is caused by or is comorbid with cardiovascular disease.

[0899] In some embodiments, the sleep disorder is caused by cardiovascular disease.

[0900] In some embodiments, the sleep disorder is comorbid with cardiovascular disease.

[0901] In some embodiments, the sleep disorder is caused by or is comorbid with hypertension.

[0902] In some embodiments, the sleep disorder is caused by high blood pressure.

[0903] In some embodiments, the sleep disorder is comorbid with hypertension.

[0904] In some embodiments, the sleep disorder is caused by or comorbid with stroke.

[0905] In some embodiments, the sleep disorder is caused by a stroke.

[0906] In some embodiments, the sleep disorder is comorbid with stroke.

[0907] In some embodiments, the sleep disorder is caused by or is comorbid with a metabolic disorder.

[0908] In some embodiments, the sleep disorder is caused by a metabolic disorder.

[0909] In some embodiments, the sleep disorder is comorbid with a metabolic disorder.

[0910] In some embodiments, the metabolic disorder is diabetes.

[0911] In some embodiments, the sleep disorder is caused by or is comorbid with cognitive impairment.

[0912] In some embodiments, the sleep disorder is due to cognitive impairment.

[0913] In some embodiments, the sleep disorder is comorbid with cognitive impairment.

[0914] The present disclosure provides compounds that are useful as modulators of H1 / 5-HT2A function. Accordingly, the present disclosure provides methods for modulating H1 inverse agonism and 5-HT2A antagonism in vitro or in vivo. The methods comprise contacting a cell with an effective amount of a compound as defined herein, or a pharmaceutically acceptable salt thereof.

[0915] The effectiveness of the compounds of the present disclosure can be determined according to standard practice described in the art, elucidated therefor, by industry-accepted assays or disease models, and is found within the current common general knowledge.

[0916] The present disclosure also provides methods of treating a disease or condition in which H1 / 5-HT2A function is implicated in a subject in need of such treatment by administering to the subject a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.

[0917] The compounds of the present invention or their pharmaceutically acceptable salts can be administered alone as a sole therapy, or can be administered together with one or more other substances and / or treatments. In some embodiments, one or more other substances and / or treatments and the compounds of the present invention or their pharmaceutically acceptable salts can be administered close in time. Such combined therapy can be achieved by administering the individual components of the treatment simultaneously, sequentially, or separately.

[0918] In some embodiments, the methods of the present disclosure involve administering to a subject a compound of the present disclosure and an additional active agent. In some embodiments, the additional active agent can be, for example, a sedative-hypnotic drug.

[0919] In some embodiments, the methods of the present disclosure comprise administering a compound of the present disclosure alone, or a pharmaceutically acceptable derivative thereof.

[0920] In some embodiments, the methods of the present disclosure comprise administering a compound of the present disclosure, or a pharmaceutically acceptable derivative thereof, in combination with a single additional active agent.

[0921] In some embodiments, the methods of the present disclosure comprise administering a compound of the present disclosure, or a pharmaceutically acceptable derivative thereof, in combination with an active agent.

[0922] In some embodiments, the methods of the present disclosure involve administering a compound of the present disclosure, if any, at hora somni (hs) or between about 0-4 hours before bedtime.

[0923] In some embodiments, the methods of the present disclosure involve administering a compound of the present disclosure, if any, at bedtime (hs (bedtime)) or between about 4 hours before bedtime.

[0924] In some embodiments, the methods of the present disclosure involve administering a compound of the present disclosure and any additional active agent between 0 and about 4 hours before bedtime.

[0925] In some embodiments, the methods of the present disclosure involve administering a compound of the present disclosure and any additional active agent about 1 hour before bedtime.

[0926] In some embodiments, the methods of the present disclosure involve administering a compound of the present disclosure and any additional active agent about 2 hours before bedtime.

[0927] In some embodiments, the methods of the present disclosure involve administering a compound of the present disclosure and any additional active agent about 3 hours before bedtime.

[0928] In some embodiments, the methods of the present disclosure involve administering a compound of the present disclosure and any additional active agent about 4 hours before bedtime.

[0929] For example, the effectiveness of a treatment may be enhanced by administering an adjuvant (i.e., the adjuvant itself may have only minimal therapeutic benefit, but when combined with another therapeutic agent, enhances the overall therapeutic benefit to the individual). Or, by way of example only, the benefit experienced by an individual may be increased by administering a compound of Formula (I), (II) or (II') with another therapeutic agent (which also includes a treatment regimen) that also has therapeutic benefit.

[0930] In the case of a compound of the present invention being administered in combination with other therapeutic agents, the compound of the present invention does not need to be administered by the same route as the other therapeutic agents and, due to different physical and chemical properties, can be administered by different routes. For example, the compound of the present invention can be administered orally to produce and maintain good blood levels thereof, while other therapeutic agents can be administered intravenously. Initial administration can be performed according to established protocols known in the art, and then, based on the observed effects, a skilled clinician can modify the dosage, mode of administration, and time of administration.

[0931] The specific choice of other therapeutic agents will depend on the diagnosis of the attending physician and his or her judgment of the individual condition and the appropriate treatment regimen. According to this aspect of the present disclosure, there is provided a combination for treating a sleep disorder comprising a compound of the present disclosure as defined above or a pharmaceutically acceptable salt thereof and another suitable agent.

[0932] According to another aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound of the present disclosure or a pharmaceutically acceptable salt thereof, in combination with a suitable pharmaceutically acceptable diluent or carrier.

[0933] In addition to their use in therapeutic drugs, the compounds of formula (I), (II) or (II') and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardization of in vitro and in vivo test systems for evaluating H1 / 5-HT2A function in laboratory animals such as dogs, rabbits, monkeys, rats and mice as part of the search for new therapeutic agents.

[0934] In some embodiments, the methods of the present disclosure comprise administering a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, alone or in combination with a single additional active agent.

[0935] In some embodiments, the methods of the present disclosure comprise administering a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with a single additional active agent.

[0936] In some embodiments, the methods of the present disclosure comprise administering a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with an active agent.

[0937] In some embodiments, the methods of the present disclosure comprise administering to a subject a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, as co-therapy with a medical device-based therapy.

[0938] In some embodiments, the methods of the present disclosure comprise administering to a subject a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, as a combination therapy with a medical device-based therapy, such as continuous positive airway pressure (CPAP) technology or transcranial magnetic stimulation or transcranial electromagnetic stimulation technology.

[0939] In some embodiments, the methods of the present disclosure comprise administering a compound of Formula (I), (II), or (II'), or a pharmaceutically acceptable salt thereof, alone or in combination with a single additional active agent.

[0940] In some embodiments, the methods of the present disclosure comprise administering a compound of Formula (I), (II), or (II'), or a pharmaceutically acceptable salt thereof, in combination with a single additional active agent.

[0941] In some embodiments, the methods of the present disclosure comprise administering a compound of Formula (I), (II), or (II'), or a pharmaceutically acceptable salt thereof, in combination with an active agent.

[0942] In some embodiments, the methods of the present disclosure comprise administering to a subject a compound of Formula (I), Formula (II), or Formula (II'), or a pharmaceutically acceptable salt thereof, as a combination therapy with a medical device-based therapy.

[0943] In some embodiments, the methods of the present disclosure comprise administering to a subject a compound of Formula (I), (II) or (II'), or a pharmaceutically acceptable salt thereof, as a combination therapy with a medical device-based therapy, such as continuous positive airway pressure (CPAP) technology or transcranial magnetic stimulation or transcranial electromagnetic stimulation technology.

[0944] In some embodiments, the methods of the present disclosure comprise administering a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, alone or in combination with a single additional active agent.

[0945] In some embodiments, the methods of the present disclosure comprise administering a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, in combination with a single additional active agent.

[0946] In some embodiments, the methods of the present disclosure comprise administering a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, and a combination of an active agent.

[0947] In some embodiments, the methods of the present disclosure comprise administering to a subject a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, as a combination therapy with a medical device-based therapy.

[0948] In some embodiments, the methods of the present disclosure comprise administering to a subject a compound of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, as a combination therapy with a medical device-based therapy, such as continuous positive airway pressure (CPAP) technology or transcranial magnetic stimulation or transcranial electromagnetic stimulation technology.

[0949] In some embodiments, the methods of the present disclosure comprise administering compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof, alone or in combination with a single additional active agent.

[0950] In some embodiments, the methods of the present disclosure comprise administering compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof, in combination with a single additional active agent.

[0951] In some embodiments, the methods of the present disclosure comprise administering compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof, and a combination of active agents.

[0952] In some embodiments, the methods of the present disclosure comprise administering Compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof, to a subject as co-therapy with a medical device-based therapy.

[0953] In some embodiments, the methods of the present disclosure comprise administering compound 30, 31, 34, or 35, or a pharmaceutically acceptable salt thereof, to a subject as a combination therapy with a medical device-based therapy, such as continuous positive airway pressure (CPAP) technology or transcranial magnetic stimulation or transcranial electromagnetic stimulation technology.

[0954] In some embodiments, the medical device-based therapy is continuous positive airway pressure (CPAP), transcranial magnetic stimulation, or transcranial electromagnetic stimulation.

[0955] In some embodiments, the medical device-based therapy is continuous positive airway pressure (CPAP) technology.

[0956] In some embodiments, the medical device-based therapy is transcranial magnetic stimulation technology.

[0957] In some embodiments, the medical device-based therapy is transcranial electromagnetic stimulation technology.

[0958] In some embodiments, the methods of the present disclosure comprise administering to a subject a compound of Formula (I) or Formula (II) as a combination therapy with cognitive behavioral therapy (CBT).

[0959] In some embodiments, CBT is brief cognitive behavioral therapy (BCBT), cognitive emotional behavioral therapy (CEBT), structured cognitive behavioral training (SCBT), moral reconciliation therapy, stress inoculation training, or activity-guided CBT.

[0960] In some embodiments, CBT is brief cognitive behavioral therapy (BCBT).

[0961] In some embodiments, CBT is cognitive emotional behavioral therapy (CEBT).

[0962] In some embodiments, the CBT is structured cognitive behavioral training (SCBT).

[0963] In some embodiments, CBT is moral attunement therapy.

[0964] In some embodiments, the CBT is stress inoculation training.

[0965] In some embodiments, the CBT is activity-guided CBT.

[0966] In some embodiments, compounds of the present disclosure can improve sleep fragmentation.

[0967] Sleep fragmentation can be assessed by evaluating polysomnogram-derived sleep architecture and sleep depth endpoints, including the number of awakenings (measured by the number of transitions from sleep to wakefulness), sleep continuity / consolidation (measured by the average duration of sleep bouts), and sleep depth measured by EEG delta power (Fourier analysis-derived power in the 0.5-4.0 Hz frequency band in the cortical EEG during non-REM sleep).

[0968] Sleep fragmentation can be assessed by assessing the sleep architecture and depth of sleep endpoints derived from polysomnography, including the number of awakenings (measured by the number of transitions from sleep to wakefulness). Sleep fragmentation can be assessed by assessing the sleep architecture and depth of sleep endpoints derived from polysomnography, including sleep continuity / consolidation (as measured by the average duration of sleep bouts). Sleep fragmentation can be assessed by assessing the sleep architecture and depth of sleep endpoints derived from polysomnography, including the depth of sleep measured by EEG delta power (power derived from Fourier analysis in the 0.5-4.0 Hz frequency band in the cortical EEG during non-REM sleep).

[0969] In some embodiments, compounds of the present disclosure meet the minimum common required preclinical endpoints for identifying molecules that reduce sleep fragmentation.

[0970] In some embodiments, compounds of the present disclosure may improve other measures of sleep quality indicative of molecules that promote sleep maintenance.

[0971] In some embodiments, compounds of the present disclosure may improve other measures of sleep quality indicative of molecules that promote sleep maintenance, as demonstrated by increased sleep depth as measured by EEG or indirectly using other behavioral parameters.

[0972] In some embodiments, the compounds of the present disclosure can improve sleep fragmentation without producing certain unwanted side effects. In some embodiments, the unwanted side effects are selected from myorelaxation, impaired motor function, lack of rebound insomnia, and significant changes in sleep stage architecture (e.g., percentage of sleep stages per unit time).

[0973] In some embodiments, the unwanted side effect is muscle relaxation.

[0974] In some embodiments, the unwanted side effect is impaired motor function.

[0975] In some embodiments, the unwanted side effect is rebound insomnia.

[0976] In some embodiments, the unwanted side effect is a significant change in sleep stage architecture.

[0977] In any of the above-described pharmaceutical compositions, processes, methods, uses, medicaments, and manufacturing features of the present disclosure, any of the alternative embodiments of the macromolecules of the present disclosure described herein also apply.

[0978] Route of administration

[0979] The compounds of the present disclosure, or pharmaceutical compositions comprising these compounds, may be administered to a subject by any convenient route of administration, whether systemically / peripherally or locally (ie, at the site of desired action).

[0980] Routes of administration include, but are not limited to, oral (e.g., by digestion); buccal; sublingual; transdermal (including, for example, by patches, plasters, etc.); transmucosal (including, for example, by patches, plasters, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eye drops); pulmonary (e.g., by inhalation or insufflation therapy, using, for example, via an aerosol, e.g., through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, e.g., by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcutaneous, intraarticular, subarachnoid, and intrasternal; by implantation of a reservoir or depot, e.g., subcutaneous or intramuscular.

[0981] Exemplary embodiments

[0982] Embodiment No. 1. Compound of formula (I):

[0983]

[0984] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein:

[0985] R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[0986] R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl; or

[0987] R1 and R2 together with the atoms to which they are attached form a C3-C6 saturated or partially unsaturated cycloalkyl group or a 3- to 14-membered saturated or partially unsaturated heterocyclic ring containing 1 to 5 heteroatoms selected from N, O and S;

[0988] R3 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0989] R4 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0990] R5 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0991] R6 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[0992] R7 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl;

[0993] R8 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; and

[0994] R9 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl or C3-C6 cycloalkyl,

[0995] Provided that at least one of R3, R4, R5 and R6 is H.

[0996] Embodiment No. 2. Compound of formula (II):

[0997]

[0998] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein:

[0999] X is CR7R8, O, S or NR7;

[1000] R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[1001] R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl; or

[1002] R1 and R2 together with the atoms to which they are attached form a C3-C6 saturated or partially unsaturated cycloalkyl group or a 3- to 14-membered saturated or partially unsaturated heterocyclic ring containing 1 to 5 heteroatoms selected from N, O and S;

[1003] R3 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[1004] R4 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[1005] R5 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[1006] R6 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[1007] R7 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl;

[1008] R8 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; and

[1009] R9 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl or C3-C6 cycloalkyl,

[1010] The conditions are:

[1011] (a) When R5 is H, X is CR7R8 or S;

[1012] (b) when R5 is halogen and R4 is H, R3 is not methyl, methoxy or Br, and X is CR7R8 or S; and

[1013] (c) When R5 is methoxy or methyl, R4 is not H.

[1014] Embodiment No. 3. Compound of formula (II'):

[1015]

[1016] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein:

[1017] X is CR7R8, O, S or NR7;

[1018] R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl;

[1019] R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C6 cycloalkyl; or

[1020] R1 and R2 together with the atoms to which they are attached form a C3-C6 saturated or partially unsaturated cycloalkyl group or a 3- to 14-membered saturated or partially unsaturated heterocyclic ring containing 1 to 5 heteroatoms selected from N, O and S;

[1021] R3 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[1022] R4 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[1023] R5 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[1024] R6 is H, halogen, –S(C1-C6 alkyl), –N(C1-C6 alkyl)2, –NH(C1-C6 alkyl), –NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, or C3-C6 cycloalkyl;

[1025] R7 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl;

[1026] R8 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl;

[1027] R9 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl or C3-C6 cycloalkyl; and

[1028] R 10 is H or halogen,

[1029] The conditions are:

[1030] (a) (i) when R5 is H, X is CR7R8 or S, or (ii) when R5 is H and R 10 When it is a halogen, X is O;

[1031] (b) when R5 is halogen, R4 is H, R3 is not methyl, methoxy or Br, and X is CR7R8 or S; and

[1032] (c) When R5 is methoxy or methyl, R4 is not H.

[1033] Embodiment No. 4. The compound of Embodiment 2, wherein X is O or CR7R8.

[1034] Embodiment No. 5. The compound of Embodiment 2, wherein X is O.

[1035] Embodiment No. 6. The compound of Embodiment 2, wherein X is CH2.

[1036] Embodiment No. 7. The compound of any of the above embodiments, wherein R1 is C1-C6 alkyl.

[1037] Embodiment No. 8. The compound of any one of the above embodiments, wherein R1 is methyl.

[1038] Embodiment No. 9. The compound of any of the above embodiments, wherein R2 is C1-C6 alkyl.

[1039] Embodiment No. 10. The compound of any one of the above embodiments, wherein R2 is methyl.

[1040] Embodiment No. 11. A compound according to any of the above embodiments, wherein R1 and R2 together with the atoms to which they are attached form a C3-C6 saturated or partially unsaturated cycloalkyl or a 3- to 14-membered saturated or partially unsaturated heterocyclic ring containing 1-5 heteroatoms selected from N, O and S.

[1041] Embodiment No. 12. The compound of any one of the above embodiments, wherein R1 and R2 together with the atoms to which they are attached form a cyclopropyl group.

[1042] Embodiment No. 13. The compound of any one of the above embodiments, wherein R3 is H, halogen, C1-C6 alkyl or C1-C6 alkoxy.

[1043] Embodiment No. 14. The compound of any one of the above embodiments, wherein R3 is H, F, Cl, methyl or methoxy.

[1044] Embodiment No. 15. The compound of any one of the above embodiments, wherein R3 is H.

[1045] Embodiment No. 16. The compound of any one of the above embodiments, wherein R3 is F.

[1046] Embodiment No. 17. The compound of any of the above embodiments, wherein R3 is Cl.

[1047] Embodiment No. 18. The compound of any one of the above embodiments, wherein R3 is methyl.

[1048] Embodiment No. 19. The compound of any one of the above embodiments, wherein R3 is methoxy.

[1049] Embodiment No. 20. The compound of any one of the above embodiments, wherein R4 is H, halogen, C1-C6 alkyl or C1-C6 haloalkyl.

[1050] Embodiment No. 21. A compound according to any one of the above embodiments, wherein R4 is H, F, Cl, methyl or CHF2.

[1051] Embodiment No. 22. The compound of any one of the above embodiments, wherein R4 is H.

[1052] Embodiment No. 23. The compound of any one of the above embodiments, wherein R4 is F.

[1053] Embodiment No. 24. The compound of any one of the above embodiments, wherein R4 is Cl.

[1054] Embodiment No. 25. The compound of any one of the above embodiments, wherein R4 is methyl.

[1055] Embodiment No. 26. The compound of any one of the above embodiments, wherein R4 is CHF2.

[1056] Embodiment No. 27. A compound according to any one of the above embodiments, wherein R5 is H, halogen, C1-C6 alkyl, C1-C6 alkoxy, S(C1-C6 alkyl) or C1-C6 haloalkyl.

[1057] Embodiment No. 28. A compound according to any one of the above embodiments, wherein R5 is H, F, Cl, methyl, ethyl, isopropyl, n-propyl, methoxy, -SCH3 or CHF2.

[1058] Embodiment No. 29. The compound of any of the above embodiments, wherein R5 is H.

[1059] Embodiment No. 30. The compound of any one of the above embodiments, wherein R5 is F.

[1060] Embodiment No. 31. The compound of any of the above embodiments, wherein R5 is Cl.

[1061] Embodiment No. 32. The compound of any one of the above embodiments, wherein R5 is methyl.

[1062] Embodiment No. 33. A compound according to any one of the above embodiments, wherein R5 is ethyl.

[1063] Embodiment No. 34. The compound of any of the above embodiments, wherein R5 is isopropyl.

[1064] Embodiment No. 35. The compound of any of the above embodiments, wherein R5 is n-propyl.

[1065] Embodiment No. 36. The compound of any one of the above embodiments, wherein R5 is methoxy.

[1066] Embodiment No. 37. The compound of any of the above embodiments, wherein R5 is methylthio.

[1067] Embodiment No. 38. A compound according to any one of the above embodiments, wherein R5 is CHF2.

[1068] Embodiment No. 39. A compound according to any one of the above embodiments, wherein R6 is H, C1-C6 alkyl or C1-C6 alkoxy.

[1069] Embodiment No. 40. The compound of any one of the above embodiments, wherein R6 is H, methyl or methoxy.

[1070] Embodiment No. 41. The compound of any of the above embodiments, wherein R6 is H.

[1071] Embodiment No. 42. The compound of any one of the above embodiments, wherein R6 is methyl.

[1072] Embodiment No. 43. A compound according to any one of the above embodiments, wherein R6 is methoxy.

[1073] Embodiment No. 44. The compound of any of the above embodiments, wherein R7 is H.

[1074] Embodiment No. 45. The compound of any of the above embodiments, wherein R8 is H.

[1075] Embodiment No. 46. The compound of any of the above embodiments, wherein R9 is H.

[1076] Embodiment No. 47. The compound of any one of the above embodiments, wherein R 10 For H.

[1077] Embodiment No. 48. The compound of any one of the above embodiments, wherein R 10 For F.

[1078] Embodiment No. 49. The compound of any one of the above embodiments, wherein the compound is a compound of formula (Ia):

[1079]

[1080] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein R3, R4, R5 and R6 are as described herein.

[1081] Embodiment No. 50. The compound of any one of the above embodiments, wherein the compound is a compound of formula (Ib):

[1082]

[1083] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein R3, R4, R5 and R6 are as described herein.

[1084] Embodiment No. 51. The compound of any one of the above embodiments, wherein the compound is a compound of formula (IIa):

[1085]

[1086] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R1, R2, R4, R5 and R9 are as described herein.

[1087] Embodiment No. 52. The compound of any one of the above embodiments, wherein the compound is a compound of formula (IIa-1):

[1088]

[1089] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R4 and R5 are as described herein.

[1090] Embodiment No. 53. The compound of any one of the above embodiments, wherein the compound is a compound of formula (IIa-2):

[1091]

[1092] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R4 and R5 are as described herein.

[1093] Embodiment No. 54. The compound of any one of the above embodiments, wherein the compound is a compound of formula (IIb):

[1094]

[1095] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R5 and R9 are as described herein.

[1096] Embodiment No. 55. The compound of any one of the above embodiments, wherein the compound is a compound of formula (IIb-1):

[1097]

[1098] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R3 and R5 are as described herein.

[1099] Embodiment No. 56. The compound of any one of the above embodiments, wherein the compound is a compound of formula (IIb-2):

[1100]

[1101] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R3 and R5 are as described herein.

[1102] Embodiment No. 57. The compound of any one of the above embodiments, wherein the compound is a compound of formula (IIc):

[1103]

[1104] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R6 and R9 are as described herein.

[1105] Embodiment No. 58. The compound of any one of the above embodiments, wherein the compound is a compound of formula (IIc-1):

[1106]

[1107] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R3 and R6 are as described herein.

[1108] Embodiment No. 59. The compound of any one of the above embodiments, wherein the compound is a compound of formula (IIc-2):

[1109]

[1110] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R3 and R6 are as described herein.

[1111] Embodiment No. 60. The compound of any one of the above embodiments, wherein the compound is a compound of formula (II'a)

[1112]

[1113] or a prodrug, solvate or pharmaceutically acceptable salt thereof, wherein X, R1, R2, R9 and R 10 As described herein for Formula (II').

[1114] Embodiment No. 61. The compound of any one of the above embodiments 1-60, which is selected from compound No. 1-39, a prodrug thereof, and a pharmaceutically acceptable salt.

[1115] Embodiment No. 62. The compound of any one of the above embodiments 1-60, which is selected from compound No. 1-39 and a pharmaceutically acceptable salt thereof.

[1116] Embodiment No. 63. The compound of any one of the above embodiments 1-60, which is selected from compound Nos. 1-39.

[1117] Embodiment No. 64. The compound of any one of the above embodiments 1-60, which is selected from compound Nos. 30, 31, 34 and 35.

[1118] Embodiment No. 65. A compound obtainable by or by a method described herein; optionally, the method comprises one or more steps described in Schemes 1-3.

[1119] Embodiment No. 66. A pharmaceutical composition comprising a compound according to any one of Embodiments 1-65 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

[1120] Embodiment No. 67. The pharmaceutical composition of embodiment 66, wherein the compound is selected from compound Nos. 1-39.

[1121] Embodiment No. 68. A method for alleviating symptoms of sleep disorders, treating or preventing sleep disorders in a subject, by administering the compound of any one of Embodiments 1-65 or the pharmaceutical composition of Embodiment 66 or 67 to a subject in need thereof.

[1122] Embodiment No. 69. The method of Embodiment 68, wherein the sleep disorder is increased sleep fragmentation.

[1123] Embodiment No. 70. The method of embodiment 68 or 69, wherein the compound is H1 / 5-HT 2A Receptor modulators.

[1124] Embodiment No. 71. A method according to embodiment 68 or 69, wherein the sleep disorder is caused by or is co-morbid with sleep apnea, restless legs syndrome, a high respiratory disturbance index (RDI), a neurological disease, a circadian rhythm disorder, pain, periodic leg movement disorder (PLMD), REM behavior disorder, geriatric sleep fragmentation, age-related sleep fragmentation, postmenopausal sleep disorder, substance abuse, substance abuse withdrawal, narcolepsy, a psychiatric disorder, increased sensitivity to pain, cardiovascular disease, hypertension, non-restorative sleep, stroke, a metabolic disorder, or a cognitive disorder.

[1125] Embodiment No. 72. The method of embodiment 71, wherein the sleep apnea is obstructive sleep apnea caused by a high respiratory disturbance index (RDI) associated with elevated respiratory event-related arousals (RERA), with or without accompanying apneas, hypopneas, or acute hemoglobin desaturation.

[1126] Embodiment No. 73. The method of embodiment 71, wherein the neurological disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, or Lewy body dementia.

[1127] Embodiment No. 74. The method of embodiment 71, wherein the nervous system disease is a neurodegenerative disease.

[1128] Embodiment No. 75. The method of Embodiment 74, wherein the neurodegenerative disease is a synucleinopathy.

[1129] Embodiment No. 76. The method of embodiment 75, wherein the synucleinopathy is Alzheimer's disease, Parkinson's disease, or dementia with Lewy bodies

[1130] Embodiment No. 77. The method of Embodiment 74, wherein the neurodegenerative disease is Lewy body disease, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease.

[1131] Embodiment No. 78. The method of embodiment 71, wherein the pain is acute nociceptive pain, chronic neuropathic pain, inflammatory pain, arthritic pain, cancer pain, or mixed nociceptive and neuropathic pain.

[1132] Embodiment No. 79. The method of Embodiment 78, wherein the mixed nociceptive and neuropathic pain is lowback pain.

[1133] Embodiment No. 80. The method of embodiment 71, wherein the circadian rhythm disorder is jet lag, shift work, delayed sleep phase disorder, or a non-24-hour rhythm disorder.

[1134] Embodiment No. 81. The method of embodiment 71, wherein the substance abuse is opioid abuse or alcohol intoxication.

[1135] Embodiment No. 82. The method of Embodiment 71, wherein the substance abuse withdrawal is opioid withdrawal or alcohol withdrawal.

[1136] Embodiment No. 83. The method of embodiment 71, wherein the mental disorder is depression, major depressive disorder, post-traumatic stress disorder, anxiety disorder, bipolar disorder or schizophrenia.

[1137] Embodiment No. 84. The method of any one of Embodiments 68-83, wherein the compound is administered in combination with an additional active agent.

[1138] Embodiment No. 85. The method of embodiment 84, wherein the additional active agent is a sedative-hypnotic drug.

[1139] Embodiment No. 86. The method of any one of Embodiments 68-85, wherein the compound and any additional active agent (if present) are administered at sleep time (hs (bedtime)) or between about 0-4 hours before bedtime.

[1140] Embodiment No. 87. The compound of any one of Embodiments 1-65 or the pharmaceutical composition of Embodiment 66 or 67, for alleviating the symptoms of sleep disorders, treating or preventing sleep disorders.

[1141] Embodiment No. 88. The compound or pharmaceutical composition for use according to Embodiment 87, wherein the sleep disorder is increased sleep fragmentation.

[1142] Embodiment No. 89. The compound or pharmaceutical composition for use in embodiment 87 or 88, wherein the compound or pharmaceutical composition is H1 / 5-HT 2A Receptor modulators.

[1143] Embodiment No. 90. A compound or pharmaceutical composition for use according to embodiment 87 or 88, wherein the sleep disorder is caused by or is comorbid with sleep apnea, restless legs syndrome, a high respiratory disturbance index (RDI), a neurological disease, a circadian rhythm disorder, pain, periodic leg movement disorder (PLMD), REM behavior disorder, fragmented sleep in the elderly, age-related sleep fragmentation, postmenopausal sleep disorder, substance abuse, substance abuse withdrawal, narcolepsy, a psychiatric disorder, increased sensitivity to pain, cardiovascular disease, hypertension, non-restorative sleep, stroke, a metabolic disorder, or a cognitive disorder.

[1144] Embodiment No. 91. A compound or pharmaceutical composition for use according to embodiment 90, wherein the sleep apnea is obstructive sleep apnea due to a high respiratory disturbance index (RDI) associated with elevated respiratory event-related arousals (RERA), with or without accompanying apneas, hypopneas, or acute hemoglobin desaturation.

[1145] Embodiment No. 92. The compound or pharmaceutical composition for use according to embodiment 90, wherein the nervous system disease is Alzheimer's disease, Parkinson's disease, Huntington's disease or Lewy body dementia.

[1146] Embodiment No. 93. The compound or pharmaceutical composition for use according to embodiment 90, wherein the nervous system disease is a neurodegenerative disease.

[1147] Embodiment No. 94. The compound or pharmaceutical composition for use according to embodiment 93, wherein the neurodegenerative disease is a synucleinopathy.

[1148] Embodiment No. 95. The compound or pharmaceutical composition for use according to embodiment 94, wherein the synucleinopathy is Alzheimer's disease, Parkinson's disease, or dementia with Lewy bodies.

[1149] Embodiment No. 96. The compound or pharmaceutical composition for use according to embodiment 93, wherein the neurodegenerative disease is Lewy body disease, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease.

[1150] Embodiment No. 97. A compound or pharmaceutical composition for use according to embodiment 90, wherein the pain is acute nociceptive pain, chronic neuropathic pain, inflammatory pain, arthritic pain, cancer pain, or mixed nociceptive and neuropathic pain.

[1151] Embodiment No. 98. The compound or pharmaceutical composition for use according to Embodiment 97, wherein the mixed nociceptive and neuropathic pain is low back pain.

[1152] Embodiment No. 99. The compound or pharmaceutical composition for use according to embodiment 90, wherein the circadian rhythm disorder is jet lag, shift work, delayed sleep phase disorder, or non-24-hour rhythm disorder.

[1153] Embodiment No. 100. The compound or pharmaceutical composition for use according to embodiment 90, wherein the substance abuse is opioid abuse or alcoholism.

[1154] Embodiment No. 101. The compound or pharmaceutical composition for use according to Embodiment 90, wherein the substance abuse withdrawal is opioid withdrawal or alcohol withdrawal.

[1155] Embodiment No. 102. The compound or pharmaceutical composition for use according to embodiment 90, wherein the psychiatric disorder is depression, major depressive disorder, post-traumatic stress disorder, anxiety disorder, bipolar disorder or schizophrenia.

[1156] Embodiment No. 103. A compound or pharmaceutical composition for use according to any one of embodiments 87-102, wherein the compound is administered in combination with an additional active agent.

[1157] Embodiment No. 104. The compound or pharmaceutical composition for use according to embodiment 103, wherein the additional active agent is a sedative-hypnotic.

[1158] Embodiment No. 105. A compound or pharmaceutical composition for use according to any one of embodiments 87-104, wherein the compound and any additional active agent (if present) are administered at sleep time (hs) (at bedtime) or between about 0-4 hours before bedtime.

[1159] Embodiment No. 106. Use of the compound of any one of Embodiments 1-65 or the pharmaceutical composition of Embodiment 66 or 67 in the preparation of a medicament for alleviating symptoms of sleep disorders or treating or preventing sleep disorders.

[1160] Embodiment No. 107. Use of the compound or pharmaceutical composition of Embodiment 106 in the preparation of a medicament, wherein the sleep disorder is increased sleep fragmentation.

[1161] Embodiment No. 108. Use of the compound or pharmaceutical composition of embodiment 106 or 107 in the preparation of a drug, wherein the compound or pharmaceutical composition is H1 / 5-HT 2A Receptor modulators.

[1162] Embodiment No. 109. Use of a compound or pharmaceutical composition of Embodiment 106 or 107 in the preparation of a medicament, wherein the sleep disorder is caused by or is comorbid with sleep apnea, restless legs syndrome, a high respiratory disturbance index (RDI), a neurological disease, a circadian rhythm disorder, pain, periodic leg movement disorder (PLMD), REM behavior disorder, fragmented sleep in the elderly, age-related sleep fragmentation, postmenopausal sleep disorder, substance abuse, substance abuse withdrawal, narcolepsy, a mental disorder, increased sensitivity to pain, cardiovascular disease, hypertension, non-restorative sleep, stroke, a metabolic disorder, or a cognitive disorder.

[1163] Embodiment No. 110. Use of a compound or pharmaceutical composition of Embodiment 109 in the preparation of a medicament, wherein the sleep apnea is obstructive sleep apnea due to a high respiratory disturbance index (RDI) associated with elevated respiratory event-related arousals (RERA), with or without concomitant apneic, hypopneic hemoglobin desaturation.

[1164] Embodiment No. 111. Use of the compound or pharmaceutical composition of Embodiment 109 in the preparation of a medicament, wherein the neurological disease is Alzheimer's disease, Parkinson's disease, Huntington's disease or Lewy body dementia.

[1165] Embodiment No. 112. Use of the compound or pharmaceutical composition of Embodiment 109 in the preparation of a medicament, wherein the nervous system disease is a neurodegenerative disease.

[1166] Embodiment No. 113. Use of the compound or pharmaceutical composition of Embodiment 112 in the preparation of a medicament, wherein the neurodegenerative disease is a synucleinopathy.

[1167] Embodiment No. 114. Use of the compound or pharmaceutical composition of Embodiment 113 in the preparation of a medicament, wherein the synucleinopathy is Alzheimer's disease, Parkinson's disease, or Lewy body dementia.

[1168] Embodiment No. 115. Use of the compound or pharmaceutical composition of Embodiment 112 in the preparation of a medicament, wherein the neurodegenerative disease is Lewy body disease, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease.

[1169] Embodiment No. 116. Use of a compound or pharmaceutical composition according to Embodiment 109 in the preparation of a medicament, wherein the pain is acute nociceptive pain, chronic neuropathic pain, inflammatory pain, arthritic pain, cancer pain, or mixed nociceptive pain and neuropathic pain.

[1170] Embodiment No. 117. Use of the compound or pharmaceutical composition of Embodiment 116 in the preparation of a medicament, wherein the mixed nociceptive and neuropathic pain is low back pain.

[1171] Embodiment No. 118. The method of embodiment 109, wherein the circadian rhythm disorder is jet lag, shift work, delayed sleep phase disorder, or a non-24-hour rhythm disorder.

[1172] Embodiment No. 119. Use of a compound or pharmaceutical composition according to Embodiment 109 in the preparation of a medicament, wherein the substance abuse is opioid abuse or alcoholism.

[1173] Embodiment No. 120. Use of the compound or pharmaceutical composition of Embodiment 109 in the preparation of a medicament, wherein the substance abuse withdrawal is opioid withdrawal or alcohol withdrawal.

[1174] Embodiment No. 121. Use of the compound or pharmaceutical composition of Embodiment 109 in the preparation of a medicament, wherein the mental disorder is depression, major depressive disorder, post-traumatic stress disorder, anxiety disorder, bipolar disorder or schizophrenia.

[1175] Embodiment No. 122. Use of a compound or pharmaceutical composition according to any one of Embodiments 106-121 for the preparation of a medicament, wherein the compound is administered in combination with another active agent.

[1176] Embodiment No. 123. Use of a compound or pharmaceutical composition for the preparation of a medicament according to embodiment 122, wherein the additional active agent is a sedative-hypnotic drug.

[1177] Embodiment No. 124. Use of a compound or pharmaceutical composition according to any one of Embodiments 106-123 in the preparation of a medicament, wherein the compound and any additional active agent (if present) are administered at bedtime (hs (at bedtime)) or between about 0-4 hours before bedtime.

[1178] Embodiment No. 125. Use of the compound of any one of Embodiments 1-65 or the pharmaceutical composition of Embodiment 66 or 67 in alleviating symptoms of sleep disorders, treating or preventing sleep disorders.

[1179] Embodiment No. 126. The use of embodiment 125, wherein the sleep disorder is increased sleep fragmentation.

[1180] Embodiment No. 127. The compound or pharmaceutical composition of Embodiment 125 or 127, wherein the compound or pharmaceutical composition is an H1 / 5-HT2A receptor modulator.

[1181] Embodiment No. 128. The use of embodiment 125 or 126, wherein the sleep disorder is caused by or is comorbid with sleep apnea, restless legs syndrome, high respiratory disturbance index (RDI), neurological disease, circadian rhythm disorder, pain, periodic leg movement disorder (PLMD), REM behavior disorder, fragmented sleep in the elderly, age-related sleep fragmentation, postmenopausal sleep disorder, substance abuse, substance abuse withdrawal, narcolepsy, psychiatric disorder, increased sensitiv...

Claims

1. Compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 are each methyl; or R1 and R2 together with the atoms to which they are attached form a cyclopropyl group; R3 is H, halogen, -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), -NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or C3-C6 cycloalkyl; R4 is H, halogen, -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), -NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or C3-C6 cycloalkyl; R5 is H, halogen, -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), -NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or C3-C6 cycloalkyl; R6 is H, halogen, -S(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NH(C1-C6 alkyl), -NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or C3-C6 cycloalkyl; R7 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; R8 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; and R9 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl or C3-C6 cycloalkyl, Provided that at least one of R3, R4, R5 and R6 is H.

2. The compound of claim 1, wherein R1 is methyl and R2 is methyl.

3. The compound of claim 1, wherein R1 and R2 together with the atoms to which they are attached form a cyclopropyl group.

4. The compound of claim 1, wherein R3 is H, halogen, C1-C6 alkyl or C1-C6 alkoxy.

5. The compound of claim 1, wherein R4 is H, halogen, C1-C6 alkyl or C1-C6 haloalkyl.

6. The compound of claim 1, wherein R5 is H, halogen, C1-C6 alkyl, C1-C6 alkoxy, S(C1-C6 alkyl) or C1-C6 haloalkyl.

7. The compound of claim 1, wherein R6 is H, C1-C6 alkyl or C1-C6 alkoxy.

8. The compound of claim 1, wherein R7 is H.

9. The compound of claim 1, wherein R8 is H.

10. The compound of claim 1, wherein R9 is H.

11. The compound of claim 1, wherein the compound is a compound of formula (Ia) or (Ib): or a pharmaceutically acceptable salt thereof, wherein R3, R4, R5 and R6 are as defined in claim 1.

12. The compound of claim 1, wherein the compound is or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

14. The pharmaceutical composition of claim 13, wherein the compound is or a pharmaceutically acceptable salt thereof.

15. Use of the compound according to any one of claims 1 to 12 or the pharmaceutical composition according to claim 13 or 14 in the preparation of a medicament for alleviating symptoms of sleep disorders, treating or preventing sleep disorders.

16. The use according to claim 15, wherein the sleep disorder is increased sleep fragmentation.

17. The method of claim 15, wherein the compound is H1 / 5-HT 2A Receptor modulators.

18. The method of claim 15, wherein the sleep disorder is caused by or coexists with sleep apnea, restless legs syndrome, high respiratory disturbance index (RDI), neurological disease, circadian rhythm disorder, pain, periodic leg movement disorder (PLMD), REM behavior disorder, elderly fragmented sleep, age-related sleep fragmentation, postmenopausal sleep disorder, substance abuse, substance abuse withdrawal, narcolepsy, psychiatric disorder, increased sensitivity to pain, cardiovascular disease, hypertension, non-restorative sleep, stroke, metabolic disorder or cognitive impairment.

19. The use of claim 18, wherein the sleep apnea is obstructive sleep apnea due to a high respiratory disturbance index (RDI) associated with elevated respiratory event-related arousals (RERA), with or without concomitant apneas, hypopneas or acute hemoglobin desaturation.

20. The use of claim 15, wherein the compound is administered in combination with another active agent.

21. The use of claim 15, wherein the compound and any further active agent, if present, is administered at sleep time or between 0-4 hours before bedtime.